Dendritic Cell Subsets are Key Regulators in the Immune System by Kool, M. (Mirjam)
Dendritic Cell Subsets 
are Key Regulators 
in the Immune System
Mirjam Kool

Proefschrift
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam op gezag van 
de rector magnificus
Prof.dr. S.W.J. Lamberts
en volgens besluit van het College voor Promoties
De openbare verdediging zal plaatsvinden op 
woensdag 5 november 2008 om 15:45 uur
door
Mirjam Kool
 geboren te Utrecht
Dendritic Cell Subsets are 
Key Regulators 
in the Immune System
Dendritische cel subsets zijn 
sleutel regulatoren
 in het immuunsysteem 
Promotie commissie
Promotoren 
Prof.dr. B.N. Lambrecht
Prof.dr. H.C. Hoogsteden
Co-promotor
Dr. H. Hammad
Overige leden
Prof.dr. H.A. Drexhage
Dr. A.D. Kraneveld
Dr. R.W. Hendriks
Prof.dr. M. Moser
Prof.dr. K. Thielemans
ISBN: 978-90-8559-415-4
© Mirjam Kool, 2008
All rights reserved, save exceptions by the law, no part of this publication may be produced or 
transmitted in any form, by any means, electronic or mechanical, without prior written permission 
of the author, or where appropriate, of the publisher of the articles
The work presented in this thesis was performed at the Department of Pulmonary Medicine, 
Erasmus MC, Rotterdam, The Netherlands. Financial support was provided by the Dutch Asthma 
Foundation (grant 3.2.03.65)
The publication of this thesis was financially supported by: 
Nederlands Bijwerkingen Fonds, Astra Zeneca, Boehringer Ingelheim, and GlaxoSmithKline
cover illustration: E. Kool
printing: [Optima] Grafische Communicatie, Rotterdam, The Netherlands


Contents
Chapter 1
Chapter 2
Chapter 3
Chapter 4
Chapter 5
Chapter 6
Chapter 7
Nederlandse samenvatting
List of abbreviations
Dankwoord
List of publications
Curriculum Vitae
143
149
155
159
163
9Introduction I:
Exploiting the innate immune system to generate ad-
juvants: New tricks in an old game
Alum adjuvants boosts adaptive immunity by 
inducing uric acid and activating inflammatory 
dendritic cells
Alum adjuvant stimulates inflammatory dendritic 
cells through activation of the NALP3 inflammasome
MSU crystals induce Th2 immunization independent 
of the NALP3 inflammasome
Introduction II:
Dendritic cells in asthma and COPD:  Opportunities 
for drug development
An anti-inflammatory role for plasmacytoid dendritic 
cells in allergic airway inflammation
25
49
59
77
Exposure to immune serum and TLR agonists deter-
mines the capacity of murine plasmacytoid DCs to 
present soluble antigen to CD4+ and CD8+ T cells
93
111
Chapter 8 General Discussion and Summary
Journal of Experimental Medicine, 2008, 205; 869-882
Journal of Immunology, 2008, 181;  Sept 15
Current Opinion in Immunology, 2007, 19; 1-10
131

Chapter 1
Introduction I
Exploiting the Innate Immune System
to generate Adjuvants:
New Tricks in an Old Game
10
Vaccinations have been given to people for at least 100 years of which 80 years formu-
lated in adjuvants. Despite the massive use of alum adjuvant, its mechanism of action 
has been only recently addressed. Lately, a lot of focus in improvement on vaccination 
has resulted in new adjuvants to boost the immune system. Several innate receptors 
have been proven to be useful targets. Here we introduce the employment of different 
innate receptor to improve adjuvant capacity. 
Vaccination and adjuvants 
The first described vaccination was done by Edward Jenner, an English physician, in 1796 [1]. It 
was performed in a young boy with cowpox (a mild virus related to the deadly smallpox virus). The 
boy developed fever but no great illness, however more importantly he was protected to smallpox 
thereafter. Vaccination (Latin: vacca—cow) is so named because the first vaccine was derived 
from ‘cow’-pox. The word ‘vaccination’ was originally used specifically to describe the injection 
of smallpox vaccine, but has since been adapted to any immunization that has the purpose to 
prevent disease, be it microbial or caused by another derangement of the immune system. All 
present vaccinations work by presenting a foreign antigen (e.g. microbial) to the immune system 
in order to evoke an immune response, but there are several ways to do this. First, it can be 
evoked by giving inactivated microbes, for instance heat-inactivated or formaldehyde-inactivated 
virus particles. Second, it has been administered as an attenuated vaccine, e.g. live virus particles 
selected to have very low virulence and pathogenicity. Thirdly, a subunit vaccine, an antigen is 
presented to the immune system without introducing viral particles, whole or otherwise.  Vaccines 
typically contain adjuvants used to boost the immune response. The word ‘adjuvant’ comes from 
the Latin verb adjuvare, meaning to help or aid. Tetanus toxoid and hepatitis B subunit vaccines 
are usually adsorbed onto aluminum hydroxide or aluminum phosphate (alum). In this way the 
antigen elicits a stronger immune response to the intrinsically harmless protein structure found 
in a subunit vaccine of a toxoid. Other compounds have also been used as an adjuvant. Oil-
based adjuvants are commonly used in some veterinary vaccines and recently MF59, an oil-based 
adjuvant has been approved for human use [2]. 
Pattern Recognition Receptors 
The innate immune system is the first line of host defense against pathogens, including viruses, 
bacteria, fungi, and protozoa and is mediated by phagocytes such as macrophages, neutrophils 
and dendritic cells (DCs). Adaptive immunity is involved in elimination of pathogens in the 
late phase of infection as well as the generation of immunological memory [3]. The adaptive 
immune system with its T cells and B cells has a seemingly endless capacity to recognize foreign 
antigens, through variations in its T and B cell receptors. The innate immune system lacks these 
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highly variable receptors and uses a different strategy to recognize a wide variety of pathogens. 
Every pathogen has certain characteristics that are crucial to its survival and are shared between 
closely related pathogens. These so-called pathogen-associated molecular patterns (PAMPs) are 
vital to the survival of the pathogen and consists of e.g. gram-negative cell wall endotoxin, gram-
positive peptidoglycan (PGN), or viral double-stranded RNA. Central to the concept of PAMPs 
is that they are not shared with mammalian cells. PAMPs are recognized by pattern recognition 
receptors (PPRs) expressed on or in cells of the innate immune system. PPRs including Toll-
like receptors (TLRs) and Nod-like receptors (NLRs) are present on the cell surface and in the 
cytoplasm of macrophages, neutrophils, and DCs [4-7], as well as on some structural cells that 
line the outside world, like epithelial cells. TLRs and NLRs can also recognize molecular patterns 
associated with tissue injury or cell death, the so-called damage-associated molecular patterns 
(DAMPs). These include nuclear and cytosolic proteins, like ATP, uric acid, and HMGB-1 [8]. 
The evolutionary rationale behind this might be that some pathogens that developed ways to 
subvert the innate immune system would still induce changes in the tissues which they infect and 
these changes might be sensed by the immune system.
Other innate sensing receptor, like the C-type lectin-like receptors (CLRs) and retinoic acid 
induced gene-based (RIG)-I like receptors (RLRs) may also play a role in boosting innate 
immunity. CLRs like DC-SIGN, DEC-205, and the mannose receptor recognize carbohydrates, 
which are not only present in pathogens, but also in self-glycoproteins, thereby facilitating cell 
adhesion, migration, and phagocytosis [9]. RLRs are located in the cytoplasm and can sense 
ssRNA and dsRNA [10, 11]. Alarmins, like HMGB-1 [12, 13], eosinophil-derived neurotoxin        
(EDN) [14], and defensins also play an important role in activating the immune system [15]. 
Another group of endogenous proteins activating the immune system are the endokines, which 
include heat shock proteins, interleukins (e.g. IL-1α), S100 family proteins, and nucleosomes. In 
the next paragraphs we will discuss the potency to use TLR or NLR agonist as adjuvants to boost 
the immune system to improve vaccinations.
Innate immunity shapes adaptive immunity
Triggering the PRRs mentioned above not only activates innate immunity, it also shapes the 
character of the ensuing adaptive immune response. Dendritic cells (DCs) are the master 
controllers of adaptive immunity through their capacity to take up and process antigen in antigen 
exposed areas, and present it in an immunogenic form to naive T cells following migration to 
the central lymphoid organs. DCs express virtually all PRRs as part of their descent from innate 
immune phagocytes. Triggering PRRs on the surface of DCs induces their functional maturation 
in that they become competent to induce T cell proliferation and their differentiation into effector 
cells. Additionally, PRR triggering leads to the production of polarizing cytokines by DCs that 
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induce differentiation of naive T cells into either Th1 cells (IFNγ, IL-2 production), Th2 cells 
(IL-4, IL-5, IL-13 production), or Th17 cells (IL-17, IL-21, IL-22 production) (see figure 1 for 
molecules necessary to induce differentiation).
Dendritic cell subsets
Dendritic cells (DCs) are the most potent antigen presenting cells present in the immune system. 
There are different subset of DCs, which each has its own characteristics discriminating them from 
each other. During steady state, the DCs are divided into conventional (c) DCs and plasmacytoid 
(p) DCs. In lymphoid organs, like lymph nodes and spleen, the cDCs can be subdivided into 
CD8α+ and CD8α- cDCs, with a further subdivision by there CD4 expression [16]. Also, pDCs 
are found in the lymphoid organs and they migrate between lymph nodes via the lymphatics 
[17], whereas the cDCs do not migrate between lymphoid organs [18]. Each population of DCs is 
characterized by their expression of a particular combination of surface markers, on which we will 
focus on mouse cells. Mouse pDCs express bone marrow stromal antigen-2 (BST2, recognized 
by the mAbs 120G8 and PDCA-1), the B cell marker B220, intermediate levels of CD11c, MHC 
II, and Gr-1, and low expression of CD11b [19]. On the other hand, cDCs express high levels 
of CD11c and MHC II. CD8α+ cDCs furthermore express CD8α, DEC205, DNGR-1, and low 
CD11b, whereas CD8α- cDCs express 33D1 and CD11b [20-22]. Furthermore, the cDCs reside 
in different anatomical locations in the spleen. The CD8α+ cDCs are located in the T cell zone, 
whereas the CD8α- cDCs reside in the red pulp and marginal zone of the spleen. 
In an activated state of the immune system, so during infection or inflammation, all DC subtypes 
can be activated. pDCs are activated during virus infections and will release massive amounts 
Figure 1
DCs promote different differentiation of T cells
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influence of OX-40L, CD86, and jagged expres-
sion and they differentiate under the influence 
of high IL-6 levels, low IL-12 levels, IL-33, and pos-
sibly CCL2. Th2 cells produce IL-4, IL-5, IL-13, and 
TNFα. Regulatory T cells (Treg) develop under the 
influence of ICOSL, low CD86, low CD80 expres-
sion on DCs and low IL-6 levels, low IL-12 levels, 
IL-10, TGFb, and PGD
2
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or  TGFb or suppress via cell-cell contact. Th1 and 
Th17 cells differentiate when DCs express CD80, 
ICAM-1 and delta. However, soluble factor deter-
mine if Th1 or Th17 cells will develop. Th1 differ-
entiation needs high IL-6, IL-12, IL-18, and possibly 
IFNg levels, whereas Th17 differentiation depends 
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of type 1 interferons, which have potent antiviral capacities [23-25]. Upon activation, cDCs will 
upregulate different co-stimulatory molecules, which are needed to induce a strong T cell response, 
necessary to clear infection or dampen inflammation. During inflammation or infection a fourth 
DC subtype emerges, the inflammatory DC. This subtype is characterized by the expression of 
CD11c, CD11b, MHC II on the cell surface and iNOS expression intracellular [26]. They also 
produce a lot of the cytokine, tumor necrosis factor (TNF)α. These DCs are excellent antigen 
presenting cells and take up their antigen on the site of inflammation or infection and migrate to 
the draining lymph nodes to activate adaptive immunity. A further description of DC subsets in 
the periphery, e.g. in the lung, is given in chapter 5.
Antigen presentation by DCs
The different subsets of DCs do not only express different markers, but they also process antigens 
in different ways. There is a distinction for each subset in acquiring antigen and processing in 
the MHC I or II pathways. For exogenous non-viral antigens, CD8α+ DCs are known to be 
good at cross-presenting antigens in the MHC I molecule, whereby the antigen in presented to 
cytotoxic CD8+ T cells (CTLs) (see figure 2 for details). The CD8α- DCs are primarily focused 
on presenting exogenous antigens in the MHC II molecule to CD4+ T cells [27, 28]. It has been 
shown that pDCs are capable of MHC I presentation of endogenous antigens [29]. The role in 
MHC II antigen presentation for pDCs remains controversial. 
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Figure 2
Antigen processing pathways 
in DCs
DCs can process exogenous 
antigen for MHC I presentation 
(called cross-presentation) or for 
MHC II presentation. Cross-pres-
entation occurs when an antigen 
becomes cytoplasmatic and is 
broken down in peptides by the 
proteosome. These peptides 
are loaded into MHC I in the ER, 
thereafter this complex is trans-
located to the cellsurface for 
presentation to CD8+ T cells.
For MHC II processing, the anti-
gen in cleaved into peptides in 
the lysosome. The MHC II mole-
cule is made in the ER and trans-
located to the MIIC (MHC II com-
partment). In the MIIC, the MHC II 
is loaded with antigenic peptides 
from the lysosome. Thereafter, 
the complex is exposed on the 
cell membrane to CD4+ T cells.
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There are different routes of acquiring exogenous antigens which can lead to either MHC I or 
MHC II processing and presentation [30]. For an exogenous antigen to be directed into the 
MHC I pathway, a process called cross-presentation, it has to be acquired by the DC via the 
phagocytic pathway (e.g. soluble antigen), preferentially via mannose receptors [30-32] or via Fc 
receptor mediated endocytosis (e.g. immune-complexes) [33]. When the antigen is present in the 
phagosome, there are two pathways possible. In the first, the phagosome will release the antigen, 
possibly by retro-translocation via Sec61 [34, 35], into the cytosol where it will be broken down 
to antigenic peptides by the proteasome. TAP1 and TAP2, proteins that span the membrane of 
the endoplasmic reticulum (ER), transport the antigenic peptides into the lumen of the ER. In 
the ER chaperone proteins, like calnexin, calreticulin, and ERp57 facilitate the proper folding of 
MHC I. The partially folded MHC I molecule then interacts with TAP1 and TAP2 via tapasin 
(TAP binding protein). Once the antigenic peptide is transported into the ER, it will bind into 
the groove of the MHC I molecule, which is then stabilized and will be transported to the cell 
membrane. In the second possible pathway of cross-presentation, endosomal proteases especially 
cathepsin S will break down the protein into peptides in the phagosome. Then it can fuse with 
MHC I containing vesicles leaving the ER. The peptides will then be loaded onto MHC I and the 
complex is transported to the cell membrane.
For the MHC II pathway, the antigen has to enter the DC either via pinocytosis or via scavenger 
receptors [30]. Then it will be directed into the lysosome, where acid-dependent proteases, like 
GILT, cathepsin S, H, and C degrade the antigen into antigenic peptides. MHC II is synthesized in 
the ER associated with invariant chain (Ii, trimeric form) which prevents binding of endogenous 
peptides and stabilizes the MHC II molecule. Invariant chain also facilitates transport of MHC 
II from the ER via vesicles. These vesicles will fuse with a late endosome containing the antigenic 
peptides, thereafter called the MHC II compartment, MIIC. There the MHC II-Ii complex is the 
broken down, also done by cathepsin S and L, leaving only a small fragment called CLIP (Class 
II associated Invariant chain peptides) in the peptide binding groove. An MHC II-like structure, 
H2-DM, removes CLIP from the MHC II molecule and replaces it with an antigenic peptide from 
the endosome. The stable MHC II-peptide complex is then presented on the cell membrane to 
CD4+ T cells and will induce proliferation. 
Adaptive immune response
The adaptive immune response is activated by antigen presenting cells and thus by the potent 
DCs. It consists of a cell-mediated immune response, which is governed by T cells and a humoral 
immune response in which B cells play a large role. After antigen presentation to T cells by DCs, 
these T cells will proliferate and differentiate (see figure 1). The effector CD4+ T cells will secrete 
different cytokines, which will regulate the immune response. Activated CD8+ cytotoxic T cells 
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will destroy virally infected cells and/or tumor cells. Furthermore, both CD4+ and CD8+ T cells can 
become memory T cells. These memory cells are a subset of antigen-specific T cells that persists 
long-term after an infection has resolved. Their advantage is that they can quickly expand to large 
numbers of effector T cells upon a secondary exposure to their antigen. Thereby they facilitate 
the immune system with a ‘memory’ against past infections. Memory T cells compromises of 2 
subsets, the central memory TCM cells and the effector memory TEM cells.
Effector CD4+ T cells can activate B cells. Activated B cells subsequently produce antibodies which 
assist in inhibiting pathogens until phagocytes or the complement system clears the host of the 
pathogen. Most antigens which induce B cell activation are T cell-dependent, meaning T cell help 
is required for maximal antibody production. With a T cell-dependent antigen, the first signal 
comes from antigen cross-linking of the B cell receptor (BCR) and the second signal comes from 
co-stimulation provided by Th2 cells. These Th2 cells produce cytokines which will influence B 
cell proliferation and differentiation. Isotype switching to IgG, IgA, and IgE and memory cell 
generation also depends on cytokines present in the local environment. As an example, IL-4 
produced by Th2 cells will skew B cells to undergo class switching until IgE. 
Toll-like receptors and the adaptive immune response
To date, 13 members of the TLR family have been identified in human and mice. TLRs are type 
I integral membrane glycoproteins characterized by extracellular domains containing varying 
Figure 3
TLR expression on DCs
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nizes bacterial LPS. TLR5 recognizes bacte-
rial flagellin. TLR7/8 mediates recognition 
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ognizes CpG DNA of bacteria and viruses. 
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numbers of leucine-rich-repeat (LRR) motifs which recognize the PAMPs [4]). TLR activation 
helps to eliminate invading pathogens, coordinate systemic defenses, and initiate adaptive 
immune responses [4]. Triggering of the TLR induces maturation of macrophages and DCs, 
which is essential for the adaptive immune response and thereby memory response (see figure 
3 for ligands and location of the different TLRs). Some TLRs have been highlighted as potential 
candidates for improving vaccines against cancer and infectious disease, including TLR2, TLR4, 
TLR7/8, and TLR9 [36-38]. The best investigated ligand for TLR4, LPS has been shown to have 
good stimulatory effects in mice, inducing both innate and adaptive immunity [39, 40]. However, 
LPS can also induce septic shock, since it so efficiently promotes the release of the innate cytokines 
IL-1b and IL-6 [41]. Over the last decade, LPS has been modulated, keeping its beneficial effects 
on immunity and losing its toxicity by modifying the saccharide groups. This resulted in the 
immuno-active lipid A fraction, monophosphoryl lipid A (MPL), which has been shown to induce 
good immunity to a secondary viral infection in mice [42]. Also, GlaxoSmithKline Biologicals 
(Belgium) made a novel hepatitis B vaccine containing MPL (Fendrix ®), which demonstrates 
that MPL is safe to use. Of note, this vaccine also contains aluminum phosphate. Vaccinations 
are not only used to induce immunity against viruses and bacteria, but also to boost anti-tumor 
immunity. In this prospect, the synthetic TLR2/1 agonist [tripalmitoyl-S-(bis(palmitoyloxy)pr
opyl)-Cys-Ser-(Lys)3-Lys] was used in a model of melanoma cancer and a reduced tumor load 
was observed due to directly activating the CTL response [43]. Besides exploiting the adjuvant 
effects of membrane-bound TLRs, a lot of research has focused on the stimulation of intra-
cellular TLRs, like TLR7/8 and TLR9. In human and primates, the expression of TLR9 is limited 
to plasmacytoid DCs and B cells, whereas in mice also conventional DCs express TLR9 [44]. In 
different models, like allergy, tumor and viral immunology, administration of CpG motifs as a 
TLR9 ligand has been investigated intensively [45-48]. CpG immuno-stimulatory motifs reduce 
the Th2 allergic response (both prophylactic and therapeutic properties) [49-51] and increase the 
Th1 and CTL responses [52, 53]. TLR7/8 ligands, like imiquimod and R848 have also been shown 
to be an effective adjuvant in both infection and tumor immunology [37, 54]. Imiquimod works 
even as a double-edged sword by promoting by itself tumor reduction in vulvar cancer patients 
without use of an additional tumor antigen [55].
Nod-like receptors and adjuvenicity
The NOD-like receptors (NLRs) are cytoplasmic PRRs that may have a variety of functions in 
regulation of inflammatory and apoptotic responses. Approximately 20 of these proteins have 
been found in the mammalian genome and include two major subfamilies called NODs and 
NALPs, and some other molecules (e.g. MHC Class II transactivator (CIITA), IPAF, and BIRC1) 
(see figure 4 for ligand of different NLRs) [6]. The NOD proteins include NOD1 and NOD2, 
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which are intracellular bacterial sensors and activate NF-κB signaling [5]. The NALP proteins 
contain 14 members and are cytosolic sensors of pathogens; however whether they directly 
recognize endogenous PAMPs or DAMPs is not known at the moment. Activated NALPs form 
oligomers that activate inflammatory caspases (e.g. caspase-1), causing cleavage and activation 
of inflammatory cytokines such as IL-1b, IL-18 and IL-33, and/or activate the NF-κB signaling 
pathway to induce production of inflammatory molecules [56]. From this family, the NALP1 and 
NALP3 inflammasome have been most studied. NALP1 is mainly associated with induction of 
apoptosis, through activation of caspase-2. It can also promote inflammation by inducing IL-1b 
through activation of caspase-1 and caspase-5 [57]. The last years, the NALP3 inflammasome 
has been investigated thoroughly in its role in the pathogenesis of gout [58]. It has been shown 
be activated by uric acid crystals, which are associated for decades with gout [59]. The use of 
uric acid as an adjuvant has been shown through its capacity to induce a good CTL response 
[60]. Furthermore, the use of uric acid is beneficial in autoimmune responses, like diabetes and 
cancer [61, 62]. Uric acid is not the only factor which can activate the NALP3 inflammasome. 
ATP has been shown to induce K+ influx by activating the purinergic P2X7 receptor on which the 
inactive inflammasome changes confirmation to become active [63]. This process also involves 
the pannexin-1 hemi-channel that forms a complex with P2X7 receptor, thus potentially shuttling 
endocytosed particles to the cytoplasm. Recently, ATP has also been shown to induce Th2 
responses [64]. The adjuvant aluminum hydroxide has recently been shown to exert its function 
Figure 4
NLR expression on DCs
All NLRs are located in the cytoplasm. NOD1/2 
recognize peptidoglycan from bacteria. RIG-1 
recognizes dsRNA, influenza, and paramyxovi-
russes. Inflammasomes like IPAF and NALP1b 
are activated by different bateria and toxins, 
like Salmonella, Legionella, and antrax toxin. 
The NALP3 inflammasome is activated by uric 
acid crystals, bacterial toxins, bacterial RNA, K+ 
efflux, and ATP.
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partially through the NALP3 inflammasome [65, 66], which specifies that the NALP family is a 
good target to also improve vaccinations.  
Targeting antigen to nature’s adjuvant, the dendritic cell
Instead of using adjuvants to boost the immune system via activation of DCs via PRRs, it has 
been shown that it is possible to improve vaccinations by targeting the antigen to endocytic PRRs 
of the C-type lectin family directly. Antigens, especially tumor antigens have been coupled to 
antibodies, recognizing one of the CLRs and thereby facilitating antigen uptake and processing 
by the DCs [21]. However, an additional maturation stimulus has to be given to induce immunity 
[67], otherwise the outcome is tolerance [21, 68, 69]. One member of the CLRs is DEC-205 
(CD205), which has been targeted as a vaccination strategy. In a melanoma tumor model, DEC-
205 targeting promoted anti-tumor immunity [70]. Besides DEC-205, another member of the 
CLR family, DC-SIGN has been used to target antigen to DCs. In human, DC-SIGN is one 
of the most specific DC markers, making targeting more specific. Unfortunally, in mice such 
experiments cannot be done, since they express several forms of DC-SIGN [71]. However, in 
monkeys this strategy has also been shown successful in inducing proper T cell responses [72]. 
Recently, targeting of a new member of the CLRs DNGR-1 (DC, NK lectin group receptor-1), 
more DC-specific than DEC-205 in mice, was shown to be highly effective in a therapeutic 
approach in a mouse tumor melanoma model [20]. The above described targeted CLRs all 
initiate strong CD8+ T cell responses as these are expressed on CD8α+33D1- cDCs, which are 
know to be efficient cross-presenters [30, 73]. Other CLRs are expressed on another subset of 
cDCs, namely the CD8α-33D1+ cDCs which are good CD4+ T cell stimulators [74]. For instance, 
DCIR2 (DC inhibitory receptor 2) and dectin-1 targeting on CD8α- cDCs results in strong CD4+ 
T cell responses [22, 75]. Although, one should be aware that the outcome of targeting different 
receptors is not merely dictated by the DC subset, but also other cell types which express the 
different receptors. Furthermore, antigens can be routed differently intracellular to different 
compartments (e.g. MHC I or MHC II pathway) due to the specific receptor. Furthermore, 
receptor internalization can be achieved by other endocytic receptors, like Fc receptors. It has 
been shown that human plasmacytoid DCs (pDCs) internalize antigen via FcγRII [76]. Other 
endocytic CLRs are also expressed on pDCs, like Siglec-H and BST2 [77, 78]. Targeting of CLRs 
on pDCs instead of cDCs will induce a different immune response. 
Concluding remarks
All vaccination strategies will come down to essentially one target, the antigen presenting cell, of 
which the DC is the most potent. Promoting immunity through DCs by stimulating the innate 
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response via PRRs has been proven effectively, however, the road to human use is long. Secondly, 
stimulating and targeting other endocytic receptors on DCs has proven to be effective in mice. 
Studies should be undertaken to translate this to human use.
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Aim and scope of this thesis
It is clear from the described above that DCs play a central role in the immune system, in both the 
innate and the adaptive immune response. Furthermore, different DC subsets provide different 
signals to the immune system, induce different reactions, and respond to different stimuli. In the 
first part of this thesis we investigated the different DC subsets in the primary and innate immune 
response in the context of adjuvantia and induction of Th2 responses, like allergic asthma. In 
chapter 2, the mechanism of aluminum adjuvant was examined and a role for inflammatory 
monocytes and DCs was observed. An unexpected finding was the release of uric acid during 
aluminum adjuvant injection. In chapter 3, the molecular mechanism of aluminum adjuvant 
was investigated. The activation of DCs by aluminum adjuvant was partially mediated via the 
innate receptor, the NALP3 inflammasome. In chapter 4, the adjuvanicity of uric acid crystals 
was studied and a clear induction of Th2 responses was detected. Most likely, this was achieved 
by activating inflammatory monocytes and DCs. 
In the second part of this thesis, we investigated the function of plasmacytoid DCs. In chapter 
6, the role of pDCs in the secondary immune response was investigated in a mouse model of 
experimental asthma. PDCs were shown to down-regulate the eosinophilic airway inflammation 
in already immunized mice. In chapter 7, the antigen presentation capacity of pDCs was studied. 
Un-stimulated pDCs could not present exogenous antigens to both CD4+ and CD8+ T cells. 
However, to induce CD8+ T cell stimulation pDCs had to be activated by CpG motifs. To achieve 
CD4+ T cell proliferation, pDCs should either be pre-activated with CpG motifs or exposed to 
antigen-specific immunoglobulins.
Finally, in chapter 8 the main results concerning DC subsets are summarized and discussed. 
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Aluminum-containing adjuvants have historically   served  as immuno-
potentiators in vaccines and continue to be the 
most widely used clinical adjuvants [1]. Despite 
the fact that millions of doses of aluminum-
containing adjuvants have been given to healthy 
populations, it is surprising that there is no 
consensus regarding the mechanisms by which 
they potentiate the immune system [2-7]. Three  
potential mechanisms are frequently cited to 
explain how these adjuvants increase humoral 
immunity, although scarce experimental 
evidence is publicly available; (I) The formation 
of a depot by which the antigen is slowly released 
to enhance the antibody production. (II) The 
induction of inflammation thus recruiting 
and activating antigen presenting cells that 
capture the antigen [8]. (III) The conversion of 
soluble antigen into a particulate form so that 
it is phagocytosed by antigen presenting cells 
such as macrophages, dendritic cells, and B 
cells.  It is common knowledge that aluminum 
-containing adjuvants (alum) predominantly 
induce humoral immunity, further supported 
by the recent discovery that alum induces B 
cell priming and Ca2+ mobilization via a splenic 
Gr-1+ myeloid IL-4-producing cell type [5]. 
Classical cell-mediated immunity measured 
by DTH responses and induction of CD8+ CTL 
responses to a range of polypeptide and protein 
antigens is poorly induced by alum, due to 
a lack of cross-priming [1, 9, 10]. However,  
proliferative responses of CD4+ T cells as well 
as Th2 cytokine production have been found 
to be enhanced in a number of murine and 
human studies, suggesting that alum boosts 
humoral immunity by providing Th2 cell help 
to follicular B cells [2, 8, 11].   
Dendritic cells are seen as nature’s adjuvant and 
have the potential to recognize foreign antigen, 
process it into small peptides for presentation 
onto MHC molecules to the TCR, and to provide 
the essential costimulatory molecules for 
activation of naive CD4+ and CD8+ T cells [12]. 
Dendritic cells have an immature phenotype 
in peripheral tissues, specialized for antigen 
uptake, but upon recognition of exogenous or 
endogenous ‘danger signals’ like uric acid or 
Alum is the most widely used adjuvant in human vaccines but the mechanism of its 
adjuvanticity remains unknown. In vitro studies showed no stimulatory effects on 
dendritic cells (DCs). In the absence of adjuvant, Ag was taken up by LN resident DCs 
that acquired soluble antigen via afferent lymphatics, while after injection of alum, an-
tigen was taken up, processed and presented by inflammatory monocytes that migrat-
ed from the peritoneum, thus becoming inflammatory DCs that induced a persistent 
Th2 response. The enhancing effects of alum on both cellular and humoral immunity 
were completely abolished when CD11c+ monocytes and DCs were conditionally de-
pleted during immunization.  Mechanistically, DC-driven responses were abolished 
in MyD88-deficient mice and following uricase treatment, implying the induction of 
uric acid. These findings suggest that alum adjuvant is immunogenic by exploiting 
‘nature’s adjuvant’, the inflammatory dendritic cell through induction of the endog-
enous danger signal uric acid. 
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extracellular ATP, migrate to the lymph node 
T cell paracortex where they arrive as mature 
cells, expressing all costimulatory molecules 
and having lost the capacity to take up antigens 
[13, 14]. The response of DCs to exposure to 
foreign antigens is part of the innate immune 
response, and by providing a link between 
antigen recognition and antigen processing for 
presentation to naive T cells, these cells bridge 
innate and adaptive immunity [15].  
Many agents with adjuvant activity such 
as bacterial endotoxin, Freund’s adjuvant, 
bacterial CpG motifs, monophosphoryl lipid 
A, MF59, and b-galactosylceramide boost 
immunity through induction of dendritic cell 
maturation [16-19].  It has been less clear if 
and how aluminum-containing adjuvants 
can induce dendritic cell mobilization and 
maturation. At least in vitro, alum did not 
enhance costimulatory molecule expression 
and DC maturation, although this finding 
would not preclude such an effect in vivo 
as endogenously released danger signals 
from damaged or inflammatory cells might 
indirectly activate DCs [13, 20, 21].  The issue 
is even more complex as Toll-like receptors 
and TLR signaling through the MyD88 or 
TRIF adaptor pathway, classical activators of 
innate immunity and the DC network in vivo, 
were not always necessary for alum to act as 
an adjuvant for humoral immunity [6, 21, 22]. 
In view of the crucial role of DCs in activation 
of adaptive immunity, we therefore set out to 
carefully study the effects of alum on DCs and 
their monocytic precursors in vivo following 
intraperitoneal and intramuscular injection 
of antigen (Ag) in alum and studied T cell 
activation using an adoptive transfer system of 
traceable Ag-specific T cells. Our experiments 
revealed a hitherto unappreciated role for 
monocyte derived inflammatory DCs and uric 
acid release in boosting adaptive immunity in 
alum formulated Ag preparations.
Material and Methods
Mice 
BALB/c mice (6–8 wk old) were purchased from Harlan 
(Zeist, The Netherlands). OVA-TCR transgenic mice 
(DO11.10), CD11c-DTR transgenic mice on a BALB/c 
background [31], CD45.1 and CD45.2 C57Bl/6 mice were 
bred at Erasmus University (Rotterdam, The Netherlands). 
MyD88-/- mice were provided by B. Ryffel (Centre 
Nationale de la Recherche, UMR6218, Orleans, France) 
and originally made by S. Akira (Osaka University, Osaka, 
Japan). All experiments were approved by the animal ethics 
committee at the Erasmus Medical Centre.
Antigens and adjuvant
Ovalbumin (OVA) was purchased from Worthington 
Biochemical Corp (Lakewood, NJ). At the dose used in 
our experiments, the endotoxin level of OVA measured 
by a limulus-amebocyte lysate assay (Biowhittaker, 
Verviers, Belgium) was <0.001 µg/ml. Imject-alum (Pierce 
Biochemicals) is a mixture of aluminum hydroxide and 
magnesium hydroxide and was mixed at a 1:20 ratio with 
a solution of OVA antigen in saline followed by stirring 
for at least 1 h. For immunization 500 µl of Imject-alum 
suspension (1 mg) containing 10 µg of OVA (OVA-alum) 
was injected i.p. in the right lower quadrant using a 26 G 
needle, or alternatively 10 µg of OVA in 500 µl saline was 
injected.
 
Detection of the primary T cell response to i.p. injection 
of OVA
OVA-specific TCR Tg T cells were collected form the 
lymphoid organs of naïve 4-6 week old DO11.10 mice 
and stained with CFSE (Carboxyfluorescein diacetate 
succinimidyl ester from Molecular Probes, Eugene, OR) as 
described [23]. 10x106 Cells were injected intravenously in 
the lateral tail vein of BALB/c mice (day -1). On day 0, the 
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mice received an i.p. injection of 10 µg OVA, OVA-alum, 
saline, or alum. On day 0, 1, 2, 4, 7, and 14 cervical lymph 
nodes (CLN), axillary (A)LNs, inguinal (I)LNs, mesenteric 
(Mes)LNs, mediastinal (M)LNs and spleens were removed 
and individual cell suspensions prepared as described 
[23].  
In experiments to address the functional role of DCs 
in peritoneal responses, CD11c+ cells were depleted 
by injecting 100 ng of diphteria toxin (DT) either 
intratracheally (i.t.) or i.p. in CD11c-DTR Tg mice [31, 
32]. In these mice, CD4+ T cells were purified from OVA-
specific TCR DO11.10 cells using magnetic separation 
(CD4+ T cell isolation kit, Miltenyi), and 2-5x106 cells were 
injected i.v..
In experiments to address if monocytes could restore the 
phenotype in the DT-treated CD11c-DTR Tg mice, 7,5*105 
CD11b+Ly6C+CD31- monocytes sorted from bone marrow 
of BALB/c mice were given i.p. 2 hr after OVA or OVA-
alum injection.
In separate experiments the intramuscular (i.m.) route 
of administration was investigated by giving 10 µg OVA 
coupled to 1 mg alum in 50 µl in the left hind limb. Four 
and 7 days after the injection the sacral (S)LNs, popliteal 
(P)LNs, ILNs, and muscles were removed and prepared for 
single cell suspensions.
Effector cytokine production
LN and spleen cells (200,000 cells/well in triplicates) were 
resuspended in culture medium in 96-well plates. Four 
days later, supernatants were harvested and analyzed for 
the presence of cytokines by ELISA (IL-4 and IL-5 from 
eBioscience, IL-10 and IFNg from BD Biosciences)
Chemokine production 
The peritoneal lavage was taken 2 hr after injection of 10 µg 
OVA, OVA-alum, or saline to determine levels of different 
chemokines in the supernatant by ELISA (MCP-1 and KC 
from R&D systems, eotaxine from eBioscience).
Flow cytometry
For detection of OVA-specific T cell responses, cells were 
gated for living (PI-negative) lymphocytes with CD4-APC 
and the clonotypic anti-OVA TCR antibody KJ1-26-PE. 
To acquire clear CFSE division profiles, 2.5–10 x 105 events 
were collected. The term ‘CFSE content’ gives an estimate 
of the original number of CFSE-labeled donor cells from 
which the donor-derived, divided population has arisen 
and was calculated as described [23]. It can be used to 
calculate whether the number of cells at analyzed site has 
been affected by recruitment, migration, or cell death, in 
addition to division.
For detection and sorting of DCs and monocytes, single 
cell suspensions of LNs  or peritoneal lavage were prepared 
as described [49] or prepared from bone marrow cultures. 
Cells were subsequently stained with moAbs directed 
against CD11c, CD11b, MHCII, CD80, CD86, CD40 
(eBiosciences), F4/80, Ly6C, or Ly6G (BD Biosciences) 
and with pDC specific moAb 120G8 (kindly provided 
by C. Asselin-Paturel). Sorting of CD11c+ MHCII+ DCs, 
F4/80intCD11b+Ly6G-Ly6C+ inflammatory monocytes and 
F4/80+CD11b+ macrophages was performed on a FacsAria 
high-speed cell sorter (BD). 
For antigen uptake and processing studies, 10 μg of OVA-
Alexa Fluor 647 (OVA-AF647) or OVA-DQ (Molecular 
Probes) was coupled or not to Imject-alum, injected i.p., 
and detected 24 hrs later in the peritoneal cavity or various 
nodes. Peritoneal lavage and LN cells were stained for 
seven or nine-colour flow cytometry using combinations 
of live (DAPI-negative), Ly6C-FITC and Ly6G-PE or 
CD19-PE, mPDCA1-APC, CD8α-PerCP-Cy5.5 or CD11b-
PerCP-Cy5.5, CD11c-PE-Texas Red, Ly6G-PE-Cy7 or 
CD8α-PE-Cy7, MHCII-biotin or F4/80-biotin followed 
by streptavidin-APC-Cy7, CD11b-Pacific blue, combined 
with uptake of OVA-DQ or OVA-AF647.
Acquisition of 4 colour samples was on a FacsCalibur 
cytometer equipped with Cellquest software (Becton 
Dickinson) and 7-9 colour samples on a FacsAria cytometer 
equipped with FacsDIVA software. Final analysis and 
graphical output were performed using FlowJo software 
(Treestar, Costa Mesa, CA). 
Generation of BM-DCs
Bone marrow cells were cultured for 9 days in DC culture 
medium (DC-CM; RPMI 1640 containing glutamax-I 
(Invitrogen, Carlsbad, CA) supplemented with 5% (v/v) 
FCS (Sigma-Aldrich), 50 µM 2-mercaptoethanol (Sigma-
Aldrich), 50 µg/ml gentamicin (Invitrogen), and 20 ng/ml 
recombinant mouse GM-CSF (a kind gift from Prof. K. 
Thielemans, Vrije Universiteit Brussel, Brussels, Belgium). 
16 hrs before harvesting, DCs were exposed either to 10 
µg/ml of OVA, alum or OVA-alum suspension. 
Statistical analysis
For all experiments, the difference between groups was 
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calculated using the Mann-Whitney U test for unpaired 
data (GraphPad Prism version 4.0; GraphPad, San Diego, 
CA). Differences were considered significant when 
p<0.05.
 
Results
Distribution of the primary immune response 
after i.p. injection of OVA
Despite the wide use of i.p. injection of 
experimental antigens coupled to alum 
adjuvant, the precise localisation of primary 
T cell activation after i.p. injection of antigen 
has not been studied in great detail. By analogy 
with the rapid resorption of drugs following i.p. 
injection, it is often assumed that i.p. injection 
leads to rapid systemic resorption of antigen 
and therefore i.p. injection is often regarded as 
systemic immunization. To study primary T 
cell activation, naive BALB/c mice received a 
cohort of CFSE-labeled OVA-specific TCR Tg 
cells obtained from DO11.10 mice, and mice 
were subsequently immunized one day later 
with 10 µg of OVA via an i.p. injection in the 
right lower quadrant.  Two days later, primary 
T cell divisions were readily noticed in the 
inguinal LN (ILN) on the right side, and in the 
mediastinal LN (MLN).  In Ag-injected mice, 
only the CD4+ Ag-specific T cells, recognized 
by the KJ1-26 Ab divided, whereas a co-
injected fraction of TCR Tg- population did 
not.  Strikingly, there were no primary divisions 
in the contralateral left ILN nor in the spleen 
Figure 1
The mediastinal and ipsilateral inguinal lymph node drain the peritoneal cavity following i.p. injection
Mice were injected with CFSE-labelled DO11.10 OVA-TCR Tg cells 1 day before the intraperitoneal injection of OVA 
in the right lower quadrant. (A) Two days after OVA injection, different lymph nodes and spleen were taken and T 
cell proliferation was assessed with flow cytometry, by following CFSE dilution. Only KJ1-26+ T cells divide. (B) Im-
mediately after the administration of OVA in the right lower quadrant, a sterile puncture was made at the left lower 
quadrant. Four days later proliferation was measured in the left and right inguinal LN. An example is shown of 4 mice 
(representative of at least two independent experiments).
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(Fig 1A).  The fact that antigen presentation 
occurred only in the ipsilateral ILN was due to 
the fact that the needle injection caused a break 
in the peritoneal and skin barrier.  This was 
clear when we injected the Ag in the left lower 
quadrant, in which case divisions occurred in 
the left ILN, or when we combined a right Ag 
injection with a left sterile puncture containing 
no Ag, in which case both ILNs reacted to the 
antigen (Fig 1B).  When the right ILN was 
resected prior to Ag injection on the right side, 
the ipsilateral axillary LN became Ag reactive, 
illustrating that the antigen reached the LN via 
the afferent lymphatics (data not shown).
When T cell division was followed over time 
(Suppl Fig 1), it was evident that Ag-specific T 
cell responses were restricted to the draining 
right ILN and MLN for the first 3 days of the 
Figure 2
Addition of alum adjuvant to OVA 
leads to a stronger, more peristent 
and recirculating Th2 immune re-
sponse
Mice were injected with CFSE-la-
belled DO11.10 OVA-TCR Tg cells 1 
day before the i.p. injection of OVA 
or OVA-alum. (A) Four and 7 days 
after the injection the draining LN 
(MLN), non-draining LN (CLN), and 
the spleen were analyzed for T cell 
proliferation with flow cytometry 
(n=4 mice, experiment performed 
three times). (B) CFSE content was 
calculated as described in Mate-
rial and Methods, and is shown for 
draining LN (MLN) and non-draining 
LN (ALN). Open symbols represent 
the OVA-injected mice, the black 
closed symbols the OVA-alum inject-
ed mice. (C) Seven days after the i.p. 
injection, LN cells (draining LN: MLN, 
non-draining LN: ALN) were taken 
and re-stimulated in vitro for 4 days 
with OVA. Cytokines were measured 
in the supernatants by ELISA. White 
bars represent OVA-injected mice, 
black bars the OVA-alum injected 
mice. Data are shown as mean ± SEM, 
* p<0.05. n=4-6 mice per group. 
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response.  By day 4, cells that had divided at 
least three times began to appear in the non-
draining lymph nodes and importantly also in 
the spleen. These cells expressed high levels of 
CD44 and low levels of CD69, consistent with 
their phenotype of recirculating primed T 
cells as previously reported [23, 24] (data not 
shown). However, by day 7 and 14 the majority 
of divided cells had disappeared from the 
lymphoid organs and could not be retrieved 
from the peritoneum. 
Effect of alum adjuvant on the immune 
response induced by an i.p. or i.m. injection 
of OVA
When OVA was emulsified in alum adjuvant, 
the localisation of the primary immune 
response after i.p. injection into the lower right 
quadrant was again restricted to the ipsilateral 
ILN and MLN. In some mice, there was also 
a clear primary proliferation of OVA-specific 
TCR Tg cells in the mesenteric nodes, as 
previously reported for CD8+ T cell responses 
following i.p. injection (data not shown and 
[25]). By day 4 of the response, the primary T 
cell response in the draining MLN (and ILN) 
was more pronounced in mice receiving both 
OVA and alum compared with OVA alone, with 
a total percentage of CFSE+ Tg cells of 1.7% vs. 
0.6% in the mediastinal nodes (Fig 2A).  By day 
2-4 of the response there was a clear increase in 
CFSE content (i.e. the number of CFSE+ KJ1-
26+ cells per 105 CD4+ T cells, correcting for 
the multiplying effect of cell division) in OVA-
alum immunized mice compared with mice 
only immunized with OVA or saline control, 
signifying that the increase was not only due 
to division but also recruitment of naïve Ag-
specific T to these nodes (Fig 2B). However, 
such recruitment did not occur in non-draining 
nodes. Also significantly more divided CFSE+ 
Tg+ recirculating effector cells were seen in the 
non-draining node and spleen.  By day 7, a time 
point when the majority of OVA-specific TCR 
Tg T cells have disappeared in mice receiving 
OVA, the Tg T cells persisted in the draining 
and non-draining nodes and spleen in mice 
receiving OVA-alum (Fig 2A, right panel and 
2B).  These persisting cells in the mediastinal 
nodes had Th2 effector potential in the OVA-
alum group as they produced IL-4, IL-5 and 
IL-10, but little IFNg (Fig 2C). Bulk cultures of 
mediastinal node cells from OVA immunized 
mice did not produce significant levels of 
cytokines in response to OVA restimulation. 
In the non-draining nodes, there was similarly 
a clear increase in Th2 cytokine production in 
mice receiving OVA-alum, most likely due to 
recirculating primed T cells. 
The i.p. route is most often used for 
immunization of animals because of its ease 
of use, but in humans most alum formulated 
adjuvants are injected intramuscularly or 
subcutaneously.  We therefore also studied the 
response to OVA-alum and OVA following i.m. 
injection into the gluteal muscle of mice.  In 
these mice, the primary draining LN site was the 
sacral LN.  Again, OVA injection alone led to 
transient T cell activation followed by deletion 
of dividing cells, whereas alum injection left 
behind a persistent and recirculating T cell 
response, which was most prominent in the 
sacral node (Suppl Fig 2A).  
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Response of innate immune system cells to 
i.p. injection of antigen in adjuvant
Having identified the mediastinal LN as the 
most physiological draining site following i.p. 
injection of antigen in alum, we next directed 
our interest to the innate immune response 
to adjuvant in the peritoneum and how cells 
would take up and translocate antigen from 
the peritoneum to this node. By analogy 
with other adjuvants, it is possible that alum 
adjuvant is immunogenic due to its induction of 
inflammation at the site of injection, thus 
recruiting antigen presenting cells to the 
site of antigen exposure [7]. One of the most 
prominent cell types found in the peritoneal 
cavity of unimmunized mice are the resident 
F4/80highCD11bhigh peritoneal macrophages. 
Within 6 hrs after injection, there was a dramatic 
reduction in these resident macrophages in 
mice receiving OVA-alum, but not OVA (Fig 
3A). On the contrary, OVA-alum induced a 
rapid recruitment into the peritoneal cavity 
of CD11b+F4/80intLy6G-Ly6Chigh inflammatory 
Figure 3
Alum recruits innate immune 
cells to the peritoneal cavity
Mice were injected i.p. with OVA 
or OVA alum. (A) Six, 12, and 
24h after injection, the perito-
neal lavage was taken and the 
number of macrophages (F4/
80highCD11b+SSChigh), mono-
cytes (CD11b+Ly6ChighLy6G-
F4/80int), myeloid dendritic 
cells (MHCIIhighCD11c+F4/80low), 
plasmacytoid dendritic cells 
(120G8 +CD11b dimCD11c int) , 
neutrophils (CD11b+Ly6C+Ly
6GhighF4/80-), and eosinophils 
(CD11b+Ly6CintLy6GintF4/80int) 
was determined. Open sym-
bols represent the OVA-in-
jected mice, the black symbols 
the OVA-alum injected mice. 
(B) Two hour after injection, the 
peritoneal lavage was taken 
and chemokine levels were de-
termined in the supernatant by 
ELISA. Data shown are mean ± 
SEM, * p<0.05, n=4-6 mice per 
group.
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monocytes, previously shown to be immediate 
precursors for DCs [26, 27].  Twelve and 24 
hrs after injection of OVA-alum a significant 
increase in the number of myeloid DCs 
(defined as MHCIIhighCD11c+F4/80low) and 
plasmacytoid DCs (120G8+CD11bdimCD11cint) 
could be found compared to OVA-injected 
mice. Furthermore, OVA-alum led to a marked 
increase in the numbers of neutrophils (CD11b+ 
Ly6C+Ly6GhighF4/80- cells) and eosinophils 
(CD11b+Ly6CdimLy6GdimF4/80dim) recruited 
into the peritoneal cavity.   In attempt to explain 
the increase in innate immune cells so early 
after injection of alum, we also measured the 
levels of chemokines in the peritoneal lavage 
at 2 hrs following injection of saline, OVA or 
OVA-alum.  There was a marked increase in the 
levels of the the monocyte chemotactic protein 
(MCP-1; CCL2), the neutrophil chemotaxin 
KC (CXCL1), and the eosinophil chemotaxin 
eotaxin-1 (CCL11) in mice receiving OVA-
alum versus OVA or saline (Fig 3B).  OVA by 
itself induced an intermediate level of MCP-1 
compared with saline or OVA-alum injected 
mice. 
At 24 hrs after injection, we also studied the 
presence of a population of IL-4-producing 
Gr-1+ myeloid cells, previously shown to be 
involved in inducing splenic B cell priming after 
alum injection [5].  Using IL-4-GFP reporter 
mice (4-Get mice [28]), we could detect an 
alum-induced increase in this population in 
the peritoneum and spleen, but not mediastinal 
LN. In addition, we found that alum induced 
two populations of CD11b+Gr1+ myeloid cells 
expressing IL-4 in the peritoneum, the highest 
Gr1+ one most likely being granular F4/80+ 
eosinophils, the intermediate Gr1-expressing 
one being monocytes (Suppl Fig 3).
Antigen uptake and processing by recruited 
dendritic cells
The increase in DCs following injection of 
OVA-alum led us to study the effects of alum 
on several functional aspects of DCs including 
antigen uptake, processing and functional 
maturation. To investigate if alum had an effect 
on the antigen uptake by DCs, OVA-AF647 was 
injected i.p. either alone or emulsified in alum 
and uptake by CD11c+ DCs in the peritoneal 
cavity was measured 6 and 24 hrs later.  Even 
in the absence of alum, DCs captured the 
antigen, but the mean fluorescence intensity 
representing the amount of Ag taken up was 
higher when alum was added (Fig 4A, results 
at 24 hrs shown).  Under the same conditions, 
also peritoneal B cells took up more fluorescent 
antigen when alum was added whereas 
recruited eosinophils and neutrophils did not 
take up OVA-AF647, even in the presence of 
alum (data not shown). 
To analyze antigen processing of internalized 
antigen, we utilized OVA-DQ, a form of OVA 
that is highly conjugated to the BODIPY 
fluorochrome that fluoresces in the green 
channel when taken up by cells and in the 
red channel when it accumulates at high 
densities inside endosomal antigen processing 
compartments. CD11c+MHCII+ DCs from 
OVA-DQ-alum treated mice took up and 
processed more antigen than OVA-DQ treated 
mice (Fig 4B).  When the CD11c+OVA-DQdouble 
pos cells were analyzed in the OVA-DQ-alum 
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treated mice, they expressed more MHC II 
than the OVA-DQneg cells, indicating that 
the DCs that took up and processed antigen, 
also functionally matured (Fig 4C). After 
injection of OVA-alum, we observed that the 
DC maturation marker CD86 (and CD40, data 
not shown) was induced on peritoneal lavage 
CD11c+MHCII+ DCs within 6 hrs and started 
to return to baseline from 24 hrs onwards 
compared to an injection of OVA or saline (Fig 
4D).  This effect of alum on DC maturation 
was most likely indirect as exposure of purified 
BM-derived DCs to alum in vitro did not lead 
to any direct DC activation (Fig 4D, right panel 
and [20, 21]). The ultimate definition of DC 
function is the potential to present antigen to 
naive T cells. When CD11c+MHCII+ DCs were 
sorted from the peritoneum of immunized 
mice, only DCs derived from OVA-alum 
immunized mice induced T cell proliferation 
of naive DO11.10 OVA-TCR-specific T cells 
ex vivo (Fig 4E), best explained by induction 
of DC maturation (Fig 4D) and more efficient 
antigen processing by these cells (Fig 4B). 
One aspect of DC biology that cannot be 
overestimated is their potential to migrate 
to the draining lymph node.  Uptake studies 
in mice receiving OVA-DQ-alum revealed 
that within 24 hrs, 10% of CD11c+MHCII+ 
DCs in the MLN had taken up antigen and 
processed it into immunogenic fragments, as 
did 2% of CD19+MHCII+ B cells and 10% of 
120G8+CD11cint pDCs. The addition of alum to 
OVA led to a strong increase in cells positive 
for processed OVA-DQ, from 0.05% to 0.87% 
of all live draining LN cells, particularly in DCs 
and B cells (FACS plots not shown). We could 
not detect significant OVA-DQ processing in 
any APC population in non-draining nodes. 
Injection of alum promotes antigen uptake 
by recruited monocytes and induces their 
migration and conversion into CD11c+ DCs 
in the draining nodes
Injection of OVA-alum induced the recruitment 
of inflammatory CD11b+Ly6G-Ly6C+F4/80int 
monocytes to the peritoneal cavity (see Fig 3A). 
When fluorescent OVA-AF647 was mixed with 
alum, these inflammatory monocytes massively 
took up more antigen compared with OVA-
AF647 injected alone (Fig 5A, upper panels). 
Particularly in OVA-alum-immunized mice, 
Ly6ChighCD11b+monocytes (identified using 
the same gating strategy as in the peritoneum) 
carrying fluorescent OVA-AF647 could also be 
found in the mediastinal nodes by 24 hrs after 
immunization (Fig 5A, lower panels).  Due 
to incompatible staining reagents, we could 
however not measure OVA-DQ processing in 
this monocyte subset. To prove however that 
they were processing the internalized antigen, 
Ly6C+ monocytes were sorted from mediastinal 
LN, and they induced ex vivo proliferation of 
DO11.10 T cells when obtained from OVA-
alum-immunized mice (Fig 5B).  The T cell 
division induced by sorted monocytes was 
even greater than the one induced by sorted 
mediastinal LN DCs (sorted based on classical 
characteristics).  Consistent with the induction 
of T cell proliferation, monocytes arriving in 
the mediastinal LN and carrying Ag to these 
nodes (measured by OVA-AF647) acquired 
costimulatory molecule expression (CD86 
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and CD40), upregulated MHC II and most 
importantly also acquired the CD11c integrin, 
a classical marker of DCs.  These changes 
were most pronounced in monocytes that had 
taken up antigen (Fig 5C).  As these findings 
were largely descriptive and not excluding the 
possibility that LN resident monocytes acquired 
the antigen and upregulated CD11c in situ, we 
performed adoptive transfer experiments of 
flow cytometry sorted Ly6C+CD11b+CD31- 
bone marrow monocytes obtained from 
CD45.2 congenic mice that were injected 
intraperitoneally into CD45.1 recipients, 2 
hrs after injection of OVA or OVA-alum.  As 
shown in Fig 5D, CD45.2 monocytes migrated 
from the peritoneal cavity to the mediastinal 
LN, and this migration was strongly amplified 
by addition of alum. When CD45.2 bone 
marrow monocytes were phenotyped prior to 
i.p. injection, they were negative for the DC 
markers CD11c and MHC II.  However, CD45.2 
monocytes recovered from the mediastinal 
LN 36 hrs after i.p. injection now strongly 
expressed MHC II and CD11c, up to 25% of 
Figure 4
Alum adjuvant stimulates DC function in vivo 
(A) Mice were injected i.p. with OVA-AF647 or OVA-AF647-alum. 24 hrs after injection, the peritoneal lavage was 
taken and the uptake of OVA-AF647 was assessed in F4/80-MHCII+CD11c+ DCs. (B) Mice were injected with OVA-DQ 
or OVA-DQ-alum i.p. and 24 hrs later the mDCs (F4/80-MHCII+CD11c+) in the peritoneal lavage analyzed for the up-
take and processing of DQ by flow cytometry. OVA-DQ is fluoresces green when processed in acidified lysosomes. 
Red fluorescence is caused by accumulation of OVA-DQ in endosomal processing compartments in the cell. (C) The 
CD11c+ cells were also analyzed for the expression of MHCII in the DQ negative or double positive gate. Grey filled 
histograms represent OVA-DQ negative and black line histograms represent OVA-DQ double positive CD11c+ cells. 
(D) Maturation of cDCs in the peritoneal lavage was assayed 6, 12, and 24 hrs after injection of OVA or OVA-alum 
by flow cytometry. BM-derived DCs (BM-DCs) were pulsed for 16 hrs with OVA or OVA-alum. Grey filled histograms 
represent naive mice or unpulsed BM-DCs, black dotted line histograms OVA-injected mice or OVA-pulsed BM-DCs, 
and black solid line histograms OVA-alum-injected mice or OVA-alum-pulsed BM-DCs. (E) Mice were injected with 
OVA or OVA-alum and 6 hrs later the F4/80-MHCII+CD11c+ DCs were sorted from the peritoneal lavage and placed in 
co-culture with CFSE-labelled DO11.10 Tg CD4+ T cells. After 4 days, cells were analyzed for proliferation and gated 
for CD4+, KJ1-26+ and CD25+.
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cells expressing both markers, indicative of 
conversion to DCs.
When we studied the uptake and transport 
of fluorescent antigen after i.m. injection into 
the gluteal muscle, we could similarly detect 
antigen uptake by DCs (Suppl Fig 2B) and 
inflammatory monocytes (Suppl Fig 2C) in 
the muscle.  Particularly when OVA-alum was 
administered did antigen-laden inflammatory 
monocytes also accumulate in higher numbers 
in the draining sacral nodes.
Functional effect of depleting resident or 
recruited DCs on T cell priming and humoral 
Figure 5
Inflammatory monocytes recruited by alum take up antigen, migrate to draining LN and acquire a DC pheno-
type
Mice were injected with OVA-AF647 or OVA-AF647-alum and 24h later the peritoneal lavage and draining LN (MLN) 
were taken. (A) Presence of OVA-AF647 in inflammatory monocytes (defined as CD11b+Ly6ChighLy6G-F4/80int) is shown 
in the peritoneal lavage and MLN. (B) Inflammatory monocytes and mDCs (CD11b+MHCIIhighLy6C-) were sorted and 
placed in co-culture with CFSE-labelled DO11.10 Tg CD4+ T cells. T cell proliferation was assayed at day 4 and plots 
depict PI-negative CD4+ cells. (C) Expression of CD11c, MHC II and CD86 on inflammatory monocytes determined by 
9-colour flow cytometry. Grey filled histograms represent the OVA-AF647-negative monocytes, whereas the black 
line histogram represents the OVA-AF647-positive ones. An example is shown of 4 mice. (D) CD45.1 mice were in-
jected with OVA or OVA-alum. 2 hr later they received CD45.2+ monocytes sorted from bone marrow (purity >95%). 
36 hrs later the number of CD45.2+ cells in the MLN were determined by flowcytometry. Data shown are mean ± 
SEM, ** p<0.01, n=4-5 mice per group. (E) The CD11c and MHC II expression was assessed on the CD45.2+ cells before 
injection and 36hr later in the MLN.
2.83
25.1
**
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immune response induced by OVA or OVA-
alum
The i.p. injection of OVA by itself did not 
lead to peritoneal DC activation and antigen 
presentation (Fig 4), nor recruitment of 
inflammatory antigen laden monocytes to the 
mediastinal nodes (Fig 5), yet T cell divisions 
were induced in these nodes by OVA (Figs 1,2 
Suppl Fig 1). One possibility would be that 
i.p. injected antigen reaches the LN via the 
flow of afferent lymph from the peritoneum 
in the absence of cell migration. We indeed 
observed that 2h after injection of OVA-
AF647 with or without alum, the mediastinal 
LN subcapsular sinus and B cell area became 
strongly fluorescent when we imaged sections 
directly without hydration (data not shown), 
as previously shown by others [29, 30]. We 
therefore hypothesized that in the absence of 
Figure 6
Contribution of resident versus 
recruited CD11c+ DCs on anti-
gen presentation and immuno-
potentiating effect of alum
(A) CD11c-DTR Tg mice were de-
pleted of resident MLN DCs by 
an i.t. injection of 100 ng diph-
theria toxin (DT) or PBS as a con-
trol. One day before DT, they re-
ceived a cohort of CFSE-labelled 
CD4+ DO11.10 T cells i.v.. One 
day after DT, OVA or OVA-alum 
was given i.p.. Three days after 
the last injection, proliferation 
of Tg T cells were determined 
in the draining MLN and drain-
ing right ILN. Percentages in the 
plots are the percentage Tg cells 
from total CD4+ T cells. (B) To de-
plete all CD11c+ cells (resident 
and recruited) CD11c-DTR Tg 
mice were injected i.p.  instead 
of i.t.. The rest of the treatment 
was the same as described in 
(A). (C) CD11c-DTR Tg mice were 
depleted of DCs by an i.p. injec-
tion of 100 ng DT or PBS as a 
control. One day after DT, OVA or 
OVA-alum was given i.p. with or 
without sorted monocytes from 
BALB/c mice. Thereafter treat-
ment was the same as described 
in (A). (D) CD11c-DTR Tg mice 
and nTg mice were injected with 
PBS or DT and received an i.p. in-
jection of OVA-alum and 10 days 
later serum samples were taken. 
OVA-specific IgG1 levels were 
determined by ELISA. Data are 
shown as mean ± SEM, * p<0.05. 
n=4-5 mice per group. 
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alum, antigen was presented by resident non-
migratory lymph node APCs that acquired 
the antigen via the afferent lymph, whereas in 
the presence of alum, antigen was presented 
by recruited inflammatory monocytes and 
DCs that migrated to the nodes.  To address 
this hypothesis, we used transgenic mice in 
which DCs can be conditionally depleted 
by administration of diphtheria toxin (DT). 
In these mice the human DTR receptor is 
expressed under the control of the murine 
CD11c promotor, leading to the rapid killing of 
CD11chi cells upon DT administration [31, 32]. 
Control mice in these experiments were non-
transgenic littermates that received a similar 
treatment with DT.  DT was administered 
locally via the intratracheal route, leading to 
a depletion of mediastinal resident LN (Suppl 
Figure 7
The alum response in mice depends on uric acid and MyD88 signaling
(A) Mice were injected with saline, OVA, or OVA-alum and after 2h uric acid levels were determined in the peritoneal 
lavage. Data are shown as mean ± SEM, ** p<0.01, n=5-6 mice per group. (B) Mice were injected with uricase 1 day 
and 5 min before OVA-AF647 or OVA-AF647-alum and 24h later the draining LN (MLN) were taken. The number of 
OVA-AF647+ inflammatory monocytes (defined as CD11b+Ly6ChighLy6G-F4/80int) are shown. Data are shown as mean 
± SEM, * p<0.05, n=4-5 mice per group. (C) At day 0, mice received a cohort of CFSE-labelled DO11.10 T cells i.v. and 
uricase i.p.. At day 1, mice received another injection with uricase and 5 min thereafter OVA or OVA-alum i.p.. Four 
days after the last injection, proliferation of Tg T cells were determined in the draining MLN. Percentages in the plots 
are the percentage Tg cells from total CD4+ T cells. An example is shown from 4 mice, experiment is repeated twice. 
(D) Quantification of the number of Tg cells from 4 and 7 days after OVA or OVA-alum plotted in C. Data are shown 
as mean ± SEM, * p<0.05, **p<0.01, n=4 mice per group. (E) MyD88-/- and WT mice were injected with OVA-AF647 or 
OVA-AF647-alum and 24 hrs later the draining LN (MLN) were examined. The number of OVA-AF647+ inflammatory 
monocytes (defined as CD11b+Ly6ChighLy6G-F4/80int) are shown. Data are shown as mean ± SEM, * p<0.05, n=4 mice 
per group.
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Fig 4) as well as lung-derived migratory DCs, 
while leaving all other DCs unaffected [32]. 
By taking advantage of the unique feature 
that the mediastinal LN drains both the 
lung and peritoneum, we could deplete LN 
resident DCs also draining the peritoneum 
without having to administer the toxin to the 
peritoneum.  When resident DC depleted 
mice received an i.p. injection of antigen one 
day later, T cell proliferation (measured three 
days after injection of OVA) was abolished in 
the mediastinal LN in mice receiving OVA, but 
not those receiving OVA-alum (Fig 6A).  On 
the contrary, the ipsilateral draining inguinal 
LN still demonstrated T cell proliferation 
in response to OVA even when DT was 
administered to the lung, illustrating that 
the toxin did not affect resident DC function 
outside the mediastinal node.  
To finally study the function of migratory DCs 
and monocyte derived DCs in the priming 
of the immune system by OVA-alum, we 
also administered the DT toxin systemically 
through the peritoneal route, depleting all 
CD11chi cells, including the resident ones [31]. 
When CD11c-DTR Tg mice received an i.p. 
injection of OVA-alum, adoptively transferred 
DO11.10 T cells divided strongly when CD11c+ 
cells were present (Fig 6B).  In CD11c-depleted 
mice, there was a very strong reduction in T cell 
divisions at day 4 of the response, and there was 
no occurrence of recirculating divided T cells 
in the non-draining nodes.  As the population 
of recruited inflammatory CD11b+Ly6G-Ly6C+ 
F4/80int monocytes differentiated into DCs 
in vivo (see Fig 5E) we finally tested whether 
sorted BM-derived monocytes injected i.p. 
could restore divisions in mice depleted of 
CD11chi cells. As shown in Fig 6C, injection of 
monocytes 2 hrs after injection of OVA-alum 
restored T cell divisions in Ag-specific T cells in 
the mediastinal LN of mice depleted of DCs.
Aluminum adjuvant is widely used for its 
strong induction of the humoral response, 
possibly through induction of direct priming 
of B cells by a myeloid IL-4-producing cell type 
[5] and by induction of T cell help for class 
switching. To examine if the humoral response 
would also be dependent on DCs, we treated 
CD11c-DTR mice or non Tg littermates 
with DT and injected them with OVA-alum. 
Ten days after the injection, serum samples 
were taken and OVA-specific IgG1 and IgE 
levels were determined. In DC-depleted mice 
(CD11c-DTR Tg mice given DT) a significant 
reduction in the levels of OVA-specific IgG1 
was found (Fig 6D). OVA-specific IgE levels in 
serum also showed this trend, although it did 
not reach significance (data not shown).  
The immuno-potentiating effect of alum 
depends on induction of uric acid and 
signalling through the MyD88 pathway
The fact that monocytes are recruited to the 
peritoneum and differentiate into full blown 
antigen presenting DCs does not explain how 
these cells get activated.  One striking finding 
was that alum induced a strong neutrophilic 
influx, accompanied by the production of 
CXCL1 (KC) and CCL2 (MCP-1)(Fig 3), as well 
as IL-1b and IL-18 (data not shown)[21] akin to 
the response seen when the endogenous danger 
signal uric acid is injected into the peritoneal 
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cavity [33, 34].  We therefore measured the 
level of uric acid in the peritoneal lavage 2 hrs 
following injection of saline, OVA or OVA-
alum and found that only alum induced a 
strong increase in uric acid levels (Fig 7A).  To 
test the functional significance of this induced 
uric acid, we neutralized it by treating mice 
with the uric acid degrading enzyme uricase 
prior to administration of OVA-AF647 in the 
presence or absence of alum.  The recruitment 
of OVA-laden CD11b+Ly6G-Ly6C+F4/80int 
inflammatory monocytes to the mediastinal 
LN was completely abolished in mice treated 
with uricase (Fig 7B) and consequently, T cell 
division that is normally avidly induced in vivo 
in the presence of alum was abolished back to 
the control level when uricase was given (Fig 
7C and D for quantification).   It was previously 
shown that the peritoneal response to uric acid 
is heavily dependent on the IL-1 receptor and 
downstream MyD88 signaling.  To test this 
possibility, we gave OVA-AF647 +/- alum to 
MyD88-/- C57Bl/6 mice and found that the 
recuitment of inflammatory monocytes to the 
mediastinal LN was grossly reduced compared 
with WT animals (Fig 7E).
Discussion
By carefully studying the kinetics and 
distribution of the innate and adaptive T cell 
immune response following i.p. injection of 
OVA in alum we have uncovered a previously 
unappreciated role for monocyte derived DCs 
in mediating the adjuvant effects of alum 
on cellular and humoral immunity.  This is 
underscored by the fact that inflammatory 
monocytes and DCs were attracted to the 
peritoneum following injection of OVA-alum, 
that they took up and processed the antigen 
on their way to the mediastinal LNs, that they 
acquired a functional phenotype of mature 
DCs once in the LN, and finally that removal 
of CD11c+ DCs abolished T cell proliferation 
in OVA-alum immunized mice, an effect that 
was restored by adoptive transfer of Ly6Chigh 
monocytes.
One of the aspects in our study that made 
us uncover this new mechanism of action 
of alum was the assessment of the precise 
localisation where antigen presentation 
occurred following i.p. injection. The 
peritoneal route is easily accessible and often 
used as a site for immunization to test the 
protective effect of novel vaccines against 
subsequent infection.  The good resorption of 
drugs from the peritoneal cavity has mislead 
the immunological community, as it is often 
assumed that intraperitoneal administration 
of a protein antigen leads to rapid systemic 
resorption into the bloodstream, leading to 
the common notion that intraperitoneally 
administered antigens are presented by 
antigen presenting cells in the spleen, similar 
to intravenously injected antigens. Often 
therefore, i.p. immunization is equalled to 
‘systemic immunization’ and investigators 
studying the immunogenicity of alum have 
focussed on the spleen as a site where immune 
activation might occur [5, 22]. Here we show 
that i.p. injection of the OVA antigen in the 
right lower quadrant of the peritoneal cavity 
leads to Ag presentation and antigen-induced 
T cell proliferation in the mediastinal LN and 
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the ipsilateral inguinal LN, but however not in 
the spleen.  By following T cell divisions over 
time, it was clear that only after 4 days, when 
T cells had undergone at least 3-4 divisions, 
could we detect divided cells in non-draining 
lymph nodes and spleen, very similar to what 
we and others described for immunization with 
Ags via the skin or respiratory mucosa [23]. 
Therefore, the antigen-specific reactivity that 
can be measured in the spleen ex vivo is the 
result of recirculating effector and/or memory 
cells. This finding does not exclude that there 
is immune activation occurring in the spleen 
before day 3-4 of the response. Within 24 hrs of 
injection of OVA-alum, there was induction in 
the spleen of an IL-4-producing Gr1+ myeloid 
cell, as described before by others 6 days after 
injection of alum [5]. The induction of divisions 
in the ipsilateral ILN was unexpected, but was 
due to an artefact induced by skin puncture. 
One important lesson is that ILN nodes should 
not be taken as ‘control non-draining nodes’, as 
is often done because of their easy accessibility, 
for Ags that are injected intraperitoneally.  
It was less surprising that Ag was presented in 
the MLN as previous studies in rat, mice and 
sheep have shown that the peritoneal cavity 
has a lymphatic drainage consisting of stomata 
that cross the diaphragm and drain into the 
parathymic and mediastinal LN [26, 35, 
36].  The transport of antigen could be either 
through free flowing lymph, gaining access 
to the subcapsular sinus and conduit system 
of mediastinal LNs and thus to resident DCs 
and to follicular B cells [29, 30, 37] or could 
be mediated by DCs or other APCs that pick 
up antigen in the peritoneal cavity and migrate 
to these nodes [38]. Both scenarios might 
come into play. By visualizing unhydrated LN 
slides, we could detect a massive amount of 
fluorescent Ag in the mediastinal LN within 
2 hrs after i.p. injection, irrespective of wether 
alum was added or not, which would never be 
caused by cell transport alone. Cell-mediated 
transport by inflammatory Ly6Chigh monocytes 
and DCs occurred particularly when alum was 
added. 
What is the reason for the dramatic difference 
in T cell outcome when alum adjuvant is 
added to an antigen?  We demonstrated that 
in the absence of alum, antigen was presented 
predominantly by non-migratory LN resident 
DCs that acquired the antigen via afferent 
lymph, as evidenced in experiments is which 
these resident DCs were depleted locally in the 
mediastinal node prior to OVA administration 
(Fig 6A).  Itano et al. have demonstrated that 
after skin puncture, there is a rapid flux of cell-
free Ag from the site of injection to the skin-
draining node, leading to T cell divisions in 
Ag-specific T cells, without generation of T cell 
effector potential [37].  We speculate that the 
physiological drainage of the peritoneal cavity 
through the stomata in the diaphragm also leads 
to presentation of antigen in a tolerogenic form 
by immature resident DCs, inducing deletional 
T cell proliferation [39, 40].  In contrast, 
when inflammation is induced by alum, there 
is additional recruitment of inflammatory 
monocytes and activation of already resident 
peritoneal DCs that migrate to the LN and 
arrive as CD11c+ mature cells expressing the 
necessary costimulatory molecules for naive T 
cell activation and generation of memory cells 
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[41].  Several groups have recently shown that 
CCR2+Ly6C+ monocytes are the immediate 
precursors of inflammatory type DCs, also 
called ‘TIP’-DCs under conditions of Listeria 
infection  [42], with an enhanced potential 
to induce effector T cells [27, 43, 44].   We 
believe that our data support the notion that 
alum boosts immunity by inducing these 
‘inflammatory’ DCs. When the resident LN 
DCs were depleted in the mediastinal LN using 
lung application of a selective DC depleting 
diphteria toxin [32], the induction of T cell 
division by OVA-alum was not suppressed, 
whereas when these inflammatory monocytes 
and DCs were depleted using peritoneal 
administration the toxin [31], almost all T 
cell division disappeared (Fig 6B), and there 
was no longer any priming for humoral 
immune responses (Fig 6D). The effects of 
DC depletion on T cell division were however 
completely restored when we performed an 
adoptive transfer of bone marrow derived 
Ly6C+ monocytes, cells that acquired a DC 
phenotype following arrival in the MLN. 
These data suggest that inflammatory DCs are 
strongly involved in mediating the enhancing 
effects of alum on adaptive immunity and 
also demonstrate that uptake and processing 
by other APCs is not sufficient for generating 
immunity in the absence of DCs.  This change 
of function in monocytes could be the result 
of their phagocytosis of particulate alum 
particles, as previously shown for phagocytosis 
of latex beads injected into the peritoneal cavity 
[26]. One striking feature was that all APCs 
contained more intracellular antigen when it 
was emulisfied in alum (Fig 4&5 and data not 
shown for B cells).  Particularly in monocytes, 
the cells that had internalized antigen 
demonstrated the shift in CD11c, costimulatory 
molecules and MHC II, suggesting that 
indeed antigen uptake was associated with 
DC differentiation. Inflammatory monocytes 
in the peritoneum contained fluorescent 
antigen by 6 hrs, whereas the same cells were 
found in the MLN only by 24 hrs, suggesting 
indeed migration to these nodes, a finding also 
supported by adoptive transfer experiments of 
CD45.2 congenic donors.  
As our own in vitro experiments (Fig 4D) and 
experiments by others [20] did not reveal a direct 
activation of monocytes and DCs by alum, we 
hypothesized that an endogenous danger signal 
might be released following injection of alum 
in vivo.  We measured very high levels of the 
endogenous danger signal uric acid when alum 
was injected and more importantly, recruitment 
of neutrophils, inflammatory monocytes as 
well as T cell activation induced by alum in 
the mediatinal LN was abolished when uric 
acid was neutralized by uricase treatment. Uric 
acid is released by necrotic cells and alum has 
been shown to induce a considerable degree of 
necrosis.  It is well known that alum injection 
i.p. leads to cell death and when injected into 
muscle alum leads to myofasciitis. The release 
of uric acid could explain the high degree of 
neutrophilic inflammation as well as CXCL1 
production, as a very similar response is seen 
when uric acid is injected intraperitoneally [13, 
33].  Moreover, work by others [21] as well as 
our own unpublished work demonstrated that 
alum, like uric acid, activates caspase-1 and 
leads to the release of IL-1b and IL-18 [33].  In 
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support for a predominant role for this pathway 
in activating inflammatory DCs, we found 
that the alum response was abrogated in mice 
deficient in the signalling molecule MyD88, 
involved in transducing signaling from the IL-
1 and IL-18 receptor. What we cannot explain 
however at present is the fact that the humoral 
immune response measured several weeks 
after injection of alum is variably dependent 
on MyD88 and/or IL-1 [6, 45, 46].   Although 
these differences might depend on timing of 
analysis and contamination or addition of 
different TLR ligands to alum, it could also be 
that for induction of humoral responses, IL-1 
signaling via MyD88 is redundant, whereas 
for T cell responses it is crucial [8]. Whether 
uric acid is the only endogenous innate trigger 
for DC activation remains to be shown, but 
the fact that uricase was so effective points 
towards a predominant role for it. Just like 
uric acid, alum adjuvant can activate several 
other aspects of innate immunity including 
activation of the coagulation and complement 
cascade, known to influence DC function [7, 
47].  As alum does not activate bone-marrow 
derived DCs in vitro, it is tempting to speculate 
that non-hematopoeitic structural cells of the 
peritoneal cavity might undergo necrosis and 
subsequently release uric acid, although formal 
proof of this is lacking. The rapid recruitment of 
neutrophils and eosinophils within 6 hrs along 
with DCs could subsequently be responsible 
for the indirect activation of DCs.  Indeed 
neutrophils have been shown to activate DCs 
through CD11b-DC-SIGN interactions, 
leading to secretion of chemokines and 
cytokines [48].  If eosinophils could perform 
the same task is unclear at present, but they 
could certainly represent an early source of 
Th2-polarizing cytokines, necessary for Th2 
induction by alum [28]. It has been shown that 
alum induces a Gr-1+IL-4+ myeloid population 
(eosinophils and monocytes) in the spleen 10 
days after injection [5]. We did see an increase in 
Gr-1+IL-4+ cells in the peritoneum and spleen, 
but not mediastinal LN, within 24 hrs after 
injection of alum, but do not know at present 
whether this population could be involved in 
activaton of the monocytes and DCs. 
In conclusion, through a series of in vivo 
experiments, we showed that alum adjuvant 
promotes adaptive immunity by releasing 
the endogenous danger signal uric acid 
thus inducing the differentiation of nature’s 
adjuvant, the inflammatory dendritic cell from 
recruited monocytes. 
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Supplementary figure 1
Time kinetics of the T cell proliferation induced by i.p. injec-
tion of OVA
Mice were injected with CFSE-labelled DO11.10 OVA-TCR Tg 
cells 1 day before the intraperitoneal injection of OVA. One, 2, 
4, 7, or 14 days after the OVA injection the draining LN (MLN), 
non-draining LN (CLN), and the spleen were analyzed with 
flow cytometry. An example is shown of 4 mice; the experi-
ment was repeated at least two times.
Supplementary figure 2
Intramuscular injection of OVA alum follows the same pat-
tern of T cell activation and inflammatory cell recruitment 
as i.p. injection.
(A) Mice were injected with CFSE-labelled DO11.10 OVA-TCR 
Tg cells 1 day before the intramuscular injection of OVA or 
OVA-alum. The intramuscular injection was given in the left 
gluteus muscle. After 4 and 7 days, draining LN (sacral LN) and 
non-draining LN (right ILN) were isolated and proliferation was 
determined by 
flow cytom-
etry. Dot plots 
depict PI-nega-
tive CD4+ cells. 
(B) Mice were 
injected i.m. 
with OVA-Al-
exa Fluor 647 
(O VA - A F 6 4 7 ) 
or OVA-AF647-
alum and 24h 
later the mus-
cle and drain-
ing LN (SLN) 
were taken. 
The presence 
of OVA-AF647 
was deter-
mined in F4/80-
MHCII+CD11c+ 
mDCs. (C) 
Presence of 
OVA-AF647 in 
inflammatory 
monocytes is 
shown.  Exam-
ples are shown 
from 4 mice.
47Alum boost Adaptive Immunity by inducing Uric Acid and iDCs
C
h
ap
te
r 
1
C
h
ap
te
r 
2
Supplementary figure 3
Alum injection induces IL-4+ Gr-1+ myeloid cells in the spleen, peritoneal cavity, but not the mediastinal LN
(A) 4get mice with a GFP fluorescent reporter under the IL-4 promotor were injected with OVA or OVA-alum. 24 hr 
after the injection, different organs were analyzed for the presence of IL-4-GFP+Gr1+ cells  using flow cytometry on 
live CD11b+ DAPI- cells.  Particularly in the peritoneum, a population of Gr1high cells was found, and this population 
was more granular (SSChigh) that the Gr1int population (B).
Supplementary figure 4
DCs are depleted following diphteria toxin treatment in CD11c-DTR Tg mice.
CD11c-DTR mice were injected either i.t. or i.p. with 100 ng diphteria toxin. After 24 hr, the mediastinal LN and in-
guinal LN were examined for the presence of DCs by flow cytometry. The numbers in the plots represent the percent-
age of DCs from living (PI-) cells. An example is shown out of 4 mice.
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Activation of dendritic cells (DCs) is a crucial mechanism by which vaccine 
adjuvants stimulate protective adaptive 
immunity to cancer or microbial infection 
[1]. Agonists to several Toll-like receptors 
(TLRs) are in clinical development. The most 
promising TLR ligand is unmethylated CpG 
dinucleotide containing DNA that stimulates 
TLR9 in a pathway requiring the adaptor 
MyD88, leading to the activation of DCs [2, 
3].  Nonetheless, there is a debate whether TLR 
stimulation is essential for the Ab-enhancing 
effect of vaccine adjuvants like alum.  Although 
initial studies showed that MyD88-deficient 
mice are defective in mounting a Th1 and 
B cell responses [4], this notion was recently 
challenged [5]. It has also become clear that 
an alternative pathogen detection system 
exists in addition to TLRs, which relies on a 
family of intracellular receptors called NOD-
like receptors (NLRs) [6-8]. In addition to 
pathogen-associated molecular patterns 
(PAMPs), some of these NLRs also sense the 
presence of endogenous danger signals. The 
most studied NLR member is NALP3, which, 
together with Cardinal and ASC forms a 
caspase-1 activating complex, the so-called 
inflammasome [9]. This complex is activated by 
multiple agonists including bacterially derived 
muramyl dipeptide or endogenous ATP and 
uric acid, leading to the processing and release 
of IL-1β [10, 11].  We therefore considered the 
possibility that NLRs, in addition to TLRs, are 
implicated in the effect of some adjuvants. 
Methods
Mice 
Wild-type (WT), ASC-/-, IPAF-/- (gifts from V. Dixit; 
IPAF is IL-1b-converting enzyme protease activating 
factor), MyD88-/-, and NALP3-/- mice (all mice on C57Bl/6 
background) were bred at University of Lausanne, 
Switzerland and at the University Hospital Gent, Belgium. 
Male and female mice were used between the ages of 8 
and 14 wks. All in vivo experiments were approved by the 
animal ethics committee of Ghent University.
Isolation and activation of mouse primary cells
Peritoneal macrophages were isolated 3 days after an i.p. 
injection with 10% thioglycollate and primed in vitro 
with 500 ng/ml LPS as previously described  [20]. Uric 
acid, uricase, and cytochalasin D were bought from 
Sigma-Aldrich and crystals were generated as previously 
described [12].
Adjuvants are vaccine additives that stimulate the immune system without having any 
specific antigenic effect in itself.  In this study we show that alum adjuvant induces the 
release of IL-1b from macrophages and dendritic cells and that this is abrogated in 
cells lacking various NALP3 inflammasome components.  The NALP3 inflammasome 
is also required in vivo for the innate immune response to ovalbumin (OVA) in alum. 
The early production of IL-1b and the influx of inflammatory cells into the peritoneal 
cavity is strongly reduced in NALP3-deficient mice.  The activation of adaptive cel-
lular immunity to OVA-alum is initiated by monocytic dendritic cell precursors that 
induce expansion of antigen-specific T cells in a NALP3-dependent way. We propose 
that in addition to TLR stimulators, agonists of the NALP3 inflammasome should be 
considered as vaccine adjuvants. 
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Antigens and adjuvant
Ovalbumin (OVA) was purchased from Worthington 
Biochemical Corp (Lakewood, NJ). In antigen-tracking 
experiments, OVA-Alexa Fluor 647 (Molecular Probes) 
was used. Imject-alum (Pierce Biochemicals; hereafter 
simply called alum) is a mixture of aluminum hydroxide 
and magnesium hydroxide and was mixed at a 1:20 ratio 
with a solution of OVA antigen in saline followed by 
stirring for at least 1 hr. For immunization 500 µl of Imject-
alum suspension (1 mg) containing 10 µg of OVA (OVA-
alum) was injected i.p., or alternatively 10 µg of OVA in 
500 µl saline was injected. 
Detection of cellular influx in vivo after OVA-alum 
injection
In WT and NALP3-/- mice, 2, 6, and 24 hrs after injection, 
the peritoneal cavity was washed with 3 ml PBS containing 
EDTA (peritoneal lavage) and the mediastinal lymph nodes 
ware harvested and used for flow cytometry as previously 
described [19]. 
Statistical analysis
For all experiments, the difference between groups was 
calculated using the Mann-Whitney U test for unpaired 
data (GraphPad Prism version 4.0; GraphPad, San Diego, 
CA). Differences were considered significant when 
p<0.05.
Results
Alum adjuvant activates the NALP3 
inflammasome
We first exposed peritoneal macrophages 
from WT, NALP3-/- and ASC-/- mice to various 
amounts of alum (see Material and Methods for 
composition). Even at low doses, a substantial 
amount of processed IL-1b was detected in 
the cellular supernatant, which compared well 
with the quantities of this cytokine observed 
with crystalline monosodium urate (MSU), 
one of the most potent activators of the NALP3 
inflammasome [12] (Fig 1A). IL-1b was 
absent completely absent in supernatants from 
macrophages from NALP3- and ASC-deficient 
mice, indicating a crucial involvement of 
NALP3 in caspase-1-mediated pro-IL-1b 
processing. 
Activation of caspase-1 occurs not only upon 
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Figure 1
Role of NALP3 and ASC in alum-mediated IL-1b pro-
duction
(A) Macrophages from WT, NALP3-/-, and ASC-/- mice 
were primed overnight with ultrapure LPS (500 ng/ml) 
and then stimulated with different amounts of Imject-
alum.  MSU (150 mg/ml) was used as a control.  Produc-
tion of mature IL-1b was measured by Western blotting 
in supernatants (SN) and cell extracts (XT).  (B) Alum-in-
duced IL-1b secretion is dependent on phagocytosis, K+ 
efflux and ROS. Peritoneal macrophages were primed 
as described in (A), treated with alum in the presence 
and absence of  high concentrations of extracellular  K+ 
(130mM), the ROS inhibitor APDC (100 mM), cytochalysin 
D (2 mM), and uricase (0.1 U/ml).
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assembly of the NALP3, but also the IPAF 
inflammasome [13].  However, a contribution 
of this complex in alum-triggered caspase-1 
activation is unlikely,  because alum-induced 
IL-1b secretion from macrophages derived 
from IPAF-deficient mice was still observed 
(data not shown). Also, alum adjuvant 
continued to activate caspase-1 in the absence 
of MyD88, excluding a major role of TLRs (ref 
[14] and data not shown).  
Mechanism of NALP3 inflammasome 
activation by alum and uric acid is similar 
We next investigated by which mechanism alum 
activates the NALP3 inflammasome. Recent 
studies have shown that NALP3 inflammasome 
activation is dependent on K+ efflux [15, 16] and 
the generation of reactive oxygen species (ROS) 
[15].  K+ efflux can be blocked by the addition 
of high concentrations of K+ (130mM) to the 
extracellular medium. The blockade of K+ efflux 
resulted in the inhibition of alum-induced 
caspase-1 activation and IL-1b secretion (Fig. 
1B).  Activation of inflammasome was also 
reduced when the ROS inhibitor (2 R, 4 R)-4-
aminopyrrolidine-2, 4-dicarboxylate (APDC) 
was added (Fig. 1B).
We could not exclude the possibility that 
activation of the inflammasome by alum occured 
indirectly through one of the two endogenous 
danger signals known to activate NALP3, 
namely ATP and uric acid [17] [12].  ATP, 
which is thought to be released from necrotic 
cells, potently activates the inflammasome 
via binding to the P2X7 receptor [17], while 
uric acid can form crystals that activate the 
inflammasome by an as yet poorly understood 
mechanism.  We have recently reported that 
extracellular ATP triggers inflammation by 
activating dendritic cells [18] and that in vivo 
injection of alum into the peritoneal cavity 
Figure 2  
Innate inflammatory response induced by alum is 
NALP3 dependent 
NALP3-/- or WT mice were injected i.p. with OVA or OVA-
alum. (A) 24 hrs after injection, the peritoneal lavage 
was taken and the number of neutrophils (CD11b+Ly6C+ 
Ly6GhighF4/80-), eosinophils (CD11b+Ly6CintLy6GintF4/
80int), and monocytes (CD11b+Ly6ChighLy6G-F4/80int) 
was determined by flowcytometry. (B) 2 hrs after OVA 
or OVA-alum injection, the peritoneal lavage was taken 
and cytokine levels were determined in the superna-
tant by ELISA. Data shown are mean ± SEM, * p<0.05,** 
p<0.01, *** p<0.001 n=4-6 mice per group.
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leads to uric acid (MSU) release [19].  It was 
therefore possible that MSU or ATP or both, 
were released from alum-treated cells, leading 
to the subsequent activation of the NALP3 
inflammasome.  However, we obtained no 
evidence for this hypothesis.  Uricase, which 
catalyzes the conversion of uric acid to 
allantoin [19] had only a minor effect on IL-
1b processing in vitro (Fig. 1B). Alum also still 
activated the inflammasome in macrophages 
of P2X7-deficient mice (data not shown).
Despite the fact that both ATP and MSU activate 
the NALP3 inflammasome, the initial pathways 
leading to inflammasome activation are not 
identical. MSU is a particulate matter and 
requires endocytosis [12].  In fact, endocytosis 
seems to be required for particles in general, 
including asbestos and silica to activate the 
inflammasome [20]. It was therefore expected 
that alum also required endocytosis.  The 
effect of alum, but not ATP (data not shown), 
was abrogated by the actin-destabilizing drug 
cytochalasin D (Fig. 1B). Taken together, 
NALP3 inflammasome activation in vitro by 
alum requires endocytosis of the particle, K+ 
efflux, and generation of ROS, but not release 
of ATP or uric acid.
Recruitment of inflammatory cells to the site 
of alum injection is decreased in the absence 
of NALP3 
Intraperitoneal injection of alum is frequently 
used in mice to induce cellular Th2 immunity 
and humoral immunity to emulsified protein 
antigens [21]. To assess the role of the NALP3 
inflammasome in alum adjuvanticity in 
vivo, we examined the innate inflammatory 
response caused by alum upon i.p. injection 
of OVA adsorbed to alum.  Twenty four hours 
after injection there was a massive recruitment 
of neutrophils (Ly6G+F4/80-CD11b+ cells), 
eosinophils (F4/80dimLy6G+CD11b+ cells), 
and inflammatory monocytes (CD11b+F4/80+ 
Ly6C+ cells) into the peritoneal cavity that 
was not seen when OVA was injected without 
alum (Fig 2A).  This innate response was 
severely reduced in NALP3-deficient animals 
but nevertheless still present.  Compared with 
injection of saline or OVA alone, injection of 
OVA-alum induced a rapid increase in the 
peritoneal cavity of the innate cytokines IL6 and 
IL-1b (Fig 2B). Strikingly, in NALP3-/- mice the 
increase in IL-1b was completely reduced to 
the level seen in mice receiving saline or OVA, 
whereas the level of IL-6 was only reduced but 
not abolished (Fig 2B).
Activation of dendritic cells is IL-1b and 
NALP3 dependent
DCs are seen as nature’s adjuvant and have a 
unique potential to induce adaptive immunity. 
We have recently reported that induction of T cell 
adaptive immunity following intraperitoneal 
injection of alum depends on uptake and 
transport of antigen from the peritoneal cavity 
to the mediastinal LN by resident CD11c+ 
DCs and by inflammatory CD11b+Ly6C+ 
monocytes that become CD11c+ DCs upon 
migration to the draining mediastinal lymph 
node (MLN) [19]. To address the contribution 
of inflammasome activation in this process, 
we measured the uptake of fluorescent OVA 
54
in resident Ly6C-CD11c+ DCs following 
injection of OVA or OVA-alum. Adsorption of 
OVA-Alexa Fluor 647 in alum led to a strong 
increase in DCs carrying antigenic cargo in 
wild type mice, but not in NALP3-/- mice 
(Fig 3A).  We also followed the occurrence of 
OVA-laden Ly6C+ inflammatory monocytes 
in the MLN (Fig 3B).  In WT mice there was 
a time-dependent increase in the number of 
inflammatory monocytes in the MLN at 24 
hrs, and a majority of these carried OVA.  In 
contrast, in NALP3-/- mice this increase was 
severely diminished.  This deficiency is most 
likely explained by a defective generation 
of bioactive IL-1b in NALP3-/- mice, as 
the alum-induced increase in OVA-laden 
CD11c+ monocytes in the MLN was severely 
reduced when IL-1b was neutralized in vivo, 
implying an important functional role for this 
cytokine in promoting monocyte migration 
and differentiation (Fig 3C).  Provision of 
costimulation is a necessary requisite for 
induction of adaptive immunity. Injection of 
OVA-alum induced the upregulation of the 
costimulatory molecule CD86 on inflammatory 
CD11c+ Ly6C+ monocytes in the MLN of wild 
type, but to a much lesser extent in NALP3-
/- mice (Fig 3D). A similar effect was seen for 
MHC class II (Fig 3D).  
The reduced migration of OVA-laden Ly6C+ 
monocytic cells with DC characteristics to the 
mediastinal nodes of NALP3-/- mice prompted 
us to study the activation of naive OVA-specific 
CD4+ T cells.  For this, mice first received a 
cohort of CFSE-labeled T cells obtained from 
OT-II TCR Tg mice followed by injection 
of OVA or OVA-alum, and accumulation of 
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Figure 3  
Activation of DCs by alum is NALP3 dependent
NALP3-/- or WT mice were injected i.p. with OVA-Alexa 
Fluor 647 (AF647) or OVA-AF647-alum. (A) 24 hrs after 
injection the number of OVA+ resident Ly6C-CD11c+ 
DCs was determined in the peritoneal lavage by flowcy-
tometry. (B) 6 and 24 hrs after injection the number of 
CD11c+OVA+ monocytes in the MLN was measured. (C) 
Mice were treated with anti-IL-1b mAb before OVA-alum 
injection. The influx of CD11c+OVA+ monocytes in the 
MLN was measured 24 hrs after injection. (D) CD86 and 
MHC II expression were measured on the OVA- and OVA+ 
monocytes in the MLN 24 hrs after injection of OVA-alum 
in WT or NALP3-/- mice. Data are shown as mean ± SEM, * 
p<0.05; n=4-6 mice per group.
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OVA-specific T cells was measured in the 
lymph nodes.  In WT mice OVA-alum caused a 
marked increase in the number of Ag-reactive 
T cells in the mediastinal LN at days 4 and day 
10 post immunization (Fig 4A) compared with 
injection of OVA alone.  In NALP3-/- mice, the 
number of T cells induced by OVA-alum was 
severely reduced but still higher compared 
with injection of OVA alone.  These changes 
in accumulation of T cells were mainly due to 
altered degrees of T cell division, as measured 
using CFSE dilution (Fig 4B).
We finally measured the effect of NALP3 
deficiency on the type of immunoglobulins 
induced by OVA-alum cells (Fig 4C).  Mice 
receiving OVA alone have generally low Ab 
titers to OVA (data not shown).  In WT mice 
OVA-alum induced the production of IgE, 
IgG1 and somewhat lower levels of IgG2c.  In 
NALP3-/- mice there was a significant decrease 
in OVA-specific IgE antibodies and an increase 
in OVA-specific IgG2c antibodies.  Strikingly, 
IgG1 levels were unaffected.
Discussion
In 1926, the adjuvant effect of aluminium 
compounds was first described by Glenny et 
al. [22].  Despite this early discovery, to this 
day little is known about the mode of action 
of alum adjuvant.  Adjuvants containing 
a pathogen-associated molecular patterns 
act as ligands for the Toll-like receptors 
(TLRs).  For example,  TLR9 was shown to be 
essential for the adjuvant effect of CpG oligo-
deoxynucleotides [2].  However, incubation of 
DCs with alum adjuvant fails to activate the 
DCs as indicated by increased expression of 
MHC II and co-stimulatory molecules [23]; 
yet, several authors describe an increased 
production of IL-1b secretion [24, 25]. Mice 
lacking TLR signaling components still mount 
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Figure 4
Induction of adaptive immunity by alum is NALP3 de-
pendent
(A) NALP3-/- or WT mice were injected with CFSE-labeled 
OT-2 OVA-TCR Tg CD4+ T cells 1 day before the i.p. injec-
tion of OVA or OVA-alum. 4 and 10 days after the injection 
the MLN was analyzed for T cell proliferation with flow 
cytometry (n=4 mice, experiment performed twice). (B) 
Representative CFSE profiles of adoptively transferred T 
cells on day 10 after injection. (C) On day 0, NALP3-/- or 
WT mice were injected i.p. with OVA-alum and on day 
7 boosted with OVA i.p.. At day 14 serum samples were 
taken and OVA-specific IgE, IgG1, and IgG2a levels were 
determined by ELISA. Data are shown as mean ± SEM, * 
p<0.05. n=5-11 mice per group. 
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a robust antibody response if alum is given 
as an adjuvant [5].  Thus, alum adjuvants, in 
contrast to the bacteria-derived adjuvants, do 
not directly activate TLRs. 
Entirely in agreement with two recent studies by 
Eisenbarth and Li and colleagues [14, 26], our 
data show that alum adjuvant triggers activation 
of the NALP3 inflammasome. The potential 
of alum to trigger the NALP3 inflammasome 
leads to early activation of the innate cytokine 
IL-1b and an innate cellular immune response 
at the site of injection.  Activation of the NALP3 
inflammasome and subsequent release of IL-1b 
leads to recruitment of immature monocytes 
and DCs. Production of IL-1b also leads to 
the activation of inflammatory monocytes and 
their migration to the lymph nodes draining 
the peritoneum.  This situation resembles the 
migration of skin Langerhans cells to the lymph 
nodes, which also requires IL-1b for functional 
migration and maturation to occur [27]. In 
OVA-alum-immunized mice, OVA-laden DCs 
and inflammatory monocytes take their cargo 
to the MLN and up-regulate the expression 
of critical costimulatory molecules like CD86 
with the subsequent expansion of antigen-
specific T cells [19].  All these steps are highly 
impaired in NALP3-deficient mice, indicating 
that activation of the NALP3 inflammasome 
contributes not only to the immediate 
inflammatory innate response at the site of 
injection of alum but also for the generation of 
adaptive cellular immunity. Furthermore, the 
levels of serum immunoglobulins are also to 
the generation of adaptive cellular immunity. 
Levels of serum Igs are also influenced in the 
NALP3-deficient mice, as a decreased level 
of OVA-IgE and increased levels of OVA-
IgG2c are found. This pattern of Ig synthesis 
is most likely the result of a shift towards 
IFNγ-secreting Th1-like helper cells necessary 
for Ig class switching to IgG2c and equally 
able to suppress IgE synthesis. Interestingly, 
we found that NALP3 does not influence 
IgG1 levels, whereas decreased levels of this 
subclass were found in the Eisenbarth report 
[14]. This striking difference may be due to 
a different experimental setup, as in their 
study Ab generation was determined after an 
intranasal challenge with OVA [14] whereas 
we boosted mice by injecting OVA i.p. The 
data are most consistent with the notion that 
NALP3-dependent IL-1b production by DCs 
skews the adaptive cellular immune response 
towards a Th2 type of response, as recently 
proposed [25].  
Strikingly, alum adjuvant activates the NALP3 
inflammasome directly in vitro, in agreement 
with two recent reports showing IL-1b 
secretion from alum-treated DCs [14, 24, 28]. 
We have recently found that alum also induces 
high level production of uric acid in vivo 
and that this increased level of uric acid was 
required for the infiltration of inflammatory 
cells [19].  Although how this is done and which 
cells generate or release uric acid upon alum 
administration is an open question, it suggests 
that the increased level of uric acid leads to 
an amplification of NALP3 inflammasome 
activation and, thus, IL-1b.  Interestingly, uric 
acid was identified not only as one of the most 
potent danger signals released from dying cells, 
but also as an excellent adjuvant [29].  Thus we 
propose NALP3 as the newest member of a list 
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of innate receptors that could be exploited for 
the design of new adjuvants. 
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Recent studies have shown that uric acid is an endogenous danger signal released from 
dying cells. Also, during aluminum adjuvant administration, which is used to induce 
Th2 responses, uric acid is released at the site of injection. Prior work has shown that 
uric acid crystals (MSU crystals) activate immune effectors of both the innate and 
adaptive immune system, including neutrophils and CD8+ T cell immunity. However, 
it was unclear whether MSU crystals were involved in CD4+ Th2 cell immunity. Here 
we show that when uric acid is degraded using uricase during aluminum adjuvant im-
munization, all Th2 asthma characteristics are abolished. In addition, MSU crystals 
injected with antigen could induce Th2 responses. MSU crystals have been shown to 
activate the NALP3 inflammasome, but surprisingly the induction of Th2 responses 
by MSU crystals did not depend on the NALP3 inflammasome.  In a more relevant 
asthma model using house dust mite as an antigen, uric acid is released during im-
munization and when degraded with uricase all Th2 asthma features are diminished. 
In conclusion, uric acid does not only stimulate the immune system for a proper anti-
tumor response, but can also sensitize for Th2 responses. Thereby, targeting the break-
down of uric acid in asthmatic patients could be a therapeutic strategy in future. 
Sensing the presence of pathogens or allergens is the first step in mounting an 
effective immune response. Thewideexpression   
of pattern recognition receptors (PRRs) on 
innate immune cells and other structural cells, 
including epithelial cells, is important to allow 
cells to rapidly respond to antigen exposure. 
Toll-like receptors (TLRs) were highlighted 
as the key recognition structures of the 
innate immune system in the past few years 
[1]. TLRs are capable of sensing organisms 
ranging from bacteria to fungi, protozoa, 
and viruses. Some allergens with a protease 
activity, such as house dust mite (HDM) 
extracts [2] can be recognized by protease-     
activated receptors (PAR1–PAR4) [2, 3], but 
can also trigger TLR signaling [4]. However, 
host recognition and response is not restricted 
to TLRs. A second main group of innate PRRs       
is the Nod-like receptor (NLR) family. These 
receptors are located in the cytoplasm and 
include proteins such as NOD1 (nucleotide-
binding oligomerization domain 1), NOD2, 
NALPs (NACHT-, LRR- and pyrin-domain-
containing proteins), IPAF (IL-1b converting 
enzyme-protease activating factor), and NAIPs 
(neuronal apoptosis inhibitor proteins) [5]. 
The intracellular localization of NLRs allows 
the detection of intracellular pathogens, TLR 
ligands, such as flagellin and peptidoglycan 
[6, 7], but also endogenous danger signals 
released from activated or dying cells.  The 
recognition of ligands by NLRs can lead to the 
activation of caspase-1 through the assembly 
of a cytosolic protein complex that is known 
as the inflammasome. Caspase-1 is required 
for the processing and the subsequent release 
of active pro-inflammatory cytokines such as 
interleukin-1b (IL-1b) and IL-18 [8-10]. IL-33, 
a cytokine that is involved in generating a T 
helper 2 (Th2)-cell response, is also cleaved by 
caspase-1 [11].  Therefore, antigen recognition   
by NLRs might influence the outcome of the 
immune response. Notably, polymorphisms in  
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the NLR family have also been linked to Th2 
diseases, like asthma and atopic dermatitis [12-
14]. Although endogenous danger signals can     
signal via NLRs, they can also act independently    
of PRRs. For instance, ATP activates dendritic  
cells to induce Th2-associated responses [15] 
most likely through the purinergic receptor 
P2X7 as already reported for other cell types 
[16, 17]. Recently, EDN (eosinophil-derived 
neurotoxin), an endogenous factor released by 
eosinophils has been shown to promote and/
or enhance Th2 responses via the activation of 
TLR2 [18].
In the present study, we investigated the role of 
the endogenous danger signal uric acid in the 
onset of Th2 sensitization. We have previously 
shown that uric acid is released after injection 
with aluminum hydroxide adjuvant [19]. Here, 
we show that the release of uric acid during 
priming is essential to develop strong Th2 
responses. Furthermore, a Th2 sensitization 
can be achieved by injecting mice uric acid 
crystals either i.p. or directly into the airways.
Material and Methods
Mice
BALB/c mice and C57Bl/6 mice (6–9 wks old) were 
purchased from Harlan (Zeist, The Netherlands). OVA-
TCR Tg mice (DO11.10, BALB/c background) were bred 
at Erasmus University Medical Centre. NALP3-/- and WT 
C57Bl/6 mice (6-10 wks old) were bred at University 
Hospital Gent (Gent, Belgium).  All experiments were 
approved by the animal ethics committee at Gent University 
and at Erasmus University Medical Center.
Alum sensitization
Ovalbumin (OVA) was purchased from Worthington 
Biochemical Corp (Lakewood, NJ). The endotoxin level 
of OVA measured by a limulus-amebocyte lysate assay 
(Biowhittaker, Verviers, Belgium) was <0.001 µg/ml at 
the dosage used in our experiments. Imject-alum (Pierce 
Biochemicals) was mixed at a 1:20 ratio with a solution of 
OVA antigen in saline followed by stirring for at least 1 
hr. For immunization of BALB/c mice, 500 µl of Imject-
alum suspension (1 mg) containing 10 µg of OVA (OVA-
alum) was injected i.p. or alternatively 10 µg of OVA in 500 
µl saline was injected. Mice were boosted with OVA (10 
µg/500 µl) on day 7 and challenged with OVA aerosols (1% 
for 30 min; Sigma, grade III) on day 17-19. 24 hrs after the 
last OVA exposure, blood, bronchoalveolar lavage (BAL), 
mediastinal LN, and lungs were taken. Serum was acquired 
from the blood by centrifugation and stored until further 
analysis at -20ºC. BAL cells were stained as described 
previously [20] and BAL supernatant was stored until 
further analysis. Lungs were frozen and 5-µm sections 
were prepared and stained with periodic acid to visualize 
goblet cell hyperplasia.
To assess the role of uric acid during alum sensitization, 
mice were treated 5 min before injection of OVA-alum 
with 50U of uricase i.p. (Sigma).
Monosodium urate crystal preparation
MSU crystals were prepared as described [21]. Briefly, 
saturated uric acid (5 mg/ml, Sigma) in 0.1M borate 
buffer (pH 8.5) was incubated at room temperature for 48 
hrs. After harvesting the crystals, they were washed with 
alcohol and acetone and air-dried for at least 2 days. 
MSU crystal sensitization
For immunization with MSU crystals, different amounts of 
MSU crystals (1-7.5mg in 500 µl) mixed with 10 µg of OVA 
or 10 µg of OVA in 500 µl PBS was injected i.p.. 24 hrs after 
injection, mice were sacrificed and peritoneal lavage and 
mediastinal LN were isolated.
In experiments where asthma was induced, mice were 
boosted with OVA on day 7 and challenged with OVA 
aerosols on day 17-19. 24 hrs after the last OVA exposure, 
blood, BAL, mediastinal LN, and lungs were taken.
To assess the role of uric acid during sensitization, mice 
were treated 5 min before injection of OVA/MSU (2.5mg) 
with 50U of uricase (Sigma).
For mucosal immunization, MSU crystals were instilled 
intratracheally (500 µg in 80 µl) together with 100 µg of 
OVA (grade V, Sigma) on day 0. Mice were challenged with 
OVA aerosols (1% for 30 min) on day 10-12. 24 hrs after 
the last OVA exposure, blood, BAL, mediastinal LN, and 
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lungs were harvested.
House dust mite sensitization
C57Bl/6 mice were immunized with 40 µl house dust mite 
((HDM) 10 µg, Greer Laboratories) intranasally (i.n.) 
under isoflurane anesthesia on day 0. 24 hrs later BAL fluid 
was taken to asses the amount of uric acid (Amplex Red 
Uric Acid/Uricase assay, Invitrogen). 
To investigate the role of uric acid during immunization, 
mice were treated i.n. with 10U uricase. To induce asthma, 
mice were subsequently challenged from day 7-9 with 40 µl 
HDM (10 µg) i.n. under isoflurane anesthesia. On day 11, 
eosinophilic airway inflammation and bronchial hyper-
responsiveness was assessed.
Effector cytokine production
MLN cells (200,000 cells/well) were resuspended in 
culture medium in 96-well plates with 100 mg/ml OVA 
(Worthington). Four days later, supernatants were 
harvested and analyzed for the presence of cytokines by 
ELISA (IL-4 and IL-5 from eBioscience, IL-10 and IFNγ 
from BD Biosciences, IL-13 from R&D Systems)
Determination of OVA-specific immunoglobulins
Serum samples of mice exposed to OVA aerosols were 
measured for OVA-specific IgG1, IgE, and IgG2a with 
sandwich ELISA.
Determination of broncho-hyperresponsiveness
Twenty-four hrs after the last aerosol (alum sensitization) 
or 48 hrs after the last HDM instillation, invasive broncho-
hyperresponsiveness was determined. 
To measure dynamic resistance and compliance, mice 
were anesthetized with urethane (Sigma), tracheotomized 
with an 18-gauge catheter, paralyzed using 100 µl 
of 0.125% D-tubocurarine i.v. (Sigma), followed by 
mechanical ventilation with a Flexivent apparatus 
(SCIREQ). Respiratory frequency was set at 120 breaths/
min with a tidal volume of 0.2 ml, and a positive end-
expiratory pressure of 2 ml H2O was applied. Increasing 
concentrations of metacholine (0–600 µg/kg BW, Sigma) 
were administered via a catheter in the jugular vein. 
Dynamic resistance (R) and compliance (C) was recorded 
after a standardized inhalation maneuver given every 10 
seconds for 3 minutes. 
Flow cytometric analysis
For innate response, antigen uptake, and DC migration 
studies, 10 μg of OVA-Alexa Fluor 647 ( OVA-AF647; 
Molecular Probes) was mixed with MSU crystals or not, 
injected i.p. or i.t., and detected 24-36 hrs later in the 
peritoneal cavity, mediastinal lymph nodes, or lungs. 
Peritoneal lavage and MLN cells were stained for nine 
color flow cytometry using living (DAPI-negative), Ly6C-
FITC, CD86-PE, CD11c-PE-Texas Red, MHC II-PE-
Cy5.5, Ly6G-PE-Cy7, CD11b-AF700, F4/80-APC-AF750 
(mAbs from BD Biociences and eBioscience), combined 
with uptake of fluorescent antigen OVA-AF647.
Phenotyping of cultured BM-derived DCs was done by 
staining of living (PI-negative) cells with MHC II-FITC, 
CD11c-APC, and in PE CD40, CD80, CD86, ICAM-
1, ICOS-L, PD-L1, PD-L2 or isotype Igs (mAbs from 
eBioscience, BD Biosciences, and Molecular Probes).
For detection of OVA-specific T cell responses, cells were 
gated for living (PI-negative) lymphocytes with CD4-APC 
and the clonotypic anti-OVA TCR antibody KJ1-26-PE.  
Acquisition of 4-color samples was done on a FacsCalibur 
cytometer equipped with Cellquest software (BD 
Biosciences), and 9-color samples were acquired on a 
FACS LSR II cytometer equipped with FacsDIVA software. 
Final analysis and graphical output were performed using 
FlowJo software (Treestar, Costa Mesa, CA). 
Statistical analysis
For all experiments unless stated otherwise, the difference 
between groups was calculated using the Mann-Whitney 
U test for unpaired data (GraphPad Prism version 4.0; 
GraphPad, San Diego, CA). Differences were considered 
significant when p<0.05.
    
Results
Uric acid depletion during OVA-alum 
sensitization inhibits experimental asthma
We have previously reported that the 
sensitization of mice with OVA admixed to the 
adjuvant alum leads to a rapid increase in the 
levels of uric acid in the peritoneal cavity [19]. 
We next wanted to address whether uric acid 
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Figure 1
Degradation of uric acid by uricase during alum sensitization completely abrogated Th2 sensitization and al-
lergic asthma induction
Mice were treated with PBS or uricase 5 minutes before sensitization with OVA or OVA-alum i.p. on day 0. On day 7 all 
mice were boosted with OVA i.p. and on days 17-19 challenged by OVA inhalations. On day 20 mice were sacrificed. 
(A) The cellular composition of the BAL fluid was determined by flowcytometry. (B) Lung sections were PAS stained 
to visualize goblet cell hyperplasia (pink staining). Bar: 100 mm. (C) Bronchial hyperresponsiveness (resistance (R) and 
lung compliance (C)) to metacholine was determined. (D) The BAL fluid supernatant was measured for IL-5. (E) Serum 
levels of OVA-specific Igs were determined with ELISA. (F) Cytokine levels of in vitro restimulated MLN cells. Data are 
shown as mean ± SEM, * p<0.05, **p<0.01, n=4-8 mice/group. Experiments were done twice.
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contributes to Th2 sensitization using a model 
of experimental asthma.  In these experiments, 
Th2 sensitization was achieved following OVA-
alum administration on day 0.  Mice were 
pretreated with PBS or uricase before the OVA-
alum injection, and were challenged with OVA 
aerosols 10 days after the OVA boost on day 
7. Mice pretreated with PBS before OVA-alum 
sensitization developed BAL fluid and lung 
tissue eosinophilia and lymphocytosis (Fig 1A 
and B), as well as goblet cell hyperplasia (Fig 
1B). Moreover, PBS-pretreated OVA-alum 
sensitized mice showed a substantial  Th2 
cytokine production in the BAL fluids and in 
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Figure 2
Intraperitoneal injection of MSU crystals mixed with OVA can induce eosinophilic airway inflammation and Th2 
immunization
Mice were sensitizated with OVA or OVA mixed with different amounts of MSU crystals i.p. on day 0. On day 7 all mice 
were boosted with OVA i.p. and on days 17-19 challenged by OVA inhalations. On day 20 mice were sacrificed. (A) 
The cellular composition of the BAL fluid was determined by flowcytometry. (B) Lung sections were PAS stained to 
visualize goblet cell hyperplasia (pink staining). Bar: 100 mm. (C) The BAL fluid supernatant was measured for IL-5. (D) 
Cytokine levels of in vitro restimulated MLN cells. (E) Serum levels of OVA-specific Igs were determined with ELISA. 
Data are shown as mean ± SEM, * p<0.05, n=4 mice/group. Experiment was repeated twice. 
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mediastinal LN (MLN) cell culture (Fig 1D 
and 1F), associated with high amounts of Th2-
associated IgE and IgG1 in the serum (Fig 1E). 
The pretreatment with uricase before OVA-
alum sensitization prevented the development 
of eosinophilic airway inflammation (Fig 1A 
and B), strongly reduced the levels of Th2 
cytokines in the BAL fluid and in MLN cell 
culture, as well as the levels of IgE and IgG1 
in the serum compared to PBS-pretreated 
OVA-alum sensitized mice (Fig 1D, F). IFNγ 
production in MLN cultures was not affected 
by the uricase treatment (Fig 1F).  Notably, the 
uricase pretreatment of OVA-sensitized mice 
did not significantly affect any of the features 
studies compared to PBS-pretreated OVA-
sensitized animals. 
One of the key features of allergic asthma is the 
development of bronchial hyperresponsiveness 
(BHR) in response to aspecific stimuli, like 
metacholine. BHR was assessed using an 
invasive method to measure resistance and 
lung compliance. At the dose of 600 µg/kg 
BW metacholine, PBS-pretreated OVA-alum-
sensitized mice developed a higher resistance 
and a lower compliance compared to mice 
sensitized with saline or OVA (Fig 1C). When 
mice were pretreated with uricase before the 
sensitization with OVA-alum, the degree of 
bronchoconstriction was similar to the one 
observed in mice sensitized with PBS. 
These data indicate that the degradation of 
uric acid at the time of antigen sensitization 
prevents the development of asthma features.
MSU crystals induce Th2 sensitization and 
lead to asthma development
We next addressed whether uric acid might 
be directly involved in the induction of Th2 
responses by administering monosodium 
urate (MSU) crystals to mice at the time of 
sensitization. OVA was mixed with different 
amounts of MSU crystals or PBS and injected 
i.p. on day 0. The mice received a boost with 
OVA on day 7 and were challenged with OVA 
aerosols 10 days later. 24 hrs after the last 
aerosol the mice were sacrificed. 
Mice immunized with 2 injections of OVA 
admixed to PBS developed a very mild 
inflammation, as indicated by the small 
numbers of eosinophils and lymphocytes in the 
BAL fluid (Fig 2A). Mice injected with MSU 
crystals mixed with OVA showed an increase 
in the number of eosinophils, neutrophils, and 
lymphocytes in the BAL compared to mice 
injected with OVA and PBS. This response was 
dependent on the dose of MSU crystals injected 
and reached its maximum with the dose of 2.5 
mg of MSU crystals (Fig 2A). Also, when lung 
histology was examined of mice sensitized 
with MSU crystals, they developed more goblet 
cell hyperplasia then mice sensitized only with 
OVA (Fig 2B). Moreover, the amount of IL-5 in 
the BAL fluid increased dose-dependent to the 
amount of MSU crystals (Fig 2C). Likewise, 
the cytokine response measured in the MLN 
also shown an induction in the Th2 cytokines, 
like IL-4, IL-5, IL-10 but almost no induction 
of the Th1 cytokine IFNγ could be observed 
(Fig 2D). In addition, the Th2-associated 
immunoglobulins OVA-specific IgE and IgG1 
were also induced when OVA was mixed with 
different amounts of MSU crystals (Fig 2E). 
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MSU crystals promote Th2 sensitization by 
inducing influx of inflammatory monocytes
Having shown that MSU crystals promote Th2 
responses, we next turned our attention to the 
peritoneum and looked at the innate immune 
cells recruited following MSU administration. 
By analogy with other adjuvants such as alum, it 
is possible that MSU crystals are immunogenic 
because of its induction of inflammation at the 
site of injection, thus recruiting APCs to the 
site of Ag exposure [19].  As shown in figure 
3A, the injection of MSU/OVA i.p. induced 
a significant influx of neutrophils to the 
peritoneum compared to mice injected with 
OVA alone (Fig 3A). Furthermore, the number 
of eosinophils, DCs, and Ly6Chigh inflammatory 
monocytes was significantly increased in MSU/
OVA-injected mice compared to OVA-injected 
mice. In the draining mediastinal LN of mice 
injected with MSU/OVA, a marked increase in 
the number inflammatory monocytes loaded 
with fluorescent OVA was observed (Fig 3B). 
This increased number of OVA+ monocytes 
was absent in mice injected with OVA. Also, the 
number of Ly6C- cDCs was increased following 
the injection of MSU/OVA crystals compared 
to OVA alone. The OVA+ monocytes that 
arrived in the MLN after MSU/OVA injection 
were more mature than OVA- monocytes, 
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Figure 3
MSU crystals induce the recruitment of eosinophils and inflammatory monocytes
Mice were injected with OVA-Alexa Fluor 647 (OVA-AF647) or OVA-AF647 mixed with 2.5 mg MSU crystals and 24 
hrs later the peritoneal lavage and draining LN (MLN) were taken. (A) The number of neutrophils (CD11b+Ly6C+ 
Ly6GhighF4/80-), and eosinophils (CD11b+Ly6CintLy6GintF4/80int), conventional DCs (MHCIIhighCD11c+F4/80low), and in-
flammatory monocytes (CD11b+Ly6ChighLy6G-F4/80int) was determined in the peritoneal lavage. (B) The number of 
inflammatory monocytes (CD11b+Ly6ChighLy6G-F4/80int), OVA+ monocytes, and cDCs (MHCIIhighCD11c+F4/80low) in the 
MLN was determined by flowcytometry. Data are shown as mean ± SEM, * p<0.05, n=4 mice/group.  (C) Expression of 
CD11c, MHC II and CD86 on inflammatory monocytes determined by 9-color flow cytometry. Grey filled histograms 
represent the OVA-AF647-negative monocytes, whereas the black line histogram represents the OVA-AF647-positive 
ones. An example is shown of 4 mice.
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as they expressed higher levels of CD86 and 
CD11c (Fig 3C).
Sensitization induced by MSU crystals is 
blocked with uricase pretreatment 
We have shown that MSU crystals, injected 
i.p. into mice, promoted Th2 responses in the 
airways (Fig 1). We next investigated whether 
MSU-induced Th2 sensitization was due to a 
direct effect of the crystals. To address this, 
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Figure 4
Th2 immunization by MSU crystals can be blocked by uricase treatment, but is NOT absent in NALP3-/- mice
BALB/c mice were treated with PBS or uricase 5 minutes before sensitization with OVA or OVA mixed with 2.5 mg 
MSU crystals i.p. on day 0. On day 7, all mice were boosted with OVA i.p. and on days 17-19 challenged by OVA aero-
sols. On day 20 mice were sacrificed. (A) The cellular composition of the BAL fluid was determined by flowcytometry. 
(B) The BAL fluid supernatant was measured for IL-5. (C) Cytokine levels of in vitro restimulated MLN cells. (D) WT 
(C57Bl/6) or NALP3-/- mice were sensitized with OVA or with 2.5 mg MSU crystals mixed with OVA mixed i.p. on day 0. 
On day 7, all mice were boosted with OVA i.p. and on days 17-19 challenged by OVA inhalations. On day 20 mice were 
sacrificed. The cellular composition of the BAL fluid was determined by flowcytometry. (E) Cytokine levels of in vitro 
restimulated MLN cells. Data are shown as mean ± SEM, * p<0.05, n=4 mice/group.
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mice were given uricase i.p. 5 minutes prior to 
the injection of MSU crystals (2.5 mg) admixed 
with OVA. Mice receiving MSU/OVA showed 
an increase in the number of eosinophils and 
in the levels of IL-5 in the BAL compared to 
the control mice injected with PBS (Fig 4A and 
B). The pretreatment of MSU/OVA-injected 
mice with uricase dramatically reduced the 
number of eosinophils and the levels of IL-
5 (Fig 4A and B). Notably, the reduced Th2 
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Figure 5
MSU crystals in the lung break tolerance to OVA
Mice were sensitized with OVA or OVA mixed with 500 mg MSU crystals i.t. on day 0. On days 10-12, all mice were 
challenged by OVA inhalations. Mice were sacrificed on 24 hrs later. (A) The cellular composition of the BAL fluid was 
determined by flowcytometry. (B) Cytokine levels of in vitro restimulated MLN cells. (C) Number of inflammatory 
monocytes present in the lung 36 hrs after PBS or MSU instillation. (D) OVA+ DCs in the MLN 36 hrs after instillation of 
OVA-AF647 or MSU/OVA-AF647. (E) CD86 expression on migratory DCs (MHC II high) in the MLN 36 hrs after PBS or 
MSU (500 mg) instillation. Data are shown as mean ± SEM, * p<0.05, n=4 mice/group. Experiment was done twice.
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response in the airways of uricase-pretreated 
animals was supported by a substantially lower 
Th2 cytokine production in MLN cell cultures 
compared to MSU/OVA-injected mice (Fig 
4C). To address whether the effect of uricase 
was specific, we pretreated mice with uricase 
i.p. 5 minutes before inducing sensitization by 
the i.p. administration of OVA-pulsed DCs. 
In this experiment, the OVA-DC-induced 
eosinophilic airway inflammation and the 
induction of Th2 cytokines was not affected 
by the pretreatment with uricase (data not 
shown).
Sensitization induced by MSU crystals is not 
dependent on NALP3 inflammasome 
MSU crystals have been shown to recruit 
innate immune cells such as neutrophils 
through the activation of the NALP3 
inflammasome. We next sensitized NALP3 
deficient mice with MSU/OVA and examined 
the degree of inflammation. NALP3 deficient 
mice sensitized with MSU/OVA showed an 
increased eosinophilia and lymphocytosis in 
the BAL fluid that was comparable to MSU/
OVA-injected WT mice (Fig 4D). Notably, the 
levels of IL-4 and IL-5 in the MLN cultures 
were increased in NALP3-/- and WT mice 
subjected to MSU/OVA compared to animals 
injected with PBS/OVA (Fig 4E). 
MSU crystals promote Th2 sensitization when 
directly administered in the lungs
As uric acid/MSU crystals can act as danger 
signal [22, 23] and can induce Th2 responses 
upon i.p injection (Fig 1), we next investigated 
whether a local exposure (e.g. in the airways) 
to MSU crystals would be sufficient to 
induce sensitization. To investigate this, mice 
were injected with OVA intratracheally and 
challenged 10 days later with OVA aerosols. 
We have previously shown that this protocol 
does not lead to the development of airway 
inflammation but rather induces tolerance 
[24]. Mice received MSU crystals or PBS, as a 
control, at the time of the i.t administration of 
OVA. Mice sensitized with PBS/OVA showed 
a low number of eosinophils and lymphocytes 
in the BAL fluid (Fig 5A). However, when 
MSU crystals were co-administered with 
OVA, a significant increase in the number of 
eosinophils and lymphocytes was observed. 
The levels of IL-4, IL-5, IL-10, and IL-13 were 
substantially increased in the mediastinal LN 
cell cultures of mice sensitized with MSU/OVA 
compared to mice injected with PBS/OVA (Fig 
5C). 
To better understand how MSU crystals 
can break inhalation tolerance and promote 
Th2 sensitization when given locally in the 
airways, we investigated the changes induced 
early (i.e. 36 hrs) after the administration of 
MSU crystals, and looked at the presence of 
inflammatory cells from the innate immune 
system in the lungs. In the lung, MSU 
crystals induced an increase in the number of 
inflammatory monocytes, direct precursors of 
DCs under inflammatory conditions (Fig 5D). 
Increased Th2 sensitization by MSU/OVA did 
not depend on increased DC migration (Fig 
5E), as equal amount of OVA+ DCs arrived in 
the MLN after i.t administration. However, the 
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DCs that did arrive expressed more CD86 (Fig 
5F).
House dust mite sensitization depends on the 
release of uric acid
To investigate if uric acid played a role in 
a more relevant allergic asthma model, we 
examined the release of uric acid in the BAL 
fluid of house dust mite (HDM) sensitized 
mice. 24 hrs after HDM instillation, an increase 
in the levels of uric acid could be observed in 
HDM-treated mice when compared to PBS-
treated mice (Fig 6A). To examine if uric acid 
was necessary to mount a proper Th2 response 
in response to HDM, mice were treated with 
the uric acid degrading enzyme, uricase, at the 
time of sensitization. When HDM-sensitized 
mice were subsequently challenged with HDM, 
an important influx of eosinophils in the BAL 
fluid and an increased BHR were observed 
(Fig 6B and C). When mice were treated 
with uricase at the time of sensitization, this 
increased eosinophilia and BHR were strongly 
reduced.
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Figure 6
Uric acid plays a key role in the sensitization with house dust mite
(A) Mice were sensitized with HDM or PBS and uric acid levels were determined 24 hrs later in the BAL fluid. (B) Mice 
were sensitized on day 0 with PBS, HDM, or HDM/Uricase and challenged with HDM from day 7-9. On day 11, the BAL 
fluid was examined with flowcytometry. (C) On day 11, BHR of the mice (resistance (R) and lung compliance (C)) to 
metacholine was determined. 
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Discussion
For decades, alum adjuvant has been used to 
induce Th2 responses in experimental mice. 
In a previous study, we have shown that alum 
adjuvant induced the release of uric acid in vivo 
[19]. However, the direct involvement of uric 
acid as the potential inducer of alum-driven 
Th2 responses had not been shown. Here, we 
report that uric acid also accumulates in the 
BAL fluids of mice injected with allergens, 
and that uric acid is necessary and sufficient 
to promote Th2 responses in vivo when 
administered i.p or locally in the airways. This 
allergen-induced increase in uric acid levels 
was functionally relevant since asthma features 
were clearly suppressed when uric acid was 
degraded using uricase. 
The exact cellular source of allergen-induced 
uric acid in vivo is still unknown but it has 
been reported that uric acid can be released 
from stressed and injured cells [22]. Although 
it is known that adjuvants such as alum, or 
environmental triggers such as ozone,  air 
pollutants and respiratory infections induce 
high levels of uric acid likely by inducing high 
levels of stress in cells, we still do not know 
how allergens mediate this production [19, 25-
28]. The excessive levels of uric acid have been 
associated with the development of several 
inflammatory diseases including gout and 
contact hypersensitivity [29, 30]. The levels of   
uric acid are controlled by uricase, an enzyme 
that degrades uric acid in most mammals 
[31]. In humans, however, uricase is absent 
and thus humans might have a low capacity to 
control increases in uric acid, thus leading to 
inflammatory disorders. Notably, we observed 
that exogenously added MSU promotes 
sensitization to inhaled antigen. Inhalation of 
a harmless protein antigen such as ovalbumin 
normally is a tolerogenic event [24], which can 
be turned into robust Th2 priming by adding 
as little as 100 ng of endotoxin, thus triggering 
cDC maturation [32]. Intrapulmonary 
application of MSU together with OVA in naive 
mice similarly potentiated the Th2 response to 
subsequent OVA challenge, suggesting that 
uric acid might work as an adjuvant to enhance 
the immune response, like endotoxin. The 
adjuvant properties of uric acid are in keeping 
with the hypothesis that it can function as 
danger signals that alert the immune system to 
tissue damage [22, 23]. 
Since uric acid promotes Th2 responses in 
vitro, trying to reduce the allergen-induced 
levels of uric acid might be a good approach 
to limit Th2 responses. Here, we show that 
the pretreatment of mice with uricase before 
sensitization with OVA-alum or HDM strongly 
reduced the number of innate immune cells 
recruited to the peritoneum and the subsequent 
development of asthma features. The exact 
mechanism by which uric acid neutralization 
reduces recruitment of inflammatory cells 
requires further study, but uricase might 
likely prevent the production of several pro-
inflammatory chemokines. Indeed, MSU 
promote the early recruitment of neutrophils, 
eosinophils and inflammatory monocytes (Fig 
2, [33]). In addition, it has been reported that 
uric acid can directly activate monocytes and 
neutrophils to produce chemotactic factors 
that recruit other inflammatory cells, and in 
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this way contribute to the amplification of 
the inflammatory response induced by MSU 
crystals [34, 35]. Although we did not formally 
show it, it is tempting to speculate that uricase 
would control the reactivity of inflammatory 
cells to the relevant chemokines, and in this 
way limit the extent of Th2 sensitization.  There 
are also other possible scenarios to explain 
why inflammation is reduced when uric acid 
is blocked, one of them being alteration of 
DC function. DCs are crucial for asthmatic 
inflammation because they recruit Th2 
lymphocytes to the airway wall and trigger 
local Th2 effector cytokine production [36, 37]. 
MSU  crystals have been reported to directly 
activate DCs in vitro and in vivo by increasing 
the expression of co-stimulatory molecules, 
and to promote strong DC-induced T cell 
response [30, 38]. Some of these molecules 
(CD80 and CD86) are necessary to drive 
Th2 differentiation [39]. Alternatively, it has 
been suggested that MSU crystals activate 
caspase-1 and lead to the release of IL-1b and 
IL-18 through the activation of the NALP3 
inflammasome [11, 21, 40]. However, although 
NALP3 deficient mice showed a small 
reduction in the degree of eosinophilia, some 
features of Th2 responses such as the antibody 
production remained intact [38], suggesting 
a NALP3 independent pathway used by uric 
acid. Our data are in line with this possibility 
since Th2 sensitization by MSU crystals only 
partially depended on NALP3 inflammasome 
activation (Fig 4). Other pathways by which 
MSU crystals can activate the immune system 
have also been shown. Liu-Bryan et al. showed 
that the uptake of MSU crystals could be 
mediated by the pattern recognition receptors 
CD14, TLR2, and TLR4 [41, 42]. Notably, we 
previously showed that some effects induced by 
alum adjuvant administration were abolished 
in MyD88-/- mice [19]. Although we did not 
formally address this point, we would like to 
envision the activation of this pathway by 
alum-induced uric acid. 
In summary, we have identified uric acid as an 
endogenous danger signals that can promote 
and contribute to the maintenance of Th2 
responses in the lung. The neutralization of uric 
acid might be of interest to suppress asthmatic 
inflammation.
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The lung contains many subsets of dendritic cells that are distributed in various ana-
tomical compartments.  In homeostatic conditions, a fine-tuned balance exists be-
tween plasmacytoid and myeloid dendritic cells necessary for maintaining tolerance 
to inhaled antigen and avoiding overt inflammation.  These subsets of DCs also play 
important roles in establishment of airway inflammation seen in asthma and chronic 
obstructive pulmonary disease.  Based on these new insights on airway DC biology, 
several approaches that interfere with DC function show potential as new interven-
tion strategies for these ever increasing diseases. 
Obstructive airway disease, broadly divided clinically into asthma or chronic obstructive pulmonary disease (COPD) are a significant cause of morbidity and mortality.  In allergic 
asthma, allergen-specific T helper type 2 (Th2) cells produce key cytokines like IL-4, IL-5 and 
IL-13 that regulate the synthesis of allergen-specific IgE and control tissue eosinophilic airway 
inflammation and remodeling of the airways. In the lungs of COPD patients, predominantly CD8 
lymphocytes and neutrophilic airway inflammation are seen, concomittant with remodeling of 
small airways and destruction of distal air spaces (called emphysema). It is increasingly clear that 
dendritic cells (DCs) are essential for inducing activation and differentiation of not only naive 
but also effector CD4+ T and CD8+ T cells in response to inhaled antigen, and it has been well 
established that these cells play a pivotal role in the initiation and maintenance phase of airway 
inflammation [1]. In this review, we will highlight the recent discoveries in airway DC biology 
with special emphasis on mouse models of asthma and COPD. Where possible, the applicability 
to the human situation and the therapeutic potential of novel findings will be discussed. 
Lung dendritic cell subsets
It has long been established that the various lung compartments (conducting airways, lung 
parenchyma, alveolar compartment, pleura) contain numerous DCs, of which the precise lineage 
or origin have been poorly defined. Recently however, many groups have refined the ways in 
which lung DCs should be studied, both in mouse [2-5] and man [6, 7]. It is clear that different          
DC subsets can be found in the lung, each with functional specialization. In the mouse, all of 
these express the integrin CD11c and subsets are further defined based on the expression of 
the myeloid marker CD11b, as well as anatomical location in the lung.  The trachea and large 
conducting airways have a well developed network of intraepithelial DCs, even in steady state 
conditions.  These cells in some way resemble skin Langerhans’ cells, and have been shown to 
express langerin and CD103 while lacking expression of CD11b [4, 8]. In the submucosa of 
the conducting airways, CD103-CD11b+CD11c+ myeloid DCs can be found particularly under 
conditions of inflammation, and these cells are particularly suited for priming and restimulating 
effector CD4+ T cells in the lung [8, 9]. The lung interstitium that is accessible by enzymatic 
digestion also contains CD11b+ and CD11b- DCs that access the alveolar lumen and migrate to 
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the MLN [2, 5, 10]. It should be noted that this population is however contaminated with DCs 
lining the small intrapulmonary bronchioles as well as those lining the vessel walls. In the nearby 
alveolar lumen, CD11chigh alveolar macrophages control the function of these interstitial DCs. 
Plasmacytoid DCs are CD11b-CD11cint cells expressing SiglecH and bone marrow stromal cell 
Ag-2 (recognized by the moAbs mPDCA-1 or 120G8). In the lungs, pDCs are predominantly 
found in the lung interstitium and produce large amounts of IFNα in response to triggering 
by CpG motifs or viral infection ex vivo [11]. How, where, and by which DC subset inhaled 
antigen is sampled from the airway lumen has been a matter of debate.  Jahnsen demonstrated  
that, analogous to that reported in the gut, a subset of rat airway intraepithelial DCs extend 
their processes into the airway lumen. This ‘periscope up’ function is constitutively expressed 
within the airway mucosal DC population, providing a mechanism for continuous immune 
surveillance of the airway luminal surface in the absence of ‘danger’ signals [12]. In the mouse, 
CD103+CD11b- intraepithelial DCs express the tight junction proteins claudin-1, claudin-7, and 
zonula-2, allowing the sampling of airway luminal contents while keeping the epithelial barrier 
function intact [4].  This subset is also found in the alveolar septa and DCs lining the alveolar wall 
can take up inhaled harmless ovalbumin or bacterial Anthrax spores by forming intra-alveolar 
extensions and migrate to the mediastinal LN in a CCR7-dependent way [5, 8, 10]. It is still a       
matter of debate however whether the uptake and transport of inhaled antigen occurs exclusively 
by alveolar wall DCs, by intraepithelial DCs lining the large conducting airways, or by both 
[2, 5]. Another controversial issue is the location and extent by which plasmacytoid DCs take 
up inhaled antigen.  Two reports describe that within 24-48 hrs following exposure of inhaled 
fluorescently labeled Ag almost 50-60% of pDCs are antigen positive [11, 13], whereas another 
report saw only a minor percentage of Ag uptake in this subset [5].  It remains to be demonstrated 
if pDCs take up antigen in the periphery of the lung and subsequently migrate, whether they get 
their antigen from another migratory DC [14], or whether they take up free afferent lymph while 
resident in the LN. How much antigen crosses the epithelial barrier passively in the absence of 
DC uptake is unknown, but heavily depends on the molecular weight of the Ag, its dose, as well 
as the potential to disrupt epithelial tight junctions. Control of epithelial barrier function could       
be under important genetic control as well, as many of the gene polymorphisms associated with 
atopy in humans control epithelial integrity (e.g. Spink5, S100 family). It is similarly possible that 
Ag uptake by lung pDCs would be facilitated by the presence of Ag specific immunoglobulins 
acting on Fc receptors, thus enhancing endocytosis [15]. 
Outcome of antigen inhalation depends on the functional state of myeloid and 
plasmacytoid DCs
The usual outcome of inhalation of harmless protein antigen in the lungs is immunological 
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tolerance (see figure 1 for a model depicting cellular interactions).  In true sense this means that 
when the antigen is subsequently given to mice in an adjuvant setting (e.g. in combination with 
the Th2 adjuvant alum) it no longers induces an immunological response that leads to effector 
cells causing inflammation [11, 16].  Inhalational tolerance is mediated in part by deletion of Ag 
-reactive T cells as well as induction and/or expansion of regulatory T cells in the mediastinal 
nodes [14, 16-18].  The latter type of tolerance is dominant and can be transferred to other mice 
by adoptive transfer.  Induction of tolerance to inhaled antigen is a function of lung DC subsets 
that migrate from the lung in a CCR7-dependent way [14]. It is often claimed that induction of 
tolerance is a function of ‘immature’ DCs, meaning that these cells lack the expression of high 
levels of MHC, adhesion and co-stimulatory molecules, However, Reis e Sousa recently argued      
that the term ‘mature DC’ should be reserved for those DCs that have the potential to generate 
Fig-
ure 1
Dendritic cell function following inhalation of harmless antigen in homeostatic conditions
When an inhaled antigen reaches the deeper airways and it is not cleared by mucociliary transport or by macro-
phages, it will be taken up by airway dendritic cells.  Both mDCs and pDCs take up antigen.  mDCs seem to do this in 
the periphery, whereas pDCs only do this in the mediastinal node.  In baseline conditions, the mDCs that reach the 
nodes are only partly “mature” and the T cell response that they induce is characterized mainly by division, but not 
by differentiation to effector cells.  Eventually many dividing cells die.  Additionally, mDCs induce Treg cells that sup-
press inflammation.  At the same time, the pDCs control the level of activity of the mDCs so that these cells are kept 
in a quiescent state. This function of pDCs is controlled by Treg control occurring via GITR-GITRL ligand and CLTA4-
CD80/86 interactions. The signals involved are not precisely known but could involve indoleamine 2,3-dioxygenase 
(2,3-IDO), or some surface expressed ligand on pDCs (programmed death ligand-1, PDL1).  The function of mDCs is 
constantly kept in check, amongst others by tonic inhibition by cyclooxygenase-2 (Cox-2) derived prostaglandins 
(PGs), as well as by complement activation acting on the C5a receptor (C5a).  The precise ligand for the class A scav-
enger receptors (MARCO and SR-AI/II) are not known.  
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effector T cells, and that expression of costimulatory molecules by DCs does not exclude the 
possibility that tolerance would be induced [19]. In the lungs, inhaled tolerance is dependent on 
signals delivered by CD86 and/or ICOSL on DCs, supporting this view [17].
Conventional lung DCs (either CD11b+ or CD11b-) are necessary for tolerance induction [14], 
but are also responsible for inducing Th2 sensitization providing there is some form of activation 
(either LPS or TNFα)[20] leading to functional DC differentiation and their capacity to prime Th2 
effector cells (see figure 2 for a model depicting cellular interactions leading to Th2 sensitization 
in the airways). In further support, Th2 sensitization can be induced by adoptive intratracheal 
transfer of GM-CSF-cultured bone marrow DCs, most closely resembling mature monocyte-
derived CD11b+ DCs, but not by Flt3L-cultured bone marrow derived DCs that more resemble the 
immature steady state DCs resident in the lymph nodes and spleen [11].  As activation of lung DCs 
is the common event leading to Th2 sensitization, it is likely that under homeostatic conditions, 
the degree of DC maturation is therefore constantly kept in check.  One such pathway of tonic 
DC suppression seems to involve COX-2 derived prostaglandins or their metabolites, most likely 
derived from nearby alveolar macrophages [21].  Chimeric mice in which the PGD2 receptor DP1 
was selectively deleted on hematopoietic cells demonstrated spontaneous maturation of lung 
cDCs and subsequently, response to harmless antigen were greatly enhanced, suggesting tonic 
inhibition of DC function by PGD2 in the lung [22]. When exposed to selective PGD2 agonists, 
myeloid DCs induced the formation of Foxp3+ Ag specific Tregs that subsequently suppressed 
airway inflammation.  A similar mechanism on DCs was found for stable PGI2 analogues [23, 
24].
When pDCs are depleted from the lungs, inhaled tolerance is abolished, and consequently pDC/
mDC balance is the lung is tightly regulated, amongst others by the cytokine osteopontin as well 
as complement C5a [11, 13, 25, 26].  How exactly pDC depletion leads to sensitization is still 
unsolved, but in vitro and in vivo data suggest that pDCs directly suppress the potential of mDCs 
to generate effector T cells [11, 26]. Plasmacytoid DCs can also stimulate the formation of Treg 
cells, possibly in an ICOS-L dependent way [11, 27].  Tregs expressing GITR could also induce the 
production of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase through reverse 
signaling in pDCs [28]. In mice depleted of pDCs, there was endogenous release of extracellular 
ATP responsible for inducing mDC maturation and Th2 skewing potential.  Th2 sensitization 
to inhaled OVA was abolished when ATP signalling was blocked using the broad spectrum 
P2X and P2Y receptor antagonist suramin. On the contrary, a non-degradable form of ATP was 
able to break inhalation tolerance to OVA [29].  How exactly purinergic receptor triggering on 
DCs promotes Th2 development is unclear at present, but could involve the formation of the 
inflammasome, a multi-protein complex that leads to activation of caspase-1 and processing and 
release of IL-1b, IL-18 and possibly IL-33. The conditions regulating ATP release in the lungs 
will have to be studied more carefully before we can conclude how important the pathway of 
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purinergic signaling is in sensitization to more common allergens, like house dust mite. 
Direct or indirect mechanisms of Th2 sensitization to inhaled antigen
Induction of tolerance or immunity to inhaled antigen by DCs is tightly controlled by signals from 
Figure  2
Model of dendritic cell function during Th2 sensitization 
Several known risk factors for atopy have been shown to interfere with DC function in the airways. Also, several 
experimental models have been developed that have seen sensitization to occur even after inhalation of harmless 
antigens to the lung, providing there is some form of DC activation.  In these models, respiratory tolerance is broken. 
Some models have induced a shift in the pDC/mDC balance, and consequently mDCs induce priming because they 
are no longer suppressed by adequate numbers of pDCs.  Activated mDCs also produce chemokines like CCL17 or 
CCL22 to further attrack Th2 cells into the response. Some adjuvants induce proper activation of mDCs (yet not suf-
ficient to induce IL-12) so that they now induce effector Th2 cells rather than regulatory T cells. Some stimuli, like 
concomittant viral infection, might have an additional effect by inducing maturation of pDCs and their production 
of IFNα. This is a know maturation stimulus for mDCs and in this way, these cells might even contribute to sensitiza-
tion upon viral infections.  Activation of epithelial cells by proteolytic allergens, virus infection, toll like receptor (TLR) 
ligands or air pollutants is an indirect way of activating and polarizing the DC network, through release of thymic 
stromal lymphopoeitin (TSLP) or granulocyte-macrophage colony stimulating factor (GM-CSF) or interleukin-1 (IL-1). 
The precise source and role of endogenous danger signals like ATP, tumor necrosis factor α (TNFα), high mobility 
group box 1 (HMGB1) or uric acid is currently being investigated. 
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alveolar macrophages, Tregs, NKT cells, complement activation, nervous system interactions, 
and epithelial activation.  When studying the literature on particular substances that can break 
inhalation tolerance and induce Th2 priming, one needs to wonder therefore whether a stimulus 
acts directly on mDCs or pDCs or whether its effects are mediated indirectly though modification 
of any of the above interactions. For systemically administered TLR agonists, like endotoxin, the 
activation of DCs occurs mainly through direct recognition by TLR4 expressed on the DC, but 
in epithelia, the response could be clearly different [30].  As an example, low dose endotoxin was 
able to break inhalation tolerance to inhaled OVA by inducing mDC/cDC maturation [20]. These   
effects could be mediated directly via TLR and MyD88-depedent pathways in DCs, but could also 
be mediated via TLRs on bronchial epithelial cells [31]. Bronchial epithelial cells could produce      
chemokines as well as crucial growth and differentiation factors that subsequently attract, activate 
and polarize lung DCs to prime Th2 responses. In this regard, the epithelial cytokines TSLP 
and GM-CSF might be crucial, as their overexpression in the lungs breaks inhalational tolerance 
[32, 33]. On the contrary, neutralization of these cytokines during priming regimens, eliminates             
much of the adjuvant effects of diesel exhaust particles (DEP) [34, 35] or pro-allergic effects of      
house dust mite [36].  Importantly, the production of these cytokines by bronchial epithelial cells 
in response to these triggers might be genetically regulated and this could be the explanation why 
some individuals become primed to inhaled antigen under the right environmental exposure 
[37]. Under some conditions, predictions about sensitizers or adjuvants can be made form in             
vitro experiments. Ambient particulate matter (APM) is ubiquitous in the environment and          
is associated with allergic diseases in inner cities.  In vitro, inhaled APM can act directly on 
human DCs as a danger signal to direct a pro-allergic pattern of innate immune activation 
thus explaining why it acts as an adjuvant [38].  Likewise, DEP induce maturation of human 
DCs indirectly, via promoting GM-CSF production in bronchial epithelial cells in vitro [35]. 
In mice, DEP and APM induce altered DC maturation directly, via nuclear factor-erythroid 2 
(NF-E2)-related factor 2-mediated signaling, implicating oxidative stress in the activation of DCs 
[39]. Whether enhancement of inflammation in Nrf-2 deficient mice, who are hypersensitive to 
oxidative stress, is also the result of overzealous DC activation remains to be shown [40].  Another 
known sensitizer is cigarette smoke.  When given concomitantly with harmless OVA, it induces 
Th2 responses, and this response is associated with enhanced DC maturation and migration [41]. 
DCs developed in a nicotinic environment (nicDCs) fail to support the terminal development 
of effector memory Th1 cells due to their differential expression of costimulatory molecules and 
lack of IL-12 production. In both man and mouse, nicDCs promoted the development of Th2 
responses [42]. As maternal cigarette smoking is a solid risk factor for becoming sensitized in 
early life, it will be important to elucidate how it leads to DC activation (e.g. whether any indirect 
mechanisms acting via epithelial TLR4 contribute) as this might provide novel intervention 
strategies. Another unsolved question is how the nearby nervous endings react to viruses or air 
84
pollution and how this could affect the way DCs react to inhaled allergen.  In this regard, the 
remodeling that occurs in the airway unmyelinated nerves following RSV virus could partly 
explain the subsequent enhanced risk of Th2 sensitization in mice.
Function of dendritic cells in allergic inflammation and tissue remodeling
Not only do DCs play a role in the primary immune response to inhaled allergens, they are also 
crucial during the effector phase of asthma. The number of CD11b+ DCs is increased in the 
conducting airways and lung interstitium of sensitized and challenged mice during the acute 
phase of the response [9, 43, 44]. However, during the chronic phase of the pulmonary response, 
induced by prolonged exposure to a large number of aerosols, respiratory tolerance develops 
through unclear mechanisms.  During this regulatory phase, the number of mDCs as well as their 
costimulatory molecules in the lungs steadily decreased, and this was associated with a reduction 
of BHR, possibly mediated by the action of Treg cells [16, 45, 46].  Inflammation however 
reappeared when mature inflammatory CD11b+ DCs were given [45].  Increased levels of class A 
scavenger receptors (MARCO and SR-AI/II) were found in the lungs of asthmatic mice, possibly 
suppressing DC-driven inflammation. These receptors are expressed on lung macrophages, DCs 
and basophils. Receptor deficient mice had more eosinophilic airway inflammation, BHR, and 
increased migration of DCs to the MLN [47].
The role of mDCs in the secondary immune response was further supported by the fact that their 
depletion at the time of allergen challenge abrogated all the features of asthma, including airway 
inflammation, goblet cell hyperplasia and bronchial hyperresponsiveness [9].  Again the defect 
was restored by intratracheal injection of GM-CSF cultured CD11b+CD11c+ mDCs, most closely 
resembling monocyte derived ‘inflammatory DCs’. The same effects were observed when DCs 
were depleted in the nose in an animal model for allergic rhinitis [48].  It therefore seems that 
inflammatory DCs are both necessary and sufficient for secondary immune responses to allergen. 
Upon allergen challenge, lung DCs upregulate the expression of CD40, CD80, CD86, ICOS-L, 
PD-L1 and PD-L2, particularly upon contact with Th2 cells [9, 11, 43, 44, 49]. Costimulatory 
molecules might be involved in activation of effector T cells in the tissues, or in regulation of Treg 
activity. In allergen-challenged mice, DCs might also be a prominent source of the inflammatory 
chemokines CCL17 and CCL22, involved in attracting CCR4+ Th2 cells to the airways, and in 
producing eosinophil-selective chemokines [26, 44]. In helminth infections, recruitment of Th2 
cells and eosinophils depends on a IL-4/IL-13 responsive bone marrow derived cell, most likely 
a DC or alternatively activated macrophage population [50]. A number of cytokines and innate 
immune response elements control the production of these chemokines. The pro-allergic cytokine 
TSLP induces the production of large amounts of CCL17 by mDCs, thus contributing to the 
recruitment of Th2 cells to the airways, explaining how it may act to enhance inflammation [32]. 
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The complement factor C5a suppresses the production of CCL17 and CCL22 [26].  A similar 
effect was seen with the cytokine IL-17, explaining how it may suppress allergic inflammation 
when given during allergen challenge. In vitro, IL-17 reduced CCL17 production and antigen 
uptake by DCs and IL-5 and IL-13 production in regional lymph nodes in vivo. Furthermore, IL-
17 is regulated in an IL-4-dependent manner since mice deficient for IL-4Rα signaling showed 
a marked increase in IL-17 concentration with inhibited eosinophil recruitment [51].  Emerging 
evidence suggests that IL-4Rα expression on lung DCs is an important feedback mechanism 
through which IL-4 producing cells (effector Th2 cells, eosinophils, basophils) might promote 
further Th2 polarization in ongoing responses [52].
As the number and activation status of lung CD11b+ DCs during secondary challenge seems 
critical for controlling allergic inflammation, studying the factors that control recruitment, 
survival or egress from the lung during allergic inflammation will be important, as this might 
reveal therapeutic targets.  In an elegant study using mixed bone marrow chimeras in which half 
the hematopoietic cells were CCR2-/- and half were CCR2+/+, it was shown by Robays et al. that 
CCR2 (and not CCR5 or CCR6) is crucial for releasing DC precursors from the bone marrow and 
attracting them into allergically inflamed lung.  This was unexpected, as CCR6 is generally seen 
as the chemokine receptor attracting immature DCs into peripheral tissues [53]. Lung mDCs 
use CCR7 ligands and CCR8 for emigration to the draining lymph node, but not the leukotriene 
C4 transporter multidrug-related protein-1 as they do in the skin [54]. Unexpectedly, disruption 
of CCR7 selective chemokines in paucity of lymphocyte T cell (plt) mutant mice, deficient in 
CCL21 and CCL19, airway inflammation and Th2 activity were enhanced [55].  Still, increased 
numbers of mDCs could be found in the draining lymph node of these mice. So, other factors 
than CCR7 ligands are involved in the migration of DCs to the draining LN, including other 
chemokine receptors [54]. Eicosanoid lipid mediators, like prostaglandins and leukotrienes can 
also influence the migration of lung DCs [22]. Leukotriene LTB4 promoted the migration of 
immature and mature skin DCs, but these effects seem to be indirect [56]. It will be important 
to study if well known inducers of LTB4 in the lungs, such as the environmental biopolymer 
chitin, derived from fungi, helminths and insects, also induces DC migration [57].  Additional 
‘druggable’ factors promoting the migration of DCs to the draining mediastinal nodes during 
inflammatory responses could be sphingosine-1-P and extracellular ATP [29, 58].  
In humans, allergen challenge leads to an accumulation of myeloid, but not plasmacytoid DCs to 
the airways of asthmatics, concomitantly with a reduction in circulating CD11c+ cells, showing 
that these cells are recruited from the bloodstream in response to allergen challenge [59, 60]. A 
recent report suggests that pDCs are also recruited into the BAL fluid, but are poor APCs [60]. 
The exact role of pDCs in ongoing allergen specific responses in asthma is currently unknown.  It 
was shown that pDCs accumulate in the nose, but not lungs, of allergen challenged atopics [61]. 
When pDCs were pulsed with pollen allergens, they were as efficient as mDCs in inducing Th2 
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proliferation and effector function [62].  Others have suggested, as in the mouse, that pDCs might 
also confer protection against allergic responses [13].  In children at high risk of developing atopic 
disease, the number of circulating pDCs was reduced.
Dendritic cells as drug targets in allergic diseases
If DCs are so crucial in mounting immune responses during ongoing inflammation in the lung, 
nose and skin, then interfering with their function could constitute a novel form of treatment 
for allergic diseases.  Additionally, pharmacological modification of DCs might fundamentally 
reset the balance of the allergic immune response in favor of regulatory T cells and thus lead 
to a more long lasting effect on the natural course of allergic disease.  Steroids are currently 
the cornerstone of anti-inflammatory treatment in allergic disease. Inhaled steroids reduce the 
number of lung and nose DCs in patients with allergic asthma and allergic rhinitis [63]. Steroids 
might also interfere with a GITRL driven induction of the enzyme indoleamine 2,3-dioxygenase 
(IDO) in plasmacytoid DCs, thus broadly suppressing inflammation [28]. Recently several other 
new molecules have surfaced that may alter DC function in allergic inflammation and thus treat 
disease. Many of these compounds were first discovered by their potential to interfere with DC 
driven Th2 sensitization. The sphingosine-1-P analogue FTY720 is currently used in clinical trials 
for multiple sclerosis and transplant rejection.  When given to the lungs of mice with established 
inflammation, it strongly reduced inflammation by suppressing the T cell stimulatory capacity 
and migratory behavior of lung DCs [58].  Also selective agonists of particular prostaglandin 
series receptors might suppress DC function.  The DP1 agonist BW245C strongly suppressed 
airway inflammation and bronchial hyperreactivity when given to allergic mice by inhibiting the 
maturation of lung DCs [22].  A very similar mechanism was described for inhaled iloprost, a 
prostacyclin analogue acting on the IP receptor expressed by lung DCs [24]. Extracellular ATP 
might be released by platelets upon allergen challenge.  Neutralization of ATP via administration 
of the enzyme apyrase or the broad spectrum P2 receptor antagonist suramin reduced all the 
cardinal features of asthma by interfering with DC function [29]. A specific small molecule 
compound (VAF347) that blocks the function of B cells and DCs was also shown to be effective 
in suppressing allergic airway inflammation in a mouse model of asthma [64].  Finally, specific 
inhibitors of syk kinase were shown to suppress DC function and cure established inflammation 
[65].
A role for dendritic cells in COPD
Several investigators have initiated studies to investigate the role of DCs in COPD. In this 
disorder, inflammation is predominantly rich in neutrophils and CD8+ lymphocytes.  In a model 
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of cigarette smoke exposure, increased numbers of CD11c+ DCs were seen upon sub-acute (5 
weeks) and chronic (6 months) exposure, the increase being explained by increased levels of 
MCP-1 and MIP3α.  Increase numbers of DCs as well as the occurrence of emphysema was 
also seen in SCID mice lacking adaptive immune cells [66].  Lung DCs exposed to cigarette 
smoke produced increased levels of the matrix metalloproteinase MMP12, possibly contributing 
to tissue damage [67]. In support, mice deficient in CCR6, the chemokine receptor expressed on 
pulmonary DCs as well as B cells, had reduced emphysema formation [68]. Studying occurrence 
of emphysema in mice depleted of DCs is less convenient as no models currently exist that allow 
a prolonged depletion of lung DCs in vivo. 
It is possible that this pathway is also operative in COPD patients, as increased numbers of 
DCs were found in the epithelium and adventitia of small airways, correlating with increased 
levels of MIP3α in induced sputum [69]. One report did not find an increase in mucosal DCs 
in smoking asthma patients, suggesting that the increase in DCs might be specific for COPD 
[70]. One striking finding that awaits further study is the discovery that airway smooth muscle 
cells of COPD patients produce more TSLP, a critical DC maturation factor [71].  How exactly 
DCs contribute to initiating or perpetuating airway inflammation and emphysema is still largely 
unknown, further complicated by the fact that the antigen specificity of CD8+ T cells in COPD is 
not known.  Whether DCs also contribute to the occurrence of organized lymphoid tissues seen 
in end stage COPD remains to be studied.
Conclusion
Our understanding of DC biology in the airways has grown considerably.  The concept that 
different subtypes of DCs perform different functions not only during sensitization but also during 
established inflammation is a theme that will persist in the coming years. Slowly, therapeutic 
strategies are emerging from these basic studies in animal models of asthma and COPD, which 
could one day reach clinical application.  However, detailed knowledge of DC biology in human 
airways is still lacking. 
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It was previously shown that administration of recombinant human Fms-like tyrosine 
kinase receptor-3 ligand (Flt3-L) prior to allergen challenge of sensitized mice sup-
presses the cardinal features of asthma through unclear mechanisms.  Here, we show 
that Flt3-L dramatically alters the balance of conventional to plasmacytoid dendritic 
cells (cDC/pDC) in the lung favoring the accumulation of pDCs. Selective removal 
of pDCs abolished the anti-inflammatory effect of rhFlt3-L, suggesting a regulatory 
role for these cells in ongoing asthmatic inflammation. In support, we found that im-
mature pDCs are recruited to the lungs of allergen-challenged mice irrespective of 
rhFlt3-L treatment. Selective removal of pDCs during allergen challenge enhanced 
airway inflammation, whereas adoptive transfer of cultured pDCs prior to allergen 
challenge suppressed inflammation. Experiments in which TLR9 agonist CpG motifs 
were administered in vitro or in vivo demonstrated that pDCs were anti-inflamma-
tory irrespective of their maturation state. These findings suggest a specialized immu-
noregulatory role for pDCs in airway inflammation. Enhancing the anti-inflamma-
tory properties of pDCs could be employed as a novel strategy in asthma treatment.
Allergic asthma is a chronic disease of the airways characterized by bronchial 
hyper reactivity (BHR) to non-specific stimuli, 
chronic eosinophilic airway inflammation, 
goblet cell hyperplasia, and airway structural 
changes in response to a chronic Th2 immune 
response to inhaled antigen, also reflected 
by Th2-dependent increased serum levels of 
allergen-specific immunoglobulin E (IgE) and 
immunoglobulin G1 (IgG1)[1, 2].  
Various forms of (anti-) cytokine therapy have 
been employed in an attempt to suppress allergic 
inflammation, with variable success. One such 
recently described strategy was to administer 
the hematopoietic growth factor Fms-like 
tyrosine kinase receptor-3 ligand (Flt3-L) to 
allergic mice prior to allergen challenge.  In 
these mice, all the cardinal features of asthma 
were abolished [3-5].  The precise mechanism 
of this anti-inflammatory effect has not been 
addressed.  Flt3-L has broad actions in the 
hematopoietic and immune system and was 
shown to selectively enhance the number of 
NK cells and dendritic cells (DCs) in vivo [6, 
7].  A specific subset of DCs induced by this 
cytokine in vivo and in vitro are the so-called 
plasmacytoid (p) DCs, mainly known for their 
function in anti-viral immunity and rapid 
production of type I interferons [8]. It was also 
shown that systemic administration of Flt3-L 
to mice led to an expansion of semi-mature 
lung conventional (c)DCs [9].
The effects of Flt3-L on DCs could be important 
to understand the anti-inflammatory effects of 
this cytokine in asthma. There is evidence for 
distinct roles of cDCs and pDCs in regulating 
T cell mediated adaptive immunity in the lung 
[10, 11]. Inflammatory DCs promote Th2 
sensitization to inhaled antigen after reaching 
the mediastinal lymph nodes [12-14], whereas 
pDCs mediate tolerance to inhaled antigen 
through induction of regulatory T cells [15-
18]. Increasing evidence supports the notion 
that DCs also contribute to ongoing airway 
inflammation beyond the sensitization phase 
of asthma as CD11c-diphteria toxin receptor 
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transgenic mice no longer developed signs 
of asthma when airway DCs were depleted 
during secondary and tertiary challenge with 
antigen [14]. 
In this paper, we show that rhFlt3-L greatly 
enhanced the number of pDCs in the lungs 
of allergen-challenged mice, while reducing 
Th2 associated eosinophilic inflammation. 
Removing pDCs from rhFlt3-L-treated mice 
prior to allergen challenge abolished the 
anti-inflammatory actions of this cytokine. 
These studies also led us to investigate the 
contribution of pDCs in ongoing allergic 
responses to aerosolized antigen. Upon 
allergen challenge of sensitized mice, pDCs 
were recruited to the lungs. Selective removal 
of pDCs using a depleting antibody 120G8 
enhanced inflammation whereas adoptive 
transfer of cultured pDCs suppressed it. These 
effects occurred irrespective of pDC maturation 
state. Our data therefore demonstrate a 
previously unrecognized function of pDCs in 
controlling ongoing allergic inflammation that 
could be exploited for the better design of anti-
inflammatory compounds.  
Material and Methods
Animals
Female BALB/c mice were purchased from Harlan (Zeist, 
The Netherlands). All mice were housed under specific 
pathogen-free conditions and were between 6-8 weeks 
of age at the start of an experiment. All experiments 
were conducted with the approval of the Animal Care 
Committee of Erasmus Medical Center, Rotterdam, The 
Netherlands.
Induction of experimental asthma
Mice were sensitized by two intraperitoneal (i.p.) injections 
of 10 µg ovalbumin (OVA: Worthington) adsorbed onto 1 
mg aluminum hydroxide (alum; Imject, Pierce) in 500 µl 
saline (OVA-alum) on days 0 and 7. Ten days after the last 
injection, the mice were challenged by inhalation of OVA 
aerosols (grade III, 1% wt/vol in PBS (Sigma)) generated by 
a jet nebulizer for 30 min. Depending on the experiment, 
the aerosols were administered between 1 to 7 times on 
consecutive days. 
Treatment of mice with recombinant Flt3-L
Mice were injected with 10 µg recombinant human Flt3-L 
(rhFlt3-L; kindly provided by Amgen) i.p. for 8 days before 
the secondary challenge phase.
Treatment of mice with pDC-depleting antibodies
Mice were treated i.p. with 200 µg monoclonal 120G8 
antibodies (kindly provided by C. Asselin-Paturel, 
Schering-Plough, Dardilly, France; [20]) or as a control 
with 200 µg rat IgG (Sigma). Mice were either injected 
for 3 days on consecutive days starting 1 day before OVA 
challenge or treated also after the OVA challenge on 
alternate days for 3 times (see Fig 3A and C).
Treatment of mice with CpG motifs
Unmethylated CpG motifs (10 µg; ISS-ODN 1680; CpG 
(5’-TGACTGTG-AACGTTCCGAGATGA-3’); Sigma-
Genosys) [53] were administered intratracheally (i.t.) in a 
volume of 80 µl PBS in OVA-alum sensitized mice. One 
day after the i.t. treatment mice were exposed to three OVA 
aerosols (see Fig 5F).
Purification of plasmacytoid dendritic cells (pDCs)
Bone marrow was cultured for 4 days with culture medium 
(CM) supplemented with 200 ng/ml rhFlt3-L and 50 
ng/ml murine rmSCF (Peprotech) in a 6-well plate, at a 
concentration of 1*106 cells/ml. At day 4 of the culture, 
all non-adherent cells were collected, centrifuged and 
placed back into culture with 200 ng/ml rhFlt3-L. On day 
10 of the culture, the cells were pulsed with LPS-low OVA 
(Worthington; LPS contamination of 2.9 ng/mg protein) 
and/or 1 µM unmethylated CpG motifs. On day 11, the 
cells were sorted based on their expression of 120G8, B220, 
CD11c, and CD11b using a FACSAria flow cytometer (BD). 
A purity of ≥96% was obtained. Three days before the start 
of OVA aerosols, 1*106 pDCs were injected intravenously 
via the tail vein (see Fig 4A). 
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Isolation of Broncho-alveolar lavage, lungs, and MLN
Mice were sacrificed by an overdose of 2.5% avertin, 
followed by bleeding. Broncho-alveolar lavage (BAL) was 
performed by inserting a canula in the trachea of the mouse. 
By lavage of 3 x 1 ml PBS containing 0.1 mM EDTA, cells 
were extracted from the lung alveolar space. Lungs were 
either inflated with PBS/OCT for histology or perfused 
with PBS through the pulmonary artery prior to mincing 
them to obtain a single cell suspension as described before 
[54]. To determine the cytokine levels, MLN cells were 
plated in 96-wells round bottom plates at a density of 2*105 
cells per well and re-stimulated with 10 or 100 µg/ml OVA 
for 4 days. After 4 days, supernatants were harvested and 
stored at –20°C until further examination. Using ELISA, 
the amount of IL-4, IL-5, IFNg (all eBioscience), IL-10 (BD 
Bioscience), and IL-13 (R&D Systems) was measured in 
the supernatants.
Flow cytometry of BAL, lung, and MLN
All staining reactions were performed at 4°C. In all staining 
reactions, 2.4G2 Fc receptor Ab (CD16/CD32) was added 
to reduce non-specific binding. Dead cells were excluded 
using propidium iodide and the cellular composition of 
the BAL fluid was determined as described before [55]. 
The BAL, lung, and MLN were furthermore stained for 
DC subsets using 120G8-FITC, B220-PE (RA3-6B2) or 
MHC class II-PE (M5/114; BD Biosciences), and CD11c-
APC (HL3; eBioscience) or CD11b-APC (MAC-1; BD 
Biosciences). In experiments in which the expression of 
the costimulatory molecules was investigated, 120G8-FITC 
and CD11c-APC, and in FL-2 channel CD80-PE (16-10A1; 
BD Biosciences), ICOSL-PE (B7rp1; BD Biosciences), or 
isotype-PE were used.
Histology 
Frozen sections (6 µm) of the lung were stained with 
Periodic Acid Schiff ’s reagent (Sigma-Aldrich) to address 
the amount of inflammation and goblet cell hyperplasia. 
To identify pDCs, immuno-histochemical staining was 
performed on formaldehyde-fixed sections. Endogenous 
peroxidase was blocked with 0.1% NaN3/0.01% H2O2 in 
PBS for 30 min, non-specific binding was blocked with 
10% NGS, and sections were subsequently incubated 
with 120G8, goat-anti-rat Ig-AP, rat-APAAP, hamster 
anti-CD11c, and goat anti–Armenian hamster PO. PO 
was visualized with AEC substrate and AP with Fast blue 
substrate. 
Statistical analysis
For all experiments, the difference between groups was 
calculated using the Mann-Whitney U test for unpaired 
data (GraphPad Prism version 4.0; GraphPad, San Diego, 
CA). Differences were considered significant when 
p<0.05.
Results
Effect of systemic rhFlt3-L administration 
on allergic airway inflammation in OVA-
sensitized mice
It has been shown that administration of Flt3-L 
for 10 days prior to a secondary OVA allergen 
challenge in OVA-sensitized mice suppresses 
the cardinal features of asthma [4].  Using a 
modified protocol, we administered rhFlt3-L 
intraperitoneally for 8 days prior to giving a 
series of three OVA aerosols to OVA-sensitized 
mice (Fig 1A) and focused on dendritic cells 
(DCs). To allow later on comparisons with pDC 
depleting Abs, mice received isotype control 
rat IgG Abs during secondary challenge (see 
below). As expected in OVA-sensitized and -
challenged mice, PBS-treated mice developed 
a strong eosinophilia in the BAL fluid (Fig 
1B) and showed inflammatory lesions around 
the bronchi and the blood vessels in the lung 
(Fig 1C). Challenge with PBS aerosols did not 
induce any changes of airway inflammation 
(data not shown and [13, 19]). The eosinophilic 
inflammation was associated with substantial 
Th2 cytokine production by MLN cells in vitro 
(Fig 1D). Compared with administration of 
PBS, Flt3-L treatment strongly suppressed 
eosinophilic and lymphocytic airway 
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Figure 1
Effect of Flt3-L treatment is dependent on pDCs
(A) Mice were sensitized by 2 i.p. injections of OVA-alum on days 0 and 7. Seven days after the last injection, the 
mice were treated with 8 injections of rhFlt3-L (10 mg i.p.) or with PBS as a control. 3 days after the last rhFlt3-L injec-
tion, mice were treated with mAb 120G8 or rat IgG (200 mg i.p.). Thereafter, mice were subjected to 3 OVA aerosols. 
(B) Inflammation was analyzed in the BAL with flow cytometry. (C) A PAS staining was done on lung slides (50x 
magnification) to visualize goblet cell hyperplasia. (D) Cytokine production in the supernatants of MLN cells 4 days 
after restimulation with OVA in vitro. (E) Lung slides were stained for DCs (in blue 120G8 and red CD11c). pDCs were 
double positive for 120G8 and CD11c, whereas cDCs are positive for CD11c. (F)  Gating strategy for pDCs and cDCs 
on lung cells. pDCs are depicted as small cells, 120G8+, and CD11cint. cDCs are shown low autofluorescence, MHC II+, 
CD11c+. An example is shown of a rhFlt3-L-treated mouse. (G) Number of pDCs and cDCs were determined lung by 
flow cytometry. Results are expressed as mean ± SEM for n=5-6 mice/group. Experiment was repeated twice.
A
B C
Time schedule Flt3L treatment before secondary response:
0 7 24 25 26 27
IgG / 120G8 
OVA aerosol
OVA-alum
28
S
14 15 16 17 18 19 20 21
PBS / Flt3L treatment
Eo
sin
op
hil
s
Ne
utr
op
hil
s
Ly
mp
ho
cy
tes
Ma
cro
ph
ag
es
0
100000
200000
300000
400000 *
*
*
*
N
um
be
r 
of
 c
el
ls
PBS/IgG Flt3L/IgG Flt3L/120G8
D
PBS/IgG
Flt3L/IgG
Flt3L/120G8
PBS/IgG Flt3L/IgG Flt3L/120G8
E
F
cDC gating
MHC II
C
D
11
c
PI
FSC
SS
C
CD11c
12
0G
8
pDC gating G
0
1000000
2000000
3000000
4000000 *
PBS / IgG / PBS aerosol
PBS / IgG / OVA aerosol 
Flt3L / IgG / OVA aerosol
Flt3L / 120G8 / OVA aerosol
N
um
be
r 
of
 c
D
C
s
0
1000000
2000000
3000000
4000000 ** *
*Nu
m
be
r 
of
 p
D
C
s
IL-5 IL-10 IL-13
0
5000
10000
15000
20000
25000
30000
35000
**
***
C
yt
ok
in
es
 (p
g/
m
l)
0
200
400
600
800
1000
****
PBS/IgG
Flt3L/IgG
Flt3L/120G8
PI
FSC
98
inflammation as assessed by BAL fluid analysis 
(Fig 1B), tissue infiltration of eosinophils 
and goblet cell hyperplasia (Fig 1C). Upon 
rhFlt3-L treatment, the levels of IL-13 and 
IFNg, but not IL-5 or IL-10 were reduced. In 
view of the known alteration of DC numbers 
by Flt3-L, we determined the number and 
assessed the phenotype of lung DC subsets in 
OVA-sensitized and -challenged mice, treated 
with rhFlt3-L or not. On lung histology, we 
identified a clear increase in the number of 
CD11c+ cells in the lung interstitium of mice 
receiving Flt3-L, and a significant proportion 
of these cells also expressed the marker bone 
marrow stromal antigen-2, recognized by the 
monoclonal 120G8 Ab, consistent with a pDC 
phenotype [20] (Fig 1E).  To more carefully 
address the precise subset of DC induced, we 
confirmed the presence of pDCs and cDCs in 
lung tissue using flow cytometry. Plasmacytoid 
DCs in the lung were identified based on live/
dead discrimination, small size, intermediate 
expression of CD11c and expression of 120G8 
marker, as previously described (Fig 1F) [21] 
[15], whereas conventional DCs were identified 
based on lack of auto-fluorescence and strong 
expression of CD11c and MHC II [22] (Fig 
1F).  OVA challenges in OVA-sensitized mice 
increased the number of pDCs and cDCs in the 
lungs compared to PBS challenges (Fig 1G). In 
OVA-challenged mice, rhFlt3-L treatment led 
to a further substantial and selective increase in 
the number of pDCs compared to PBS-treated 
OVA-challenged mice. (Fig 1G). 
To study whether the selective increase in 
pDC number in rhFlt3-L-treated mice was 
responsible for the associated reduction in 
airway inflammation, we injected the pDC 
depleting 120G8 Ab or control rat IgG Abs into 
Flt3-L-treated mice [15, 20] at the time of OVA 
challenge (Fig 1A). Through this treatment, 
the increase in number of pDCs in the lungs 
of Flt3-L-treated mice could be prevented (Fig 
1G), whereas it had no effect on the number of 
cDCs. Furthermore, airway inflammation was 
completely restored, as seen in eosinophilic 
and lymphocytic recruitment to the lung 
interstitium (Fig 1B) and goblet cell hyperplasia 
(Fig 1C). Also, cytokine levels produced by 
MLN cells were restored to the levels produced 
by PBS-treated OVA-challenged mice (Fig 1D). 
These data clearly demonstrate that the anti-
inflammatory effects of Flt3-L are in a large 
part mediated by pDCs.
Effect of OVA aerosol challenge on the number 
of pDCs in OVA-sensitized mice
We next addressed if the number of pDCs in 
the lung would also be affected during airway 
inflammation in the absence of Flt3-L treatment. 
In these experiments, OVA-sensitized mice 
were subjected to different numbers of OVA 
aerosols (Fig 2A). As expected the degree of 
eosinophilic inflammation increased with 
increasing numbers of OVA aerosols (Fig 2B). 
Previous work by van Rijt et al [19] reported 
that different number of PBS aerosols did 
not change the composition of the BAL fluid. 
Therefore, as a control, mice were only exposed 
to the maximum number of PBS aerosols. 
The number of pDCs in the BAL fluid of 
allergic mice was increased up to 7 times with 
increasing numbers of aerosols (Fig 2C). The 
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increase in cDC numbers in the BAL followed 
the same trend as for pDCs. We next looked 
whether the level of maturation of pDCs and 
cDCs would be affected by increasing numbers 
of OVA aerosols. In the BAL fluid, lungs, and 
MLN of OVA-challenged mice, pDCs showed 
no increase in the expression CD40, CD80, 
CD86, MHC II, PD-L1, PD-L2 or ICOS-L. 
However, we could observe an upregulation 
of costimulatory molecules (CD40, PD-L2) on 
cDCs in the BAL as previously reported ([14] 
and data not shown).
Effect of selective removal of pDCs on 
OVA-induced airway inflammation in OVA-
sensitized mice
As OVA-induced airway inflammation 
caused an increase in the number of pDCs, 
we wondered what effect depletion of pDCs 
would have on the severity of eosinophilic 
inflammation. To address this point, we 
depleted pDCs using 120G8, administered 
at the time of challenge (Fig 3A). Injection of 
120G8 Abs decreased the number of pDCs 
in most organs by 80-90%, and the effect of 
120G8 administrations was observed for at 
least 4 days after the last injection (data not 
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Effect of OVA aerosol challenge on pDC numbers in the BAL 
(A) Mice were sensitized by 2 i.p. injections of OVA-alum on days 0 and 7. Ten days after the last injection, they were 
subjected to either 7x PBS, 1x, 3x, or 7x OVA aerosols. (B) Inflammation in the BAL fluid of PBS aerosolized mice (white 
bars) or mice subjected to 1 (black bars), 3 (light shaded bars) or 7 OVA aerosols (dark shaded bars). (C) The number 
of pDCs (white bars) and cDCs (black bars) in the BAL fluid. Results are expressed as mean ± SEM for n=4 mice/group, 
*p<0.05. Similar results were obtained in two different experiments.
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shown). As expected in OVA-sensitized and 
–challenged groups, mice injected with rat 
IgG control Ab developed eosinophilic airway 
inflammation (Fig 3B, D) and showed a Th2 
cytokine profile in the draining MLN (data not 
shown). In mice depleted of pDCs by injection 
of 120G8 Ab, the number of eosinophils in the 
BAL was increased 24 hrs and 4 days after the 
last aerosol (Fig 3B). Seven days after the last 
challenge, the eosinophilia in the BAL fluid was 
no longer different between the groups, and the 
inflammation was completely resolved by day 
14 after the last challenge (data not shown). 
The fact that at day 7 after the last aerosol, 
airway inflammation was no longer different 
between 120G8 Ab- and rat IgG-treated mice 
could suggest that pDC depletion was no 
longer complete during the resolution phase 
of airway inflammation. Therefore, mice 
were additionally given 120G8 Ab during the 
resolution phase (Fig 3C). Mice treated with 
rat IgG throughout challenge and resolution 
still demonstrated a strong BAL lymphocytosis 
and eosinophilia 7 days after the last aerosol 
exposure (Fig 3D, white bars), accompanied 
by Th2 cytokine production by MLN cells 
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Figure 3
pDCs are important in regulat-
ing inflammation in the sec-
ondary response
(A) Mice were sensitized by 2 i.p. 
injections of OVA-alum on days 
0 and 7. Ten days after the last 
injection, they were subjected 
to 3 OVA aerosols. During or 
after the challenge, mice were 
treated with the 120G8 Ab or rat 
IgG (200 mg i.p.) as a control. (B) 
Inflammation in the BAL fluid 
was determined by flow cytom-
etry. (C) Mice were treated dur-
ing challenge and during the 
resolution phase with 120G8 
or rat IgG (200 mg i.p.). (D) BAL 
inflammation was determined 
by flow cytometry. White bars 
represent the rat IgG-treated 
OVA challenged mice, the black 
bars the OVA challenged mice 
treated with 120G8 during chal-
lenge, and the grey bars OVA 
challenged mice treated with 
120G8 during challenge and 
resolution. Results are expressed 
as mean ± SEM for n=4-6 mice/
group, *p<0.05, **p<0.01. Simi-
lar results were obtained in two 
different experiments.
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(data not shown). In mice depleted of pDCs 
only during challenge (black bars), the number 
of inflammatory cells in the BAL fluid was 
not different from this response. However, in 
mice depleted of pDCs during the challenge 
and resolution phase, the degree of airway 
inflammation was again dramatically increased 
(Fig 3D, grey bars). 
Effect of exogenous pDC administration on 
OVA-induced airway inflammation in OVA-
sensitized mice
Since depletion of pDCs during the secondary 
response altered the inflammatory response 
(Fig 3), and the anti-inflammatory effect 
of Flt3-L was pDC-dependent (Fig 1), we 
examined if ex-vivo cultured pDCs would 
also have an effect on airway inflammation. 
Mice were injected with bone marrow (BM)-
derived pDCs 3 days before submitting them 
to OVA aerosols (Fig 4A). As expected in OVA-
sensitized and -challenged mice not injected 
with pDCs, lymphocytosis and eosinophilia 
was observed in the BAL (Fig 4B) and Th2 
cytokine production by MLN cells (Fig 4C) 
was induced. A strong decrease in the number 
of BAL fluid eosinophils and lymphocytes 
was observed in pDC-injected mice (Fig 4B). 
This decrease occurred irrespective of whether 
pDCs were pulsed in vitro with OVA or not. 
The administration of pDC had no effect on 
the levels of Th2 cytokines produced by MLN 
cells (Fig 4C). 
Effect of pDC maturation state on their 
capacity to control airway inflammation
Since endogenous and exogenous pDCs can 
suppress allergen-induced eosinophilic airway 
inflammation (Fig 1, 3 and 4), we next studied 
if this effect was dependent on their maturation 
status. BM-derived pDCs were exposed to 
unmethylated CpG motifs (ISS ODN 1680) in 
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Effect of exogenous pDCs in the secondary response 
of lung inflammation
(A) Mice were sensitized by 2 i.p. injections of OVA-alum 
on days 0 and 7. Three days before the first aerosol, mice 
received 1*106 pDCs i.v.. (B) Inflammation of the BAL 
was analyzed. White bars represent mice receiving PBS, 
black bars mice receiving unpulsed pDCs, and shaded 
bars OVA-pulsed pDCs before challenge. (C) Cytokine 
levels in the supernatants of MLN cell cultures re-stimu-
lated in vitro with OVA for 4 days. Results are expressed 
as mean ± SEM for n=4-6 mice/group, *p<0.05. Similar 
results were obtained in two different experiments.
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vitro, before injecting them into mice. pDCs 
exposed to CpG showed an up regulation of 
CD80 (Fig 5A), CD40, CD86, ICOS-L, and 
MHC II (data not shown) [23, 24]. When 
injected, fully mature pDCs pulsed with OVA 
and CpG were as efficient as immature OVA-
pulsed pDCs or unpulsed pDCs in reducing the 
number of inflammatory cells in BAL fluids (Fig 
5B). These data show that cultured pDCs are able 
to dampen airway inflammation irrespective of 
their degree of maturation. We next addressed 
whether endogenous maturing pDCs exposed 
to CpG motifs in vivo would have the same 
capacity. Direct instillation of unmethylated 
CpG motifs in naive mice induced a rapid and 
massive increase in the number of pDC in the 
lungs compared to PBS instillation (Fig 5C/D). 
In mice injected with CpG motifs, lung pDCs 
showed a mature phenotype as assessed by the 
upregulation of CD80 and ICOS-L compared 
to pDCs of mice injected with PBS (Fig 5E). 
It has been shown by others that instillation 
of CpG motifs in sensitized animals before 
subjecting them to OVA aerosols led to a 
marked decrease in eosinophilic inflammation 
[25-28]. In support, we also observed a decrease 
in airway inflammation and Th2 cytokine 
profile following local CpG motif treatment 
(Fig 5H). Similar to the effects of CpG motifs 
in naive mice, the lungs of CpG motif-treated 
OVA-challenged mice (CpG/IgG) showed an 
increase in the number of pDCs compared to 
PBS-treated OVA-challenged mice (Fig 5G). 
To address a role for pDCs in the CpG motif-
induced reduction in airway inflammation, 
mice were concomitantly treated with CpG 
motifs and 120G8 Abs (Fig 5F). The increase 
in pDC number by CpG motif instillation was 
neutralized by 120G8 treatment (Fig 5G). A 
partial restoration of the airway eosinophilia 
could be observed when pDCs were depleted 
in CpG motif-treated mice (Fig 5H).  This 
could also be seen in the cytokines, like IL-5 
produced by MLN cells (Fig 5I).
Discussion
Several key findings in this paper point to an 
intrinsic anti-inflammatory role for pDCs in 
eosinophilic airway inflammation in allergically 
Figure 5
Mature pDCs are still able to dampen eosinophilic inflammation
(A) CD80 expression of BM-derived pDCs after 20 hrs pulse with OVA (100 mg/ml) with or without CpG (1 mM). (B) 
Inflammation was analyzed in the BAL of mice treated i.v with PBS (white bars), 1*106 unpulsed pDCs (black bars), 
OVA-pulsed pDCs (light shaded bars), or OVA and CpG motif-pulsed pDCs (dark shaded bars). (C) Mice were injected 
i.t. with 10 mg CpG motifs or PBS, lungs were analyzed 48 hrs later for pDCs and cDCs. A typical example is shown 
of the lungs stained with 120G8 and CD11c. (D) Number of pDCs in the lung of CpG-motif-treated mice (black bar) 
or PBS-treated mice (white bar), analyzed with flow cytometry. (E) CD80 and ICOS-L expression of lung pDCs in vivo 
48 hrs after i.t. instillation of CpG (10 mg) (open histogram) or PBS (shaded histogram). (F) Mice were sensitized by 
2 i.p. injections of OVA-alum on days 0 and 7. Nine days after the last injection, the mice were treated i.t. with CpG 
(10 mg) or PBS. Thereafter, they were subjected to 3 OVA aerosols. During i.t. instillation, mice were also treated with 
either moAb 120G8 or rat IgG (200 mg i.p.). (G) The number of pDCs was examined in the lungs by flow cytometry, 
1 day after the last challenge. The white bar represents the PBS-treated OVA-challenged mice, the black bar CpG-
motif/IgG- treated OVA-challenged mice, and the grey bar the CpG motif/120G8-treated OVA-challenged mice. (H) 
Inflammation in the BAL analyzed with flow cytometry. (I) Cytokine levels in the supernatants of MLN cell cultures re-
stimulated in vitro with OVA for 4 days. Results are expressed as mean ± SEM for n=4-6 mice/group, *p<0.05. Similar 
results were obtained in two different experiments.
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sensitized mice.  First, pDCs are recruited to 
the airways of allergen challenged mice with 
kinetics similar to other inflammatory cells. 
Second, their removal using a specific pDC 
depleting antibody enhances inflammation and 
prevents the resolution of inflammation once 
allergen challenge is stopped. Finally, increasing 
the numbers of pDCs through adoptive transfer 
of cultured pDCs, or expansion of endogenous 
pDCs by administration of Flt3-L dampens 
inflammation. 
In previous studies, Flt3-L was shown to 
suppress all the cardinal features of asthma in 
models of experimental airway inflammation 
[3, 4]. In this study, we specifically set out to 
study the mechanism of this anti-inflammatory 
effect. Systemic administration of Flt3-L is 
known to expand the number of NK cells, 
conventional DCs (cDCs), and plasmacytoid 
DCs (pDCs) in vivo [6, 7]. All of these cell 
types have been implicated in the pathogenesis 
of asthma.  Although we did not directly test 
the effect of Flt3-L on lung NK cell distribution 
or function in asthma, it is unlikely that the 
anti-inflammatory effects of Flt3-L were caused 
by NK cell alterations.  Korsgren et al. have 
previously shown that depletion of NK cells in a 
very similar model of asthma decreased disease 
severity, suggesting that it is a pro-inflammatory 
player in this disease [29].  We therefore favor 
the hypothesis that the effects of Flt3-L were 
due to alterations in DC homeostasis. DCs 
are thought to be the most important antigen 
presenting cells that determine the outcome 
of allergen inhalation in the lung [11]. 
Inflammatory dendritic cells (iDCs) are held 
responsible for inducing Th2 sensitization to 
inhaled antigen and are similarly crucial for the 
establishment of secondary immune responses 
to inhaled allergen in allergen-sensitized mice 
[12, 14, 19].  As administration of cDCs to mice 
exacerbates the severity of the disease, and their 
depletion ameliorates disease [14], it is unlikely 
that Flt3-L would have its anti-inflammatory 
effects via increasing the number and/or 
function of this subset. We hypothesized that 
it is predominantly through the recruitment of 
pDCs that Flt3-L suppresses inflammation. In 
support of this hypothesis, we have previously 
reported that pDCs play an essential role 
in maintaining tolerance in the lung when 
naive mice were exposed to harmless inhaled 
antigens [15]. The critical involvement of DCs 
in promoting or dampening inflammation has 
been reported in several other models, in which 
also viral antigens were used [30-35]. However, 
these experiments were done in the context of a 
primary immune response as pDCs were given 
or depleted at the time of sensitization. In the 
present paper, we show that pDCs, like cDCs, 
play a role beyond the sensitization phase. 
Flt3-L treatment given before the secondary 
challenge induced a massive recruitment 
of pDCs, accompanied by a suppression of 
eosinophilic airway inflammation. Importantly, 
this pDC recruitment was necessary for the 
anti-inflammatory effect, as removal of pDCs 
using the specific pDC depleting Ab 120G8 
restored airway eosinophilia and Th2 cytokine 
levels in draining nodes. 
The exposure of OVA-sensitized mice to 
OVA aerosols resulted in a Th2-dependent 
airway eosinophilic inflammation and in the 
recruitment of cDCs and iDCs to the lung 
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and the broncho-alveolar lavage, as already 
reported [14]. Interestingly, the number of 
pDCs was also increased following OVA 
challenges, and correlated with the degree of 
airway inflammation. Again, the function of 
these cells was to dampen inflammation as 
120G8 treatment exacerbated the degree of 
immuno-pathology. How pDCs are recruited 
to inflamed airways is still unclear but could 
involve several inflammatory mediators 
[36]. Indeed, inflammatory chemokines 
such as CCL2 (MCP-1), CCL3 (MIP1α), 
CCL5 (RANTES), CCL12 (MCP-5), CXCL10 
(IP10), CXCL12 (SDF-1) and are upregulated 
in allergic lungs [37] and pDCs express the 
receptors for most of these chemokines (CCR1, 
CCR2, CCR5, CCR7, CXCR3, and CXCR4 
[38-40]).  A second possibility would be the 
involvement of ChemR23, a receptor involved 
in DC migration and expressed on pDCs [41]. 
Its ligand, chemerin, is found in inflammatory 
fluids [42], but more importantly directs pDC 
migration to inflamed tissues [41, 43]. Whether 
chemerin is expressed in the lungs after 
repeated exposures to OVA aerosols remains to 
be established. Alternatively, DC subsets might 
be recruited to the airways by osteopontin, a 
cytokine involved in autoimmune and allergic 
diseases. Osteopontin is increased in BAL fluids 
of OVA-sensitized and challenged mice, but has 
the potential to dampen airway inflammation 
and BHR, and interestingly contributes to pDC 
recruitment during allergic responses [33]. 
Increasing pDC numbers at the site of allergic 
airway inflammation may be part of an 
inherent protective mechanism, as suggested 
by the fact that the disease was exacerbated 
following removal of these cells at the time of 
challenge, and by the fact that administration of 
pDCs prior to secondary challenge diminished 
the severity of inflammation. One striking 
observation was the fact that prior to adoptive 
transfer, pDCs did not have to be pulsed with 
OVA antigen for the suppressive effect to 
occur.  This is in contrast to the situation in 
naive mice, where pDCs had to be pulsed with 
OVA antigen for prevention of alum-induced 
sensitization, as previously reported by our 
group [15].  The most likely explanation is that 
in sensitized mice, unpulsed pDCs acquired 
and processed inhaled antigen delivered via 
aerosol exposure.  In already sensitized mice, 
the uptake of OVA could be facilitated by the 
presence of OVA-specific immunoglobulins, as 
previously reported for human pDCs [44] and 
our unpublished data suggest. 
How pDCs exert their suppressive functions 
in vivo still remains to be elucidated. There 
is evidence showing that pDCs can down-
modulate immune responses by directly 
interfering with effector T cell function, 
by inhibiting cDC function or by inducing 
regulatory T cells [17]. Increasing regulatory 
T cells numbers and functions during the 
secondary phase is a strategy to inhibit airway 
inflammation [45-47]. We have previously 
reported that immature lung OVA-pulsed 
pDCs could induce regulatory T cells when 
co-cultured with naive CD4+ T cells [15]. 
One way by which pDCs might promote the 
formation of regulatory T cells, is their poor 
expression of co-stimulatory molecules.  In 
our experiments, the instillation of CpG motifs 
strongly reduced airway inflammation, similar 
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to previous reports [25-27]. The explanation 
for this effect has been the inhibition of both 
Th2 cell activation and IgE-mediated cytokine 
induction [28]. In our paper, we show not 
only that the effect induced by CpG motifs 
was partially mediated by pDCs but also 
that the degree of maturation of these pDCs 
did not seem to influence their suppressive 
effect. Indeed, CpG motif-exposed pDCs, 
although very mature, were still very potent at 
suppressing eosinophilic airway inflammation 
in vivo. Recently, Gilliet’s group demonstrated 
that mature CpG motif-pulsed pDCs were able 
to induce the generation of IL-10-producing 
regulatory T cells via the ICOS/ICOS-L 
pathway [16, 48]. Interestingly, in mice instilled 
with CpG motifs, pDCs in the lung upregulated 
ICOS-L.  It is tempting to speculate that CpG 
motif-exposed pDCs exert their function in the 
lung by increasing regulatory T cell numbers 
in an ICOS-L dependent way.  Certainly, when 
CpG motif-matured pDCs were co-cultured in 
vitro with CD4+ T cells, we could observe an 
increased number of Foxp3+ T cells, consistent 
with the phenotype of regulatory T cells (data 
not shown). However, ICOS-L-/- pDCs in our 
asthma model could still reduce eosinophilic 
airway inflammation (data not shown), so 
their suppressive capacity does rely on ICOS-
ICOSL interactions. It is however noteworthy 
that pDCs are still able to induce regulatory 
T cells when mature, whereas cDCs drive the 
generation of IL-10–producing regulatory T 
cells only when they are immature and lose 
this ability upon maturation [49, 50]. This 
difference may suggest a specialized role for 
pDCs in immuno-regulation during allergic 
airway inflammation. 
Another mechanism that might be used by pDCs 
to suppress eosinophilic airway inflammation 
would be to down-regulate the function of 
cDCs [17]. cDCs are known to be critical in 
the maintenance of airway inflammation as 
their removal at the time of challenge reduced 
the features of asthma [14]. Moreover, cDCs 
of allergen-sensitized and -challenged animals 
selectively produce CCR4 ligands CCL17 
(TARC) and CCL22 (MDC) as a means to 
recruit Th2 cells to sites of inflammation 
[17, 51]. Kohl et al elegantly showed that 
in conditions where the cDC/pDC ratio is 
shifted to pDCs, the levels of MDC and TARC 
were decreased [17]. This might offer a likely 
explanation as to why Th2-dependent airway 
inflammation is decreased when the number of 
pDCs is increased in the airways. Alternatively, 
pDCs stimulated with unmethylated CpG 
motifs are a major source of IFNα. There is 
evidence that IFNα can block the recruitment 
of eosinophils and CD4+ T cells to the site of 
inflammation [52]. In an attempt to pinpoint a 
role for this cytokine in the suppressive effect 
induced by pDCs, the type I IFN receptor was 
blocked using specific antibodies at the time of 
pDC administration i.e. before the secondary 
challenge. No differences in terms of degree 
of airway inflammation were found between 
anti-IFN receptor mAb and isotype treated 
allergic mice (unpublished data), ruling out 
a role for this cytokine in the pDC-induced 
suppression. 
In conclusion, our paper provides definite 
proof that pDCs serve an anti-inflammatory 
role during eosinophilic airway inflammation 
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irrespective of their maturation state. The 
therapeutic effectiveness of Flt3-L on airway 
inflammation validates the concept that 
enhancing pDC functions during established 
airway inflammation could be a potential new 
strategy for the treatment of asthma. 
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Dendritic cells (DCs) are the most potent antigen presenting cells. There are different 
subsets of DCs, that each has a different capacity to present exogenous and endog-
enous antigens to either CD4+ or CD8+ T cells. However, how and when murine plas-
macytoid (p) DCs present exogenous antigen to either CD4+ or CD8+ T cells is cur-
rently not clear. Is this study we investigated the capacity of pDCs to induce CD4+ or 
CD8+ T cell responses in vitro. Plasmacytoid DCs can present exogenous antigens to 
CD4+ and CD8+ T cells, providing they have been stimulated properly or took up the 
antigen in the proper context. Simultaneous or sequential activation with the TLR9 
agonist CpG motifs and exogenous antigen to pDCs made them capable of inducing 
CD8+ or CD4+ T cell proliferation. CD4+ T cell proliferation could also be induced 
when pDCs were exposed to exogenous antigen in the presence of antigen-specific 
immunoglobulins. In conclusion, pDCs can act as proper antigen presenting cells as 
long as they are in the appropriate milieu.
Adaptive immunity requires activation of T lymphocytes by dendritic cells 
(DCs) which present antigen bound by major 
histocompatibility complex (MHC) molecules. 
‘Endogenous’ antigens (Ag) that are synthesized 
intracellularly (for example those of viral 
or tumor origin) are presented by MHC I 
molecules and activate CD8+ cytotoxic T cells. 
In contrast, ‘exogenous’ (extracellular) Ag that 
gain access to the cell via an endosomal route 
are presented by MHC II molecules to activate 
CD4+ T cells. However, the separation of these 
distinct pools of source proteins is less stringent 
than originally believed.  A mechanism termed 
cross-presentation permits some forms of 
exogenous antigen to also stimulate CD8+ T 
cells via the MHC I pathway [1]. On the other     
hand, intracellular endogenous proteins can be 
presented by MHC II to CD4 cells, in a process 
termed autophagy whereby cytoplasmic content 
is engulfed into the endosomal pathway [2].  
There are various subtypes of antigen    
presenting DCs and a commonly emerging 
theme is that there is division of labor 
between various subsets in various anatomical 
locations. Splenic CD8α+ conventional (c)DCs 
are specialized in cross-presenting exogenous 
antigens to CD8+ T cells, whereas CD8α-33D1+ 
cDCs are specialized in presenting exogenous 
Ag to CD4+ T cells [1, 3]. The reason for these 
specializations are determined by differential 
expression of antigen uptake receptors [4, 5] or 
by differential expression levels of the various 
enzymes and chaperone molecules associated 
with antigen processing [6].  Although this 
division of labor has been clearly described 
in baseline conditions, it is possible that upon 
prolonged microbial stimulation, through 
ligation of pattern recognition receptors like 
Toll-like receptors (TLRs), the different cDC 
subtypes can perform multiple functions.
The most recent member of the DC family is 
the plasmacytoid (p)DC.  They are a specialized 
cell type that produce high levels of type I 
interferon upon viral stimulation and play a 
role in the clearance of some viral infections 
[7-10]. Plasmacytoid DCs also play a critical 
role in immunoregulation by preventing 
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overzealous inflammation in the course of a 
cellular immune response, by inducing the 
formation of regulatory T cells [11-15]. 
Although the potential of pDCs to present 
peptide Ag or to stimulate allo-specific T 
cells during the mixed leukocyte reaction 
has been shown on numerous occasions [16, 
17], the relative strength of soluble antigen 
uptake and processing of pDCs versus cDCs 
for mounting CD4+ and CD8+ T cell responses 
is still a controversial issue [11, 18, 19]. For 
presentation to CD8+ T cells, some authors 
conclude that pDCs only present endogenous 
Ag, but fail to cross-present exogenous Ag 
[5, 20, 21]. It could be that cross-presentation 
only occurs in special conditions, such like 
TLR triggering by bacterial CpG motifs or 
viral infection [22, 23], or following targeting 
of soluble Ag to specific endocytic receptors 
expressed by pDCs [23, 24].  For presentation 
to CD4+ T cells, pDCs were initially thought to 
present exogenous protein Ag only to already 
primed T cells [11, 25].  Contrasting these early 
reports, it was shown recently that lymph node 
pDCs were able to present soluble Ag to naive 
CD4+ T cells when the antigen was targeted 
to the bone marrow stromal Ag-2 receptor 
(BST2) via mPDCA-1, but strangely enough 
this effect was not seen in splenic pDCs. [21]. 
Additionally, it was demonstrated that the 
presence of Ag-specific immunoglobulins 
stimulate the uptake of Ag by human pDCs, 
thus promoting the presentation to primed 
CD4+ Th cells [26].  In many of these studies the 
possibility that ex vivo purified pDCs or pDC 
specific targeting studies were contaminated by 
Ag presentation by other APC subsets was not 
rigorously excluded.
In view of these emerging, yet conflicting 
and somewhat confusing studies we thought 
it would be of interest to study in greater 
detail under which conditions highly purified 
pDCs acquire and process exogenous and 
endogenous antigen and present it to CD4+ 
and CD8+ T cells.  Our results demonstrate 
that pDCs express the necessary enzymes for 
processing Ag for MHC I loading and are good 
at presenting endogenous and cross-presenting 
exogenous Ag to CD8+ T cells, providing 
there is simultaneous TLR stimulation.  We 
found that pDCs present exogenous antigen 
to naive CD4+ T cells only after prolonged 
TLR stimulation, leading to upregulation of 
critical MHC II-loading molecules,  and when 
immune serum immunoglobulins target the Ag 
to acidic MHC II antigen processing organelles 
via the intermediate affinity Fcγ receptor 
IIB for immunoglobulin G. Presentation of 
endogenous Ag on MHC II to CD4+ T cells 
was not constitutive, and required the presence 
of a specific Ii80 sorting signal, directing 
the cytosolic antigen to the endosomal 
compartment.
Material and Methods
Mice
Female C57BL/6 mice were purchased from Harlan (Zeist, 
The Netherlands). OT-I (C57BL/6 background) Tg mice 
containing OVA-specific TCR CD8+ T cells [27] and OT-II 
(C57BL/6 background) Tg mice containing OVA-specific 
TCR CD4+ T cells [28] were bred at Erasmus University. 
At the start of an experiment, mice were between 6-11 wks 
of age. All experiments were approved by the animal ethics 
committee at the Erasmus Medical Centre.
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Generation of BM DCs in hFlt3-L
Bone marrow (BM) cells were seeded in petridishes (106 
cells/ml) in DC culture medium (DC-CM, RPMI 1640 
containing GlutaMAX-I (Invitrogen) supplemented 
with 5% FCS (HyClone), 50 µM 2-mercapthoethanol 
(Sigma) and 50 µg/ml gentamycin (Invitrogen)) with 200 
ng/ml human FMS-like tyrosine kinase 3 ligand (hFlt3-
L, Amgen) and 50 ng/ml recombinant murine stem cell 
factor (rmSCF, PeproTech). At day 4, cells were harvested 
and re-plated (1*106 cells/ml) in DC-CM supplemented 
with 200 ng/ml hFlt3-L. At day 7 fresh medium was added. 
The DCs were harvested and sorted at day 10. BM cells 
were cultured with hFlt3-L alone to obtain pDCs, CD24+ 
and CD24- cDCs to evaluate the mRNA levels of MHC I 
and MHC II associated proteins.
Flow cytometry
For sorting of pDCs and cDCs, the BM Flt3-L/SCF culture 
was stained with mAbs against 120G8-FITC (provided by 
C. Asselin-Paturel), CD11c-APC, CD11b-PercP-Cy5.5 and 
B220-PE-Cy7 (eBioscience). Sorting of 120G8+ CD11b- 
B220+ CD11c+ pDCs and 120G8- CD11b+ B220- CD11c+ 
cDCs was performed on a FACS Aria (BD Biosciences). BM 
Flt3-L culture was additionally stained with anti-CD24-PE 
(BD Bioscience) to be able to discriminate between CD24- 
and CD24+ cDCs. 
For analysis of antigen uptake, BM Flt3-L/SCF culture 
was incubated o/n with 10 µg/ml OVA-Alexa Fluor 647 
(Molecular Probes). Cells were harvested and stained with 
120G8, CD11c, CD11b and B220 to determine the antigen 
uptake by pDCs and cDCs. To analyze the antigen uptake 
and processing capacity inside acidic endosomes, OVA-
DQ (Molecular Probes) was added to sorted pDCs and 
cDCs. After o/n incubation fluorescence emitted by OVA-
DQ was measured. 
To determine the expression of Fc receptors on pDCs, the 
BM Flt3-L/SCF culture was stained with mAbs directed 
against CD11c, CD11b, B220, 120G8, FceRI alpha 
(eBioscience), FcgRI (BD), FcgRIII and FcgRII/III (R&D). 
Normal human serum was used to prevent nonspecific 
antibody binding. 
For sorting experiments and T cell stainings, 2.4G2 (anti 
FcgRII/III) was used to reduce non-specific antibody 
binding. Acquisition of 6 color samples was done on a 
FACS ARIA (BD Biosciences). Acquisition of 4 color 
samples was done on a FACS Calibur (BD Biosciences) 
and FlowJo software (Tree Star, Inc.) was used for analysis. 
In all flow cytometry experiments either propidium iodide 
(PI), TOPRO-3 (Molecular Probes), or DAPI (Molecular 
Probes) was used to discriminate between live and dead 
cells.
Antigen uptake and processing by pDCs
To determine the antigen uptake and processing sorted 
pDCs were plated at a concentration of 1*106 cells/ml with 
10 mg/ml OVA-DQ with or without CpG motifs (ISS-ODN 
1668, 10 mg/ml). Simultaneously heat-inactivated normal 
mouse serum (NMS), OVA-immune serum (serum from 
mice sensitized twice with OVA-alum and challenged with 
OVA aerosols [29]), or OVA-immune serum pre-treated 
with protein G-sepharose beads was added to the pDCs. 
To investigate the role of FcγRIIB, pDCs were pre-
incubated with 10 µg/ml K9361 (anti FcγRIIB, a kind gift 
from J.N. Samsom, ErasmusMC, The Netherlands, [30]) 
for 1 hr at RT, thereafter the antibody was present during 
o/n incubation. 
In some experiments, part of the pDCs was pulsed with 
CpG motifs (10 µg/ml) o/n before exposure to OVA-DQ. 
Uptake and processing of OVA-DQ was measured 8 hrs 
after exposure to OVA-DQ. 
Antigen presentation to T cells in vitro
OVA-specific TCR Tg CD8+ T cells (OT-I) or CD4+ T cells 
(OT-II) were isolated from spleen and lymph nodes by 
depletion of non-CD8+ or non-CD4+ T cells respectively, 
using MACS (Miltenyi Biotec) and labeled with CFSE 
(Invitrogen) as previously described [31]. 2*104 pDCs 
or cDCs were cultured with 2*105 CD8+ or CD4+ T cells 
in the presence of OVA-peptide (2 ng/ml SIINFEKL 
(MHC I peptide) or 0.1 µg/ml ISQAVHAAHAEINEAGR 
(MH II peptide, OVA323-336) or 10 µg/ml OVA protein 
(Worthington).  After 4 days, cells were harvested and 
OVA-specific T cell proliferation was determined by 
staining CFSE labeled OT-I or OT-II cells with anti-Vb5-
PE (BD Bioscience) and anti-Vα2-APC (eBioscience) [32]. 
Data are shown as percentage of T cells recruited into cell 
division, calculated as previously described [33]. 
Retroviral transduction of BM cells
For the production of retrovirus the retroviral vector MFG, 
derived from moloney murine leukemia virus was used. 
MFG-tOVA contains cDNA encoding a truncated form of 
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the OVA protein (amino acids 40-386) and MFG-Ii80-OVA 
contains amino acids 242-353 of the ovalbumin protein 
fused to invariant chain of which the CLIP sequence was 
skipped. Retroviral particles were produced by transient 
transfection of phoenixECO as described [34].  
BM DCs were generated as described above with minor 
modifications. At the start of the culture lineage positive 
cells are removed from the BM using anti-CD4, anti-CD8, 
anti-CD45R, anti-Ly6G and anti-I-A/I-E antibodies. The 
lineage negative cells are plated in 24-well culture plates 
(106 cells/ml, 1 ml/well) with DC-TC supplemented with 
200 ng/ml hFlt3-L and 50 ng/ml rmSCF.  Transduction 
with MFG-tOVA and MFG-Ii80-OVA was performed as 
previously described [35].
Real-time quantitative RT-PCR
Frozen cell pellets were homogenized, RNA was isolated 
using RNeasy miniprep (Qiagen) with on column DNase 
I treatment according to manufacturer’s protocol. 100 ng 
RNA was reverse transcribed using random hexamers 
(Amersham Biosciences, Roosendaal) and Superscript 
II (Invitrogen) for 50 min at 42oC. Quantitative PCR 
was performed with Taqman Universal PCR Mastermix 
(Applied Biosystems, Foster City, CA) and pre-designed 
primers and probe mixes (Assay on Demand, Applied 
Biosystems). PCR conditions were 2 min at 50°C, 10 min 
at 95°C, followed by 40 cycles of 15 secs at 95°C and 60°C 
for 1 min using an ABI PRISM 7000 (Applied Biosystems). 
PCR amplification of the housekeeping gene ubiquitin C 
was performed during each run for each sample to allow 
normalization between samples.
Results
Plasmacytoid DCs cross-present exogenous 
protein antigen to CD8+ T cells only when 
triggered simultaneously with TLR9 agonist, 
but fail to present it to CD4+ T cells
There a several papers describing pDCs to be 
good APCs for CD4+ and CD8+ T cell responses, 
although some only show antigen presentation 
of antigenic peptides and not whole protein. 
Also, the purity of the pDCs used for 
stimulation could confuse the interpretation 
of data, since we found that contamination of 
only 4-5% cDCs contributes significantly to the 
antigen presentation capacity of pDCs (data 
not shown). We therefore used highly purified 
pDCs, derived from bone marrow cultures 
in Flt3-L and SCF, and purified using high 
speed cell sorting to over 98% purity based 
on expression of CD11c, BST2 (recognized by 
the clone 120G8), B220, and lack of expression 
of CD11b. Conversely, cDCs were identified 
based on expression of CD11c, CD11b and lack 
of 120G8 and B220, as previously described 
[31].  To exclude any possible bystander effects 
of cDCs on the potential of pDCs to take up 
and process antigen, pDCs were separated 
from cDCs before exposure to ovalbumin 
(OVA) antigen overnight.  BM-derived 
pDCs were viable after overnight culture in 
the presence of exogenous OVA, but were 
incapable of inducing cell division in purified 
OVA-specific CD8+ or CD4+ T cells taken 
from naive OT-I or OT-II mice respectively 
(Fig 1A).  However, sorted pDCs loaded with 
OVA MHC I or MHC II peptide induced CD8+ 
and CD4+ T cell proliferation.  The induction 
of naive T cell division by APCs is a function 
of provision of signal 1 (MHC-peptide) and 
signal 2 also known as costimulation, that is 
often induced by triggering of innate pattern 
recognition receptors such as TLRs.  In the 
presence of the well known endosomal TLR9 
agonist bacterial CpG motif, OVA-pulsed 
pDCs upregulated the expression of numerous 
costimulatory molecules (including CD80, 
CD86 and CD40, data not shown) and at this 
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time induced CD8+ T cell proliferation, as 
shown by an increase in the percentage of OT-
I cells recruited into cell division (from 1.07% 
without CpG to 13.94% with CpG). However, 
a concomitant CD4+ T cell response was not 
induced under these conditions. As a control, 
cDCs could induce both a CD8+ and CD4+ 
T cell response after exposure to the OVA 
protein and MHC I and MHC II peptide, and 
additional maturation with CpG motifs showed 
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Figure 1
Mouse plasmacytoid DCs are incapable of presenting exogenous antigen to CD4+ T cells
Plasmacytoid and conventional DCs were cultured from bone marrow with Flt3-L and SCF. On day 9, they were puri-
fied by FACS sorting. (A) Purified cells were pulsed o/n with OVA or OVA-peptide with or without CpG motifs. On day 
10, the cells were washed and placed in co-culture with either CFSE-labeled CD8+ T cells or CD4+ T cells. On day 14, 
T cell proliferation was measured by flowcytometry. Percentages in plots indicate percentage of cells recruited into 
cell division (see M&M for calculation). (B) Purified cells were pulsed o/n with OVA-Alexa Fluor 647 (AF647). On day 10 
the antigen uptake was measured by flowcytometry. (C) Purified cells were pulsed o/n with OVA-DQ with or without 
CpG motifs. On day 10 the antigen processing was measured by flowcytometry. All plots represent experiments 
repeated 2-5 times.
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a stronger CD4+ T cell proliferative response 
and a reduction in CD8+ T cell proliferation 
(Fig 1A, bottom panels). 
The absence of T cell responses to exogenous 
OVA protein induced by immature pDCs 
could be due to a lack of uptake of the protein. 
However, the capability of freshly sorted pDCs 
to internalize protein antigen was shown by 
uptake of OVA-Alexa Fluor 647 (Fig 1B), 
although on a per cell basis, pDCs acquired 
less antigen than cDCs (392 fold increase 
of the fluorescent signal over unpulsed cells 
compared to 1288 fold increase in cDCs). 
Loading of MHC II molecules occurs in an 
acidic endosomal compartment, rich in MHC 
II molecules, the so-called MIIC compartment. 
To follow if OVA would be targeted to these 
acidic organelles, OVA-DQ was used as a tracer. 
OVA-DQ is a quenched non-fluorescent protein 
that becomes fluorescent green when present 
in acidic endosomes and also fluorescent red 
when it accumulates at high concentrations in 
these compartments. Unstimulated pDCs did 
not show any positive signal for either OVA-
DQ green or red, showing an incapability of 
targeting the antigen to acidic endosomes or an 
inefficiency in acidifying the endosomes (Fig 
1C), whereas cDCs showed clear accumulation 
of OVA-DQ in these endosomes (50% of 
cDCs showing evidence of accumulation). 
The addition of CpG motifs only marginally 
increased the processing of OVA-DQ in pDCs 
from 2.09% to 7.93%.
pDCs and cDCs differentially express enzymes 
and chaperones involved in MHC I and MHC 
II processing
Many of the proteins that regulate MHC I 
and MHC II processing pathways have been 
described and their expression documented 
in DCs [6]. To evaluate if pDCs had intrinsic 
differences compared with cDCs in the 
expression of any of these proteins, the 
mRNA levels were compared by q-RT-PCR. 
In view of the recent findings that different 
subtypes of cDCs have differential intrinsic 
expression of these factors [6], we additionally 
separated CD24+ cDCs (in vitro equivalent of 
splenic CD8α+ cDCs [31]) from CD24- cDCs 
(equivalent to CD8α- splenic cDCs) from the 
Flt3-L BM culture. As expected, and lending 
further proof to the idea that CD24 expression 
reliably separates the different subsets of cDCs, 
we found that CD24- cDCs and CD24+ cDCs 
differentially expressed components of the 
MHC I and MHC II pathway.  mRNA levels of 
proteins which regulate the MHC I processing 
(such as the chaperone molecule calnexin, 
the peptide loading complex consisting of 
TAP, thiol-oxidoreductase ERp57, calreticulin 
and tapasin; and the ER retrotranslocation 
machinery Sec61a1, Sec61b and Sec61g) were 
expressed in both subsets of cDCs (Fig 2A). 
Notably however, expression of the MHC II 
degradative enzymes (Cathepsins S, H and 
C; asparagine endopeptidase; GILT and the 
cathepsin regulator Cystatin C), the chaperone 
molecule Invariant chain (Ii), and the CLIP 
exchanger H2-DMb1 were highest in the CD24- 
cDC subset.  In comparison with cDCs, the 
pDCs had lower expression of TAP1 and TAP2, 
although the rest of the MHC I processing 
machinery resembled the CD24+ cDCs. pDCs 
had very little MHC II processing machinery 
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compared with CD24- cDCs, and notably the 
expression of the chaperone molecule Ii and 
the CLIP exchanger H2-DMb1 was almost 
absent in freshly isolated pDCs (Fig 2B).
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Figure 2
Mouse plasmacytoid DCs express low RNA levels of proteins associated with the MHC II pathway
Plasmacytoid and conventional CD24+ and CD24- DCs were cultured from bone marrow with Flt3-L. On day 9, all 3 
cell populations were purified by FACS sorting. (A) RNA levels of proteins associated with the MHC I pathway. (B) RNA 
levels of proteins associated with the MHC II pathway.
119Capacity of pDCs to present soluble antigen to T cells
C
h
ap
te
r 
7
invariant chain
pD
C
cD
C
0
100
200
300
400
with CpG
without CpG
H2-DMb1
pD
C
cD
C
0
500
1000
1500
2000
Lamp1
pD
C
cD
C
0
100
200
300
400
500
GILT
pD
C
cD
C
0
100
200
300
400
500
Cathepsin H
pD
C
cD
C
0
100
200
300
Cathepsin S
pD
C
cD
C
0
100
200
300
400
500
600
Tap1
pD
C
cD
C
0
100
200
300
400
500
600
Ex
p
re
ss
io
n
 r
el
at
iv
e 
to
 N
TC
Cystatin C
pD
C
cD
C
0
2000
4000
6000
8000
with CpG
without CpG
0.68 0.86
1.0997.4
0.2 5.7
24.469.7
0.81 0.29
0.7798.1
0.61 1.49
6.4491.5
0.31 0.41
1.6897.6
0.089 0.02
0.4699.4
without CpG
with CpG
unpulsed
OVA-DQ 
Simultaneous
OVA-DQ
Sequential
A
B C
D
OVA-DQ greenO
VA
-D
Q
 re
d
  CD4+ T cell proliferation
without CpG
with CpG
CD8+ T cell proliferation
CFSEV
β5
.1
/5
.2
Sequential Simultaneous
unpulsed unpulsedOVA OVAOVA OVAOVA-peptide OVA-peptide
Sequential Simultaneous
1.13%
1.86%
1.60%
1.10%
65.26%
77.01%
1.10%
21.16%
0.59%
1.37%
0.67% 21.98%
42.39%7.48%
1.13%
2.37%
Ex
p
re
ss
io
n
 r
el
at
iv
e 
to
 N
TC
Ex
p
re
ss
io
n
 r
el
at
iv
e 
to
 N
TC
Figure 3
Activation of mouse plasmacytoid DCs with CpG motifs increases MHC II antigen processing
Plasmacytoid and conventional DCs were cultured from bone marrow with Flt3-L and SCF. (A) On day 9, cells were 
purified by FACS sorting and pulsed o/n with or without CpG motifs. RNA levels of proteins associated with the MHC 
II pathway. (B) RNA levels of TAP1 associated with the MHC I pathway. (C) On day 9, purified pDCs were either simul-
taneous or sequentially pulsed with or without CpG motifs and OVA-DQ. (D) On day 9, purified pDCs were either 
simultaneous or sequentially pulsed with or without CpG motifs and OVA. On day 10 they were placed in co-culture 
with CFSE-labeled CD8+ or CD4+ T cells. On day 14, T cell proliferation was measured by flowcytometry. Percentages 
in plots indicate percentage of cells recruited into cell division. All experiments are repeated at least 2 times.
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TLR9 ligation by CpG motifs influences the 
MHC class I and II processing machinery in 
pDCs and cDCs differentially
Since pDCs could induce CD8+ T cell 
proliferation after exposure to OVA antigen 
mixed with CpG motifs (Fig 1A), we wondered 
whether the expression profile of the critical 
MHC I and II pathway molecules would be 
influenced by CpG motif exposure. Indeed, 
factors regulating the MHC II pathway, like 
H2-DMb1, cathepsin H, cathepsin S, Lamp1, 
and invariant chain were increased when 
pDCs were exposed to CpG motifs (Fig. 3A). 
Especially the increased expression H2-DMb1, 
cathepsin S and invariant chain was striking, 
since the expression level of these mRNA 
levels in cDCs were regulated in a differential 
manner, showing a decrease upon exposure. 
Furthermore, TAP1, associated with MHC 
I pathway was increased in both pDCs and 
cDCs when compared to non-pulsed cells (Fig 
3B). Alternatively, in both pDCs and cDCs the 
expression of cystatin C was decreased. 
Since the expression of cathepsin S increased 
and its negative regulator cystatin C decreased 
whereas that of Ii invariant chain was strongly 
increased upon CpG exposure, we wondered 
if pDCs that were pretreated with CpG motifs 
before exposure to the exogenous protein 
antigen would increase their capacity to process 
the antigen for MHC II presentation. For this 
we exposed the purified pDCs for 18 hrs with 
CpG motifs and thereafter exposed cells for 8 
hrs with OVA-DQ (sequential administration) 
or exposed them for 18 hrs with CpG motifs 
and OVA-DQ simultaneously (Fig 3C). pDCs 
exposed simultaneously to CpG and OVA-DQ 
showed only a minor fraction of cells (6.4%) 
that had processed the antigen in acid organelles 
(as shown by green fluorescence of OVA-DQ), 
whereas 24.4% exposed sequentially to CpG 
and OVA-DQ showed signs of processing, and a 
small fraction of cells accumulated OVA at high 
density inside these acidic organelles, as shown 
by red OVA-DQ fluorescence.  To address if 
pre-activation of pDCs with CpG induced a 
better CD4+ T cell response, the sequentially 
treated pDCs were placed in co-culture with 
T cells and proliferation was measured. pDCs 
exposed to OVA and CpG simultaneously 
stimulated only 2.4% CD4+ T cell to go into 
division, whereas pDCs sequentially exposed 
to CpG and OVA 7.5% T cell went into division 
(Fig 3D, right panel). Strikingly, pDC pre-
activation reduced their capacity to induce 
CD8+ T cell proliferation (Fig 3D, left panel), as 
only 1.1% of T cells divided compared to 21.2% 
when simultaneously pulsed. 
The presence of immune serum dramatically 
alters the potential of pDCs to process Ag for 
presentation to CD4+ T cells
It has been shown that human pDCs could 
internalize antigen only in the presence of 
antigen-specific serum [26].  As these findings 
are at odds to our findings of constitutive 
antigen uptake by BM-derived pDCs in vitro 
(Fig 1B), we investigated the influence of 
OVA-immune serum on OVA uptake and 
processing by pDCs, and focused specifically 
on the capacity of serum to boost CD4+ T cell 
responses.  We first examined the effect of serum 
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on the capacity to direct the antigen in acidic 
endosomes for MHC II loading by exposing 
pDCs to OVA-DQ. As expected, pDCs exposed 
to OVA-DQ without serum did not show any 
signs of OVA-DQ processing. However, 40% 
of pDCs exposed to OVA-DQ in the presence 
of 5% OVA-immunized serum showed signs of 
accumulation inside acidic endosomes, an effect 
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Figure 4
Exposure of mouse plasmacytoid DCs with antigen and antigen-specific serum induces MHC II processing de-
pendent on FcgRII expression
Plasmacytoid DCs were cultured from bone marrow with Flt3-L and SCF. (A) On day 9, cells were purified by FACS 
sorting were pulsed o/n with OVA-DQ in the presence of 1 or 5% NMS or OVA-immune serum. On day 10, antigen 
processing was measured by flowcytometry. (B) On day 10, purified pulsed pDCs were placed in co-culture with 
CFSE-labeled CD4+ T cells. On day 14, T cell proliferation was measured. Percentages indicated in the plots represent 
the percentage of cell recruited into cell division. (C) OVA-immune serum was pretreated with protein-G beads before 
exposure to purified pDCs and OVA-DQ o/n. (D) Expression levels of different FcR on mouse pDCs. Grey histograms 
represent isotype control, black line the depicted FcR. (E) Purified pDCs were treated with a blocking FcgRII mAb 
before and during exposure to OVA-immune serum and OVA-DQ o/n. After 20 hrs antigen processing was measured 
by flowcytometry. (F) Purified pDCs were treated with a blocking FcgRII mAb before and during exposure to OVA-
immune serum and OVA o/n. After 20 hrs, treated pDCs were placed in co-culture with CFSE-labeled CD4+ T cells. 
Percentages in plots represent percentage of T cells recruited into cell division. All expts were repeated 2-4 times.
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not seen when NMS was added (Fig 4A). To 
address the effect of serum on Ag presentation, 
pDCs exposed to OVA-immunized serum 
and OVA were cultured with antigen-specific 
CD4+ T cells. Again, pDCs pulsed with OVA 
did not induce CD4+ T cell proliferation, but 
pDCs exposed to OVA in the presence of 
OVA-immune serum could induce CD4+ T 
cell proliferation, an effect that was further 
enhanced when CpG motifs were added (Fig 
4B).  The effect of serum could be any serum 
factor, like complement or immunoglobulins, 
or the presence of a cytokine factor. Heat-
inactivated OVA-immunized serum induced 
a comparable processing of OVA-DQ as non-
heat-inactivated OVA-immunized serum 
(data not shown), arguing against a role for a 
cytokine or complement activation.  However, 
when OVA-immunized serum was depleted of 
IgGs by protein G-sepharose beads, OVA-DQ 
processing was decreased by at least 50% (Fig 
4C). 
Immunoglobulins bind to a variety of Fc 
receptors (FcγRI-IV) on the surface of 
phagocytic cells. Examination of FcγRs and 
FcεRs on pDCs showed that only FcγRII was 
expressed as the mAb detecting FcγRIII did 
not show specific staining whereas the 2.4G2 
antibody recognizing FcγRII/III did (Fig 
4D). Blocking the FcγRII using a specific Ab 
before and during exposure to OVA-immune 
serum and OVA-DQ reduced the processing of 
OVA-DQ significantly (from 52.4% OVA-DQ 
green to 7.66%) (Fig 4E) and consequently, T 
cell proliferation was also reduced, implying 
that the presence of serum immunoglobulins 
enhanced Ag presentation by routing Ag to the 
acidic endosomal compartment where MHC II 
is loaded with peptide.
Presentation of endogenous Ag by pDCs 
to CD4+ and CD8+ cells depends on its 
localization inside the cell 
It has been suggested that pDCs only present 
endogenous, but not exogenous protein and 
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Figure 5
Only when OVA is targeted to MIIC mouse plasmacytoid DCs can induce CD4+ T cell proliferation
Plasmacytoid DCs were cultured from bone marrow with Flt3-L and SCF and transduced with MFG-EGFP, MFG-tOVA 
or MFG-Ii89-tOVA as described in the M&M. On day 10, pDCs were purified using a FACS sorter and placed in co-cul-
ture with CFSE-labeled CD8+ or CD4+ T cells. On day 14, T cell proliferation was measured. Percentages indicated in 
the plots represent the percentage of cell recruited into cell division. Transduction efficiency was 46%. Experiment 
was repeated twice.
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viral antigen to CD8+ and CD4+ T cells [20]. To 
address this question, we made use of retroviral 
over-expression of a cytoplasmic truncated 
form of OVA (tOVA), coding for amino acids 
40-386, from which the ER translocation 
sequence is removed and thus is not secreted 
by transduced cDCs in the supernatant, 
nor presented to CD4+ T cells [34]. pDCs 
transduced with this form of OVA did present 
Ag to CD8+ T cells, an effect that was strongly 
enhanced when also exposed to CpG bacterial 
motifs overnight prior to T cell stimulation 
(Fig 5, left panel). Some endogenous Ag 
can be presented by MHC II molecules, in a 
process relying on autophagy. However, tOVA-
transduced DCs did not present to CD4+ T cells, 
not even after CpG exposure overnight (Fig 5, 
right panel). One of the possible reasons for 
this deficiency to present to CD4+ T cells might 
be the expression of tOVA in the cytoplasm, 
thus effectively shielding the antigen from 
endosomal routing.  To redirect the tOVA to 
the MHC II rich endosomal compartment 
(MIIC), we additionally transduced pDCs with 
a retrovirus carrying a fusion protein of tOVA 
and the Ii sorting sequence (Ii80) that is involved 
in routing of Ii to the MIIC compartment [36]. 
When pDCs were transduced with Ii80-tOVA 
(Fig 5, right panel), they were still able to 
induce CD8+ T cell proliferation, but strikingly 
also capable of inducing strong CD4+ T cell 
proliferation, but only when cells were pulsed 
with CpG motifs.
Discussion
One of the most predominant tasks of a 
dendritic cell is its potential to take up, process 
and present antigen to CD4+ and CD8+ T cells. 
Antigen uptake and processing for MHC I 
or MHC II restricted Ag presentation might 
depend on intrinsic properties of particular 
DC subsets [4, 37].  As such it was suggested 
that the way antigen is taken up by DC subsets 
differs fundamentally between cDC subsets, 
endocytosis via the mannose receptor and 
early endosomes favoring cross-presentation 
to CD8+ cells and uptake via pinocytosis or 
scavenger receptors leading to routing to 
acidic late endosomes and lysosomes and thus 
favoring CD4+ T cell responses.  Additionally, 
cDC subsets differ fundamentally in the level 
of expression of enzymes and chaperones 
implicated in MHC I and MHC II processing 
[6].
Here, we have addressed the controversial issue 
whether pDCs are good antigen presenting cells 
and perform specialized tasks differentially 
from cDCs in presenting exogenous or 
endogenous Ag to CD4+ or CD8+ T cells.  For 
this, we have used highly purified pDCs that 
we obtained from the bone marrow of mice 
grown in Flt3-L, and sorted to purity by high 
speed cell sorting prior to exposure to antigen, 
to avoid any bystander effects of other APCs on 
the potential of pDCs to process and present 
antigen.  Indeed, a contamination of even a few 
percents of cDCs to a pDC preparation might 
dramatically mislead the conclusion whether a 
pDC can present or not.  
Plasmacytoid DCs were first considered to have 
a minor role in antigen uptake [19] compared 
with cDCs [11]. It was only very recently shown 
again that human blood-derived pDCs did not 
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take up soluble antigen, unless antigen specific 
immune serum was added in vitro, acting to 
enhance Ag uptake [26]. This is at odds with a 
report by Sapovnikov et al showing uptake of 
subcutaneously injected Ag by mouse lymph 
node pDCs and our own previous studies in 
which inhaled fluorescent OVA was found 
inside vacuoles of mediastinal LN pDCs of 
naive mice [11, 21].  The acquisition of soluble 
Ag could be indirect in the latter studies, and 
obtained after transfer from other APCs. We 
now show in this paper that highly purified 
bone marrow-derived pDCs do take up soluble 
antigen in the absence of serum components. 
Conventional DCs were compared with pDCs 
obtained from the same Flt3-L culture, and were 
also shown to take up Ag constitutively, albeit at 
higher levels than pDCs.  The addition of serum 
immunoglobulins did affect the cellular routing 
of antigen by pDCs, as assessed by the use of 
the pH-sensitive OVA-DQ probe, allowing 
us to see a routing of Ag to acidic endosomal 
organelles, where antigen is loaded onto MHC 
II molecules, in the presence of serum. The 
cDCs did not require the presence of serum to 
route OVA-DQ into these acidic endosomes. 
The serum-mediated routing of pDCs was due 
to a heat stable component in serum, was only 
seen when OVA-immune serum was used, was 
neutralized by prior treatment and extraction 
of serum by protein G affinity magnetic beads 
and was neutralized to a large extent when the 
FcγRII receptor was blocked.  This strongly 
implies the influence of serum Ag-specific 
immunoglobulins in influencing the routing 
of Ag to acidic organelles. The internalization 
of immune complexes via FcγRII might have 
a similar effect as entry via the scavenger 
receptor found on CD8α- splenic cDCs and 
macrophages, which also route their Ag to 
the acidic endosomes [4]. The same FcγRII 
receptor was also implied in a prior human 
study to mediate Ag uptake by human pDCs 
[26].  We cannot explain at present however 
why human pDCs would also rely on this 
receptor for uptake in addition to routing of 
internalized antigen.
We also addressed the functional capacities 
to present Ag to CD4+ and CD8+ T cells. For 
presentation to CD4+ T cells, pDCs were 
initially thought to present exogenous protein 
Ag only to already primed but not to naive T 
cells [11, 25].  Contrasting these early reports, 
it was shown recently that lymph node, but 
not splenic, pDCs were able to present soluble 
Ag to naive CD4+ T cells in vivo when the 
antigen was targeted to the BST2 receptor via 
mPDCA-1. [21].  In the latter study, residual 
Ag presentation in mice depleted of cDCs 
using CD11c-mediated expression of diphteria 
toxin receptor was taken as evidence that pDCs 
presented Ag to CD4+ T cells.  These studies 
are not without technical difficulties and in our 
hands cDC depletion is never total in CD11c-
DTR mice given DT [10, 38, 39].  We found, 
using BM-derived pDCs that fresh BM-pDCs, 
in contrast to cDCs sorted from the same 
cultures,  did not present exogenous Ag to 
CD4+ T cells, whereas they readily did present 
processed peptide to CD4+ T cells, particularly 
when exposed to CpG motifs to induce 
phenotypical maturation. The reason for the 
failure to present Ag to CD4+ T cells might 
be the lack of expression of invariant chain 
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(Ii), critical for sorting of MHC II molecules 
to the acidic MIIC endosomal compartment 
and of the other enzymes involved in MHC 
II processing such as cathepsin S, Cathepsin 
C, GILT, LAMP1, legumain and the peptide 
exchanger H2-DMb1.  In this regard, pDCs 
resembled the expression pattern of the CD24+ 
cDCs from the same Flt3-L culture.  It is exactly 
this subset that is the in vitro equivalent of the 
CD8α+ cDC subset from the spleen that is also 
known to be poor at presenting exogenous Ag 
to CD4+ T cells [6, 31].  Another explanation 
for the lack of CD4+ T cell responses to 
exogenous Ag induced by pDCs might be the 
routing of internalized Ag away from acidic 
endosomes (see discussion above) where MHC 
II complexes are loaded. 
An overnight exposure to CpG motifs followed 
in sequence by Ag exposure led to an increase 
in Ii expression and H2-DMb1 expression and 
consequently, more CD4+ T cell proliferation 
was induced. Strikingly, the inverse was seen in 
cDCs exposed to CpG motifs. There was also 
increased routing of internalized OVA-DQ into 
acidic organelles by sequential CpG motifs and 
OVA exposure (see Fig 3C).   Antigen uptake 
could have changed due to endocytic receptor 
expression changes, thereby directing cargo to 
different cellular compartments. This seems 
unlikely as we could not detect any increase 
in c-type lectin receptor (CD206, Ly49Q) 
expression on pDCs after CpG activation ([40] 
and data not shown). Even more strikingly, the 
combination of CpG motifs and OVA-immune 
serum on pDCs induced T cell proliferation 
in 27% of CD4+ T cells (Fig 4B), an effect of 
almost identical strength as that induced by 
cDCs exposed to CpG motifs (37% Fig 1A). 
We also addressed whether endogenous Ag, 
expressed from a retroviral vector as a truncated 
form that is not secreted into the supernatant, 
would be presented to CD4+ T cells by pDCs. 
This process has been shown to occur in cells 
undergoing macro-autophagy or chaperone 
mediated autophagy (MCA), a process by 
which cytosolic proteins can gain access to the 
acidic endosomal organelles [41].  We did not 
find evidence for this pathway in pDCs (Fig 
5).  However, when the endogenous Ag was 
artificially routed to these acidic endosomes 
using the Ii80 sorting sequence [34], strong 
CD4+ T cell responses were seen, particularly 
following CpG motifs exposure, illustrating 
that there is an intrinsic capacity of pDCs to 
present to CD4+ T cells, providing the antigen 
is in the right intracellular compartment. 
We therefore favor the view that pDCs can 
prime CD4+ T cell responses predominantly 
to exogenous Ag, but only when previously 
stimulated adequately by microbial stimuli and 
in the presence of specific immune globulins.  
For presentation to CD8+ T cells, some 
authors have suggested that pDCs only present 
endogenous Ag, but fail to cross-present 
exogenous Ag [5, 20, 21].  Our findings now 
clearly show that purified pDCs can indeed 
present an endogenously expressed antigen to 
naive CD8+ T cells almost constitutively (Fig 
5), and the process is enhanced by exposure 
to CpG motifs, the latter acting most likely by 
increasing the expression of co-stimulatory 
molecules that promote T cell expansion. In 
support, pDCs expressed all the machinery to 
load cytosolic peptides into the ER for loading 
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onto MHC I (Fig 2). 
As for cross-presentation of exogenous Ag (Fig 
1), we found that exogenous OVA was presented 
only under particular conditions, and pDCs 
were weaker at presentation compared with 
cDCs. Concurrent exposure of OVA antigen 
with CpG motifs was necessary to promote 
cross-presentation by pDCs (Fig 1).  The CpG 
motifs induced the expression of TAP1 to levels 
seen in cDCs.  Recently, it has been shown that 
cross-presentation is biased to antigens which 
contain microbial molecular patterns [37], 
which could also explain why pDCs pulsed 
with CpG and antigen simultaneously induce 
stronger CD8+ T cell responses. Additionally, 
the antigens which are cross-presented are 
better protected from proteases when high 
NADPH oxidase (NOX2) levels are present 
[42]. It has been shown that pDCs release more 
O2- radicals (NADPH oxidase is the source of 
O2- radicals) after TLR ligation [43]. Strikingly, 
a sequential exposure of CpG motifs followed 
by exogenous Ag abolished the potential of 
pDCs to cross-present OVA (Fig 3) whereas 
it boosted CD4+ T cell responses under these 
conditions.  This could be due to the routing 
of Ag into more acidic organelles induced by 
prior stimulation by CpG motifs (see Fig 3C), 
or an acidification of endosomal organelles 
in response to prolonged CpG, thus exposing 
endocytosed material to a more hostile 
proteolytic environment not conductive to 
cross-presentation [37, 44]. 
We believe therefore that the conclusions drawn 
by Salio on the inefficiency of CpG-matured 
pDCs to cross-present soluble Ag to CD8+ T 
cells can be explained by effects of timing of 
CpG exposure in relation to Ag exposure [20]. 
On the contrary, the findings of Sapoznikov that 
pDCs fail to cross-present might be explained 
by the fact that no maturation stimulus in the 
form of CpG or viral infection was used at all 
to boost pDC maturation [21]. As supported 
by our data, cross-presentation by pDCs has 
indeed been shown to occur only after TLR 
triggering by bacterial CpG motifs [22], viral 
infection [23], or targeting of soluble Ag to the 
SiglecH endocytic receptor expressed by mouse 
pDCs [24] or BDCA2 on human pDCs [23] in 
combination with a proper pDC maturation 
stimulus.  
In conclusion, we have demonstrated the 
conditions under which pDCs might better 
present endogenous or exogenous antigen to 
CD4+ and CD8+ T cells.  Although our study 
was performed purely in vitro, our findings 
might help to understand immunoregulation 
by pDCs in vivo. As the function of constitutive 
presentation of endogenous self antigen to 
CD8+ T cells in the absence of pDC maturation 
might be the maintenance of peripheral 
tolerance in the immune system [45], this 
might have implications for understanding 
autoimmunity. Cross-presentation occurs 
only upon simultaneous exposure of antigen 
and CpG motifs, as one would expect during 
acute infection, and might contribute to the 
generation of CD8+ T cells that are necessary 
to kill infected cells [8, 22]. Conversely, pDCs 
present antigen to CD4+ T cells only after 
prolonged TLR stimulation and in the presence 
of Ag specific immunoglobulins, a conditions 
under which they no longer cross-present 
to CD8+ T cells.  This situation could occur 
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late during viral or bacterial infections when 
serum immunoglobulins start to be produced. 
We have some preliminary evidence that 
pDCs exposed to Ag specific serum and CpG 
motifs promote the generation of CD4+Foxp3+ 
Treg cells, which might serve to terminate 
the inflammatory reaction towards the end 
of a viral or bacterial infection. Alternatively, 
pDCs might work by promoting CD4+ T cell 
responses that might help immunoglobulin 
class switching, thus acting as a positive 
feedback loop on immunoglobulin synthesis 
[10].   Further in vivo work will have to be 
performed to address these possibilities.
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Dendritic cells (DCs) are the masters of command of innate and adaptive immunity. First, through their capacity to release cytokines and chemokines necessary to kill an invading 
microbe and attract/stimulate other cells involved in innate immunity, like neutrophils and 
macrophages. Secondly, through their capacity to take up and process antigen in antigen exposed 
areas, and present it in an immunogenic form to naive T cells after migration to the central 
lymphoid organs. However, in steady state DCs also play a crucial role in regulating the immune 
response to self-antigens. 
Steady state
DCs are heterogeneous. Recently, the discrimination has been made accordingly to difference 
between steady state and during inflammation and/or infection [1]. In steady state, the different 
DC subsets can be divided into plasmacytoid DC (pDC), precursor DC (monocytes), and 
conventional DC (cDC) (see figure 1). The latter can be further divided into migratory and 
lymphoid tissue-resident cDC. The migratory cDCs serve as sentinels in the periphery, e.g. lungs 
or skin. After antigen capture in the peripheral tissue, these cDCs migrate to the draining lymph 
nodes, and present antigen to naive T cells in the lymph node. 
The lymphoid tissue-resident DC can be divided into CD8α+ cDC and CD8α- cDC, with a further 
subdivision classified by CD4 expression. These cDCs do not migrate through lymph vessels, but 
they collect their antigen from the surrounding lymph. This can either be self-antigens or soluble 
antigens which have reached the lymph node via the lymphatics. Yet, the CD8α+ cDCs process 
the antigen different than the CD8α- cDCs. It has been shown that CD8α+ cDCs are good at cross-
presentation (presenting exogenous antigen in MHC I) and CD8α- cDCs at MCH II presentation 
[2]. We could confirm by q-RT-PCR that indeed the CD24+ cDCs (in vitro equivalent of CD8α+ 
cDCs in Flt3-L culture) expressed more TAP1 and TAP 2 (associated with MHC I processing 
[3]) than CD24- cDCs (Chapter 7). On the other hand, CD24- cDCs (in vitro equivalent CD8α- 
cDCs in Flt3-L culture) expressed more MHC II proteins than CD24+ cDCs. This confirmed 
that the CD24+ and CD24- cDCs in culture resemble the CD8α+ cDC and CD8α- cDCs in vivo 
and have the same antigen processing capacities. The pDCs found in steady state are thought to 
have a regulatory role, facilitating either the formation of regulatory T cells [4], T cell anergy [5], 
or keeping the cDCs immature (unpublished data). Chapter 7 shows that pDCs do not present 
exogenous antigen to either CD4+ or CD8+ T cells in an immature state. However, when the 
antigen is endogenously present (in the case of viral transduction of pDCs with OVA), the antigen 
is presented only to naive CD8+ T cells. The phenomenon that pDCs can present endogenous 
antigens has been described before for viral antigens [6, 7]. 
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Inflammation or infection
During inflammation or infection, DCs behave in a different way. First, they are activated through 
recognition of microbes via their pattern recognition receptors (PRRs), after which they release 
different anti-viral or anti-inflammatory cytokines [8, 9]. pDCs are well known for their anti-viral 
function [10-13]. Upon encounter with a virus, the pDC is activated via TLR9, TLR7, or TLR8, 
which recognizes either unmethylated CpG motifs (DNA) or ssRNA [14]. The activated pDCs 
release massive amounts of type 1 interferon, mainly IFNα, which has strong anti-viral properties 
[15]. After activation, pDCs can acquire antigen and present it to either memory CD8+ or memory 
CD4+ T cells [7, 13, 16-18]. Mainly endogenous antigens (e.g. viral antigens) have been described          
Figure 1
Different dendritic cell subsets in steady-state and inflammation or infection
Steady state DCs (pDC, CD8α+ cDC, and CD8α- cDC) arise from common myeloid progenitors (CMP) and/or common 
lymphoid progenitors (CLP) and differentiate under the influence of Flt3-L. In inflammation or infection these steady 
state DCs all become activated and inflammatory DCs arise from inflammatory monocytes under the influence of 
GM-CSF.
Steady state
Inflammation/Infection
pDC
activated
pDC
CD8α+ cDC
activated
CD8α+ cDC
activated
CD8α- cDC
CD8α− cDC monocyte
inflammatory DC
Flt3-L
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for pDC antigen presentation and not exogenous antigens [6, 19, 20]. In Chapter 7, we discuss 
the antigen presentation capacity of pDCs and found that they can present exogenous antigen to 
naive CD8+ T cells when matured by CpG motifs. Furthermore, they can acquire antigen, process 
it and present it on MHC II to naive CD4+ T cells when either pre-activated to CpG motifs or 
exposed to exogenous antigen in the context of antigen-specific immunoglobulins. 20 hrs after 
activation with CpG motifs, mRNA levels of the proteins associated with MCH II processing are 
upregulated, indicating that the processing machinery is turned on after activation. 
pDCs have been shown to be important in several viral infections [10, 21], however their other 
immunological settings, like allergy or transplantation [22] pDCs have also been shown to have 
effects. De Heer et al have shown that pDCs are crucial to keep the lungs in a tolerant state 
[23]; moreover in tolerant mice pDCs outnumber cDCs [24]. Normally when an antigen is 
presented via the lung mucosa without an activation stimulus the outcome will be tolerance. As 
a consequence, when pDCs are depleted during exposure of a harmless antigen, the outcome is 
immunity [23]. In Chapter 6 we studied the capacity of pDCs to dampen an immune response in 
immunized mice, so if they are able to regulate a secondary encounter with antigens. Exogenous 
generated pDCs could dampen the eosinophilic inflammation induced by OVA aerosols, when 
administered before the challenge. Moreover, by increasing the endogenous pDCs with growth 
factor Flt3-L before the challenge phase the inflammation was also dampened, an effect already 
described by others [25-27]. Administration of Flt3-L increases both pDCs and cDCs. We show 
that the anti-inflammatory effect of Flt3-L was completely dependent on the increase of pDCs, as 
depleting pDCs with the mAb 120G8 completely abolished the Flt3-L effect. Surprisingly, pDCs 
can reduce eosinophilic airway inflammation irrespective of their maturation state. However, it 
has been described that only mature pDCs could induce regulatory T cells [4, 17, 28-32]. Liu et 
al showed that pDCs can induce regulatory T cells, which are known to dampen inflammation, 
probably via the interaction ICOS-ICOS-L on T cells and pDCs [33]. Only activated pDCs have 
ICOS-L expression on their cell surface.
In inflammation, also the cDCs become more activated and will then prime T cells. This can 
either lead to tolerance, protective immunity, or autoimmunity [34-36]. In Chapter 2, it was 
shown that an antigen (in this case OVA coupled to a fluorescent dye for tracking) injected 
intraperitoneally can passively flux to the draining mediastinal lymph node. There it will be 
taken up by the lymphoid-resident cDCs, processed and presented to CD4+ T cells. However, 
without an additional activation stimulus, after 7 days these proliferating CD4+ T cells have died. 
It was also clear that the lymphoid-resident cDCs were responsible for antigen presentation 
when only OVA (so no danger signal) was injected, since depletion of the lymphoid-resident 
cDCs (by intratracheal administration of diphteria toxin in CD11c-DTR mice) blocked the T cell 
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response. 
Under inflammatory conditions, circulating monocytes can differentiate into inflammatory 
DCs [37-41], and not when injected into non-inflamed or non-infected mice [42, 43]. These 
inflammatory monocytes (Ly6C+ CCR2+) are attracted to site of inflammation as they respond to 
the chemokine MCP-1 [44-46] produced by several cells after activation. In mice injected with 
alum adjuvant (Chapter 2) or mono-sodium urate (MSU) crystals (Chapter 4) an increase in 
MCP-1 and in the number of Ly6C+ monocytes can be detected already 2-6 hrs after i.p. injection 
into the peritoneal cavity. These monocytes efficiently take up the antigen, migrate to the draining 
mediastinal LN and differentiate into inflammatory DCs. There, these inflammatory DCs 
efficiently prime CD4+ T cells and induce effector T cells [47, 48]. In vitro the equivalent of these 
inflammatory DCs can be generated by culturing bone marrow cells with GM-CSF. These DCs 
resemble the TIP (TNFα-iNOS producing)-DCs [49], which efficiently prime for Th2 responses, 
when injected intratracheally [50]. However, the Flt3-L generated cDCs and pDCs can not induce 
immunity when injected intratracheally (unpublished data). 
Therapeutic implications to target the different DC subsets
The use of adjuvants has been around for at least 80 years, when people started to vaccinate with 
a booster (adjuvant) in the formula. Aluminum hydroxide and/or aluminum phosphate (alum) 
had been found to have these adjuvant activities. However, nowadays alum adjuvant is not only 
given to vaccinate against viral pathogens (e.g. hepatitis), but also to promote desensitization 
in the case of severe allergy. In this way, people try to overcome the aberrant Th2 response. The 
choice to use alum as an adjuvant is quit striking, since in mice alum adjuvant is used to induce 
strong Th2 responses [51]. So, in this way one should think if this approach is clever or not. 
However, in humans it has been shown that alum induces the formation of IgG4 (an isotype 
of not much knowledge in the mouse) [52]. IgG4 in humans is believed to act by neutralizing 
allergen and blocking both IgE-dependent activation of mast cells and basophils [53, 54]. B cells   
switch to the production of IgG4 by IL-10 and IL-4 [55], cytokines also produced in mice after 
alum sensitization (Chapter 2). It will need further investigations if the production of IgG4 is the 
main difference between human and mice in the context of alum immunotherapy.
In mice, alum injection leads to the release of uric acid (Chapter 2). Chapter 4 shows that 
uric acid crystals (monosodium urate (MSU) crystals) can mimic Th2 responses induced 
in mice comparable to the responses induces by alum sensitization. It can either be delivered 
intraperitoneally (as alum is) or via the airways. The latter would suggest that there maybe a role 
for uric acid in ongoing allergic disease, as during some environmental triggers induce the release 
136
of uric acid in the epithelial ling fluid. Uric acid can be released as an anti-oxidant reaction, but 
when it is locally present in high concentrations, it can form MSU crystals.  Higher uric acid 
levels can also be found in mice exposed to influenza [56]or house dust mite (Chapter 4), maybe 
implicating a role for uric acid in exacerbating allergic disease, e.g. asthma. 
MSU crystals have also been shown effective in promoting CD8+ T cytotoxic cell responses [57-
59], which is a beneficial property for an adjuvant. MSU crystals bind to a member of innate PPRs, 
namely the NALP3 inflammasome [60]. Different bacterial compounds, like muramyl dipeptide 
(MDP, product of bacterial cell wall, bacterial DNA, or even whole bacteria (e.g. Staphylococcus 
aureus) can activate the NALP3 inflammasome [61]. We (Chapter 3) and others have shown that 
the effect of alum adjuvant partially works via the NALP3 inflammasome. As ligands for another 
group of PPRs, namely the Toll-like receptors (TLRs) are subjugated to generate new adjuvants, 
exploitations of ligands of Nod-like receptors (NLRs) of which NALP3 is a member should also 
be proven a successful strategy.
Recently, strategies to target antigen in vivo to inflammatory or steady-state cDCs have been used 
in tumor immunology [62, 63]. In addition, in vitro generated DCs pulsed with antigen could 
reduced tumor load in different cancer models [64-68]. The use of DCs or targeting to specific DC 
subsets has been proven to be very efficient in promoting CTL responses and thereby reducing 
tumor load. Recently, DNGR-1, a specific receptor on CD8α+ cDCs, was used target with mAbs to 
the CD8α+ cDCs, thereby induced  strong CD8+ T cell responses, and facilitating a reduced tumor 
load [62]. However, in the concept of using Abs to target DC subsets should be important that 
targeting to specific DCs should be done carefully. The Ab of use should be extremely specific, as 
expression on other celltypes can be unfavorable.
Tricks to target inflammatory DCs or cDCs to reduce inflammation can be exploited as well. 
Targeting the cDCs with antigen in vivo without any maturation stimulus promotes tolerance (e.g. 
T cell anergy or regulatory T cells) instead of immunity [62, 69, 70]. This strategy could be proven 
useful in models of autoimmunity or allergy. Furthermore, targeting antigen to plasmacytoid DCs 
could be exploited to generate responses to dampen inflammation, as pDCs induce regulatory T 
cells. pDCs express markers specific for this population in naive mice, however in inflammation 
some markers are also upregulated on other cells, like BST2 (bone marrow stromal antigen-2 
recognized by PDCA-1 and 120G8 mAb) [71]. On the other hand, increasing pDCs by Flt3-L 
administration completely abolishes the eosinophilic airway responses. So, this pathway should 
also need further investigation to be proven useful as an adjuvant strategy. Indeed, it has been 
shown that Flt3-L administration increases T and B cell responses, obligatory properties of an 
adjuvant [72]. However, in this context they describe the effects found to the activation and 
number of cDCs found in the lymphoid organs [72].
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Triggering adjuvanicity via TLRs, like CpG motifs is an approach used in anti-tumor and anti-
viral vaccinations [73, 74]. Furthermore, CpG motifs have been used to dampen eosinophilic 
airway inflammation [75-78], an effect partially dependent on the recruitment of pDCs to the 
lung compartment (Chapter 6). The dampening effect of pDCs on eosinophilic inflammation did 
not depend on there maturation status (Chapter 6), but rather improved the reduction. 
Concluding, DC subsets can be used to promote either immunity or tolerance and thereby are 
key to regulating the immune system.
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Het immuunsysteem beschermt het lichaam tegen gevaarlijke microben, zoals bacteriën en virussen, maar ook tegen het ontstaan van tumoren. De Latijnse term immunis betekent 
vrijgesteld, verwijzend naar bescherming tegen indringers van buiten. Dit wordt gedaan door 
verschillende cellen die in het immuunsysteem voorkomen. De reactie wordt in gang gezet 
door eiwitten die door het immuunsysteem herkend worden, zogenaamde antigenen. Deze 
antigenen kunnen worden gepresenteerd door speciale antigeen-presenterende cellen, waarvan 
de dendritisch cellen (DC’s) enorm effectief zijn. Deze antigenen worden gepresenteerd via 
bepaalde structuren die op het celoppervlak tot expressie worden gebracht, zogenaamde MHC 
moleculen. Het MHC II/antigeen complex wordt herkend door T cellen, die effectief kunnen 
reageren om een anti-virale of anti-bacteriele response op gang te zetten. De zogenaamde CD8+ 
T cellen, cytotoxische T cellen, zullen geinfecteerde cellen aanvallen en doden. De CD4+ helper T 
cellen worden geactiveerd en maken mediatoren die helpen bij het klaren van de ontsteking. Wat 
voor soort T cel er ontwikkelt uit de naive T cel, komt door verschillende signalen die ze van de 
dendritische cellen krijgen en dit wordt een zogenaamde ‘verworven reactie. Dit wordt gedaan in 
de zogenaamde lymfoide weefsels, zoals de lymfeklieren en de milt. Het aanpassings (verworven) 
immuunsysteem kan dagen tot weken de tijd nemen na een eerste besmetting om een effect te 
hebben.
Naast de bovenstaande functies van DC’s hebben zij ook functies tijdens de primaire reactie 
van een infectie (zogenaamde aangeboren reactie). Hierdoor worden ze ook wel ‘bevelhebbers’ 
van de aangeboren en verworven immuniteit genoemd. De aangeboren immuniteit bestrijdt 
ziekteverwekkers gebruikend defensie die snel wordt gemobiliseerd en door receptoren teweeg te 
brengen die een breed spectrum van ziekteverwekkers herkennen. Tijdens de aangeboren reactie 
maken DC’s cytokines en chemokines, stoffen die nodig zijn om de geinfecteerde cellen te doden 
en andere cellen die de infectie tegengaan aan te trekken. Dit wordt gedaan op de plaats van 
ontsteking of infectie.
Tijdens de ‘rust’ staat van het lichaam, dus als er geen infectie of tumor aanwezig is, vervullen DC’s 
ook een cruciale rol. Zij zorgen voor tolerantie tegen ‘zelf ’-antigenen. Dit is cruciaal, aangezien 
het lichaam zichzelf niet moet aanvallen, maar alleen alles wat ‘niet’-zelf is.
Rust status
Dendritische cellen zijn heterogeen. Er wordt een onderscheid gemaakt tussen stabiliteit en 
tijdens infectie of ontsteking. In ruststaat, het onderscheidt in DC subsets kan gemaakt worden 
in plasmacytoide DC (pDC), voorloper DC (ook wel monocyten genoemd) en conventionele 
DC (cDC). cDC’s kunnen nog verder opgedeeld worden in migrerende (‘transporterende’) 
and lymfeklier-residente cDC.  De migrerende cDC’s zijn ‘schildwachten’ in de periferie 
van het lichaam, zoals in de longen of de huid. Na opname van antigenen in de periferie, 
145Nederlandse Samenvatting
transporteren deze cDCs het antigeen naar de drainerende lymfeklieren, waar ze het presenteren 
aan naive T cellen. De lymfeklier-residente cDC’s worden verder opgedeelt in CD8α+ cDC’s en 
CD8α- cDC’s. Deze cDC’s migreren niet door lymfevaten, maar nemen hun antigeen op uit de 
lymfevloeistof. Dit kunnen ‘zelf ’-antigenen zijn of oplosbare antigenen die in de lymfevloeistof 
aanwezig zijn en daardoor de lymfeklier bereikt hebben. In hoofdstuk 2 laten we zien dat als 
antigeen in de buikholte wordt gespoten het naar de drainerende lymfeklier kan gaan via de 
lymfevloeistof. Op deze wijze kunnen de lymfeklier-residente cDC’s het antigeen opnemen en 
presenteren aan CD4+ T cellen. Echter, wanneer dit gebeurd zonder activatie van de DC’s zullen 
7 dagen na injectie van het antigeen zijn de CD4+ T cellen dood gegaan.
Er is een verschil in antigeen opname en verwerking tussen de CD8α+ cDC en CD8α- cDC. De 
Rust staat
Inflammatie/Infectie
pDC
geactiveerde
pDC
CD8α+ cDC
geactiveerde
CD8α+ cDC
geactiveerde
CD8α- cDC
CD8α− cDC monocyte
inflammatoire DC
Flt3-L
GM-CSF
GMV/GLV
Figure 1
Verschillende dendritische cel subsets in rust en ontsteking/infectie
Tijdens rust ontwikkelen DC’s (pDC, CD8α+ cDC, and CD8α- cDC) zich van gemeenschappelijke myeloide voorlopers 
(GMV) or gemeenschappelijke lymfoide voorlopers (GLV) onder de invloed van de groeifactor Flt3-L. Tijdens inflam-
mation of infectie worden deze ‘in rust zijnde’ DC’s geactiveerd. Verder ontstaat er een subset, de inflammatoire DC 
vanuit monocyten onder invloed van de groeifactor GM-CSF. Tijdens rust komen deze DC’s niet voor.
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CD8α+ cDC’s zijn goede ‘cross-presentators’, dit betekend dat zij antigenen uit de omgeving 
presenteren aan CD8+ T cellen via MHC klasse I moleculen. Daarintegen zijn de CD8α- cDC’s 
goed in MHC klasse II presentatie, wat betekend dat zij goed CD4+ T cellen kunnen activeren. 
Dit hebben wij ook kunnen aantonen in hoofdstuk 7, waar de CD24+ cDCs (in vitro gelijkwaardig 
aan de CD8α+ cDCs van de beenmerg Flt3-L kweek) hogere expressie hadden van MHC klasse 
I geassocieerde eiwitten, en de CD24- cDC’s (in vitro gelijkwaardig aan de CD8α- cDC’s) hogere 
expressie van MHC klasse II geassocieerde eiwitten. Dit bevestigde ook dat deze gekweekte cDC’s 
lijken op de in het lichaam-aanwezige cDC’s en dezelfde antigeen processing capaciteiten hebben. 
Verder worden er in de rust status ook pDCs gevonden. Van deze DC’s wordt gedacht dat zij 
een regulerende werking hebben door de vorming van een suppressieve T cel, de zogenaamde 
regulatoire T cel te induceren. In hoofdstuk 7 wordt de antigeen presenterende capaciteit van 
pDCs besproken en duidelijk is dat zij exogeen (in de omgeving aanwezige, extern) eiwitten niet 
aan naive CD4+ of CD8 T cellen kunnen presenteren als ze onrijp zijn. Daarintegen presenteren 
ze als ze onrijp zijn wel endogene (in de cel aanwezige, intern) eiwitten aan naive CD8 T cellen. 
Dit laatste is ook bekend van virale eiwitten.  
Ontsteking of infectie staat
Tijdens ontstekingen of infecties handelen de DC’s anders. Eerst worden zij geactiveerd/gerijpt 
door herkenning van microben door speciale receptoren, de ‘Patroon Herkenning Receptoren’ 
(PRRs). Deze receptoren vallen onder het aangeboren immuunsysteem. Na deze activatie zullen 
de DC’s verschillende anti-virale en anti-inflammatoire cytokines uitscheiden. De pDC’s staan 
bekend om hun goede anti-virale werking. Als pDC’s virussen tegenkomen, worden zij geactiveerd 
via de PRRs door herkenning van stukjes DNA, zogenaamde CpG motieven. De geactiveerde 
pDC’s zetten enorme hoeveelheden type 1 interferonen vrij, welke een sterke virale werking 
hebben. Echter, na activatie kunnen pDC’s ook antigeen presenteren aan memory (geheugen) 
CD4+ of memory CD8+ T cellen. In hoofdstuk 7 bleek dat pDC’s antigeen kunnen presenteren in 
de context van infectie of ontsteking. Als pDC’s geactiveerd worden met CpG motieven (context 
infectie) of blootgesteld worden aan antigeen met antigeen immune serum (context herhaalde 
ontsteking) dan kunnen zij aan naive CD4+ en aan naive CD8+ T cellen antigeen presenteren. 
De anti-virale werking van pDC’s is hierboven al genoemd, echter de werking van pDCs in 
immunologische omstandigheden, zoals allergy of transplantie is nog maar weinig van bekend. 
Tijdens een eerste kontakt met een antigeen via de luchtwegen, zonder dat daarbij een activatie 
aanwezig is, zal het immuunsysteem zo reageren dat er tolerantie optreedt tegen dat antigeen. 
Nu is al eerder bewezen dat wanneer de pDC’s niet in de longen aanwezig zijn tijdens zo’n 
eerste kontakt, immuniteit (dus allergie) optreedt in plaats van tolerantie. In hoofdstuk 6 is de 
remmende werking van pDC’s onderzocht tijdens een herhaalde blootstelling met het antigeen, 
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dus in een al geimmuniseerde muis. Gekweekte pDC’s gegeven voor de herhaalde blootstelling 
konden de eosinofiele ontsteking, welke karateristiek is voor allergie, onderdrukken. Verrassend 
genoeg was de remming van pDC’s niet afhankelijk van hun rijpe status, zelfs hele rijpe pDC’s 
(met CpG motieven behandeld) konden de ontsteking remmen. Het is beschreven dat juist rijpe 
pDC’s regulatoire T cellen kan induceren.
Tijdens ontsteking of infectie zullen de cDC’s ook meer geactiveerd worden en beter T cellen 
kunnen activeren. Dit kan leiden tot tolerantie, beschermende immuniteit of auto-immuniteit. 
In hoofdstuk 2 en 4 laten we zien dat als een antigeen in een adjuvant (=hulpstof), zoals alum 
gegeven wordt, of met urinezuur kristallen worden er DC’s aangetrokken die de T cellen wel een 
goede stimulatie geven. Dit zijn de zogenaamde inflammatoire DC’s, welke uit de monocyten 
rijpen. Deze inflammatoire monocyten zijn zeer efficient in de opname van antigenen en zullen 
migreren naar de drainerende lymfeklier waar ze uitrijpen naar inflammatoire DC’s. Hier zullen 
zij een sterke CD4+ en/of CD8+ T cel response aanzetten.
Concluderend, de verschillende subsets van dendritische cellen hebben elk specifieke functies. 
Ook hun reactie is verschillend als het immuunsysteem in rust is of als er een infectie is. Echter, 
de DC subsets kunnen zeer goed fungeren als doelwitten voor toekomstige therapien, afhankelijk 
van de reactie die nodig is op dat moment in het lichaam.
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1-9
7-AAD  7-aminoactinomycin
A
alum  aluminum hydroxide and magnesium hydroxide (Imject, Pierce)
ALN   axillar lymph nodes
APC  antigen-presenting cell
APC   allophycocyanin
APC-AF750 allophycocyanin-alexa fluor 750
APC-Cy7 allophycocyanin-indotricarbocyanine 7
Ag   antigen
AF647  alexa fluor 647
ASC  apoptosis-associated speck-like protein containing a CARD domain
B
BAL   broncho alveolar lavage
BCR  B cell receptor
BHR   bronchial hyperreactivity
BM   bone marrow
BSA  bovine serum albumin
BST2  bone marrow stromal antigen 2
C
CCR  chemokine receptor
CD   cluster of differentiation
cDC  conventional dendritic cell
CFSE   carboxy fluorescein diacetate succinimidylester
CLIP  class II-associated invariant peptide
CLR  C-type lectin receptor
CLP  common lymphoid progenitor
CMP  common myeloid progenitor
CM   culture medium
COPD  chronic obstructive pulmonary disease
CTL  cytotoxic T lymphocyte
D
DAPI  4’-6-diamidinc-2-phenylindole
DAMP  damage-associated molecular pattern
DC   dendritic cell
DCIR2   DC inhibitory receptor 2
DNGR-1  DC, NK lectin group receptor-1
DLN  draining lymph node
DTH  delayed type hypersensitivity
DT  diphteria toxin
DTR  diphteria toxin receptor
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E
EDTA   ethylene-diamine-tetra acetic acid
EDN  eosinophil-derived neurotoxin
ELISA  enzyme-linked immuno sorbent assay
ER  endoplasmatic reticulum
F
FACS   fluorescence activated cell sorter
FSC   forward scatter
FITC   fluorescein isothiocyanate
Flt3-L   FMS-like tyrosine kinase 3 ligand     
FcR  Fc receptor
FCS   fetal calf serum
FoxP  forkhead protein
G
GFP   green fluorescent protein
GM-CSF  granulocyte-macrophage colony stimulating factor
H
h  human
HDM  house dust mite
hrs   hours
I
ICAM   intracellular adhesion molecule
ICOS-L  inducible co-stimulator ligand
IFN   interferon
Ig  immunoglobulin
Ii  invariant chain
IL  interleukin
ILN  inguinal lymph node
i.n.  intranasal
iNOS  inducible nitric oxide synthase
IPAF  IL-1b-converting enzyme protease activating factor
i.p.   intraperitoneal
IP-10    interferon inducible protein-10
i.t.   intratracheal
i.v.   intravenous
L
LN   lymph node
LPS lipopolysaccharide   
LRR   leucin-rich repeats
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M
MACS   magnet activated cell sorting
mAb   monoclonal antibody
MCP  monocytes chemoattractant protein
mDC  myeloid dendritic cell
MDP  muramyl dipeptide
MHC   major histocompatibility complex
MLN   mediastinal lymph nodes
MSU  monosodium urate
MPL  monophosphoryl lipid A
MyD88  myeloid differentiation factor 88
N
NALP  NACHT-associated domain, leucine-rich repeat and pyrin region
NAIP  neuronal apoptosis inhibitor protein
NF-kB   nuclear factor kB
NLR  NOD-like receptor
NK   natural killer cell
NKT  natural killer T cell
NOD  nucleotide-binding oligomerization domain
O
OVA   ovalbumin
P
PAMP   pathogen-associated molecular pattern
PAS   periodic acid-Schiff
PAR  protease activated receptor
PBS   phosphate-buffered saline
pDC   plasmacytoid dendritic cell
PD-L  programmed cell death ligand
PE   phycoerythrin
PE-Cy5   phycoerythrin-indotricarbocyanine 5
PE-Cy7  phycoerythrin-indotricarbocyanine 7
PGN  peptidoglycan
PGD  prostaglandin
PI   propidium iodide
PRR   pattern recognition receptor
R
r  recombinant
RLR  Rig-I like receptor
RPMI  Roswell Park Memorial Institute medium
RT-PCR  reverse transcription-polymerase chain reaction
153Abbreviations
Q
q-RT-PCR quantitative reverse transcription-polymerase chain reaction
S
SCF  stem cell factor
SEM   standard error of the mean
T
TAP  transporter associated with antigen processing
TCR   T cell receptor
Th   T helper cell
TIP-DC  TNF-producing,  iNOS-expressing dendritic cell
TLR   Toll-like receptor
TNF   tumor necrosis factor
Treg   regulatory T cell
TRIF  TIR (Toll/IL-1R)-domain containing adaptor protein inducing IFNb
W
WT   wild type
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